CA2216796C - Quinazoline derivatives - Google Patents
Quinazoline derivatives Download PDFInfo
- Publication number
- CA2216796C CA2216796C CA002216796A CA2216796A CA2216796C CA 2216796 C CA2216796 C CA 2216796C CA 002216796 A CA002216796 A CA 002216796A CA 2216796 A CA2216796 A CA 2216796A CA 2216796 C CA2216796 C CA 2216796C
- Authority
- CA
- Canada
- Prior art keywords
- amine
- quinazolin
- phenyl
- ethynyl
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention relates to certain 4-(substitutedphenylamino)quinazoline derivatives of formula (I), their produgs and pharmaceutically acceptable salts wherein R1, R2, R3, R4, m and n are described in said formula. The compounds of formula (I), their produgs and pharmaceutically acceptable salt s are useful for the treatment of hyperproliferative diseases.
Description
WO 96/30347 PCT/IB95/004.36 _1_ QUINAZOLINE DERIVATIVES
Background of the Invention This invention relatesto 4-(substitutedphenylamino)quinazoline derivatives which are useful in the treatment of hyperproliferative diseases, such as cancers, in mammals.
Many of the current treatment regimes for cancer utilize compounds which inhibit DNA synthesis. Such compounds are toxic to cells generally but their toxic effect on the rapidly dividing tumor cells can be beneficial. Alternative approaches to anti-cancer agents which act by mechanisms other than the inhibition of DNA
synthesis have been explored in order to enhance the selectivity of action against cancer cells.
It is known that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene (i.e. a gene which, on activation, leads to the formation of malignant tumor cells). Many oncogenes encode proteins which are aberrant tyrosine kinases capable of causing cell transformation.
Alternatively, the overexpression of a normal proto-oncogenic tyrosine kinase may also result in proliferative disorders, sometimes resulting in a malignant phenotype.
Receptor tyrosine kinases are large enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor, a transmembrane domain, and an intracellular portion which functions as a kinase to phosphorylate specific tyrosine residues in proteins and hence to influence cell proliferation. It is known that such kinases are frequently aberrantly expressed in common human cancers such as breast cancer, gastrointestinal cancer such as colon, rectal or stomach cancer, leukemia, and ovarian, bronchial or pancreatic cancer. It has also been shown that epidermal growth factor receptor (EGFR) which possesses tyrosine kinase activity is mutated and/or overexpressed in many human cancers such as brain, lung, squamous cell, bladder, gastric, breast, head and neck, oesophageal, gynecological and thyroid tumors.
Accordingly, it has been recognized that inhibitors of receptor tyrosine ~;inases are useful as a selective inhibitors of the growth of mammalian cancer cells.
For example, erbstatin, a tyrosine kinase inhibitor selectively attenuates the grev~h in athymic nude mice of a transplanted human mammary carcinoma which expresses epidermal growth factor receptor tyrosine kinase (EGFR) but is without effect on the growth of another carcinoma which does not express the EGF receptor.
I
Background of the Invention This invention relatesto 4-(substitutedphenylamino)quinazoline derivatives which are useful in the treatment of hyperproliferative diseases, such as cancers, in mammals.
Many of the current treatment regimes for cancer utilize compounds which inhibit DNA synthesis. Such compounds are toxic to cells generally but their toxic effect on the rapidly dividing tumor cells can be beneficial. Alternative approaches to anti-cancer agents which act by mechanisms other than the inhibition of DNA
synthesis have been explored in order to enhance the selectivity of action against cancer cells.
It is known that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene (i.e. a gene which, on activation, leads to the formation of malignant tumor cells). Many oncogenes encode proteins which are aberrant tyrosine kinases capable of causing cell transformation.
Alternatively, the overexpression of a normal proto-oncogenic tyrosine kinase may also result in proliferative disorders, sometimes resulting in a malignant phenotype.
Receptor tyrosine kinases are large enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor, a transmembrane domain, and an intracellular portion which functions as a kinase to phosphorylate specific tyrosine residues in proteins and hence to influence cell proliferation. It is known that such kinases are frequently aberrantly expressed in common human cancers such as breast cancer, gastrointestinal cancer such as colon, rectal or stomach cancer, leukemia, and ovarian, bronchial or pancreatic cancer. It has also been shown that epidermal growth factor receptor (EGFR) which possesses tyrosine kinase activity is mutated and/or overexpressed in many human cancers such as brain, lung, squamous cell, bladder, gastric, breast, head and neck, oesophageal, gynecological and thyroid tumors.
Accordingly, it has been recognized that inhibitors of receptor tyrosine ~;inases are useful as a selective inhibitors of the growth of mammalian cancer cells.
For example, erbstatin, a tyrosine kinase inhibitor selectively attenuates the grev~h in athymic nude mice of a transplanted human mammary carcinoma which expresses epidermal growth factor receptor tyrosine kinase (EGFR) but is without effect on the growth of another carcinoma which does not express the EGF receptor.
I
Various other compounds, such as styrene derivatives, have also been shown to possess tyrosine kinase inhibitory properties. More recently five European patent publications, namely EP 0 566 226 A1, EP 0 602 851 A1, EP 0 635 507 A1, EP 0 635 498 Al and EP 0 520 722 A1 have disclosed that certain guinazoline derivatives possess anti-cancer properties which result from their tyrosine kinase inhibitory properties. Also PCT publication WO 92/20642 discloses bis-mono and bicyclic aryl and heteroaryl compounds as tyrosine kinase inhibitors.
Although the anti-cancer compounds described above make a significant contribution to the art there is a continuing search in this field of art for improved anti-cancer pharmaceuticals.
Summary of the Invention This invention is directed to 4-(substituted phenylamino)quinazoline derivatives of the formula RZ ~R3~n N (I) ~~N
~Rl~m ~ Ra N
and pharmaceutically acceptable salts and prodrugs thereof, wherein m is 1, 2, or 3;
each R1 is independently selected from hydrogen, halo, hydroxy, amino, hydroxyamino, carboxy, (C1-C4)alkoxycarbonyl, nitro, guanidino, ureido, carbamoyl, cyano, i 2a trifluoromethyl, (R6)2N-carbonyl, and phenyl-W-alkyl wherein W
is selected from a single bond, O, S and NH;
or each R1 is independently selected from aminocarbonylmethyl, aminocarbonylethyl, cyano-(C1-C4)-alkyl and R9 wherein R9 is selected from the group consisting of R5, R50, (R6) 2N, R7C (=O) , RSONH, A and RSY; R5 is (C1-C4) alkyl; R6 is hydrogen or RS wherein the Rss are the same or different; R' is R5, R50 or (R6) 2N; A is selected from piperidino, morpholino, pyrrolidino and 4-R6-piperazin-1-yl, imidazol-1-y1, 4-pyridon-1-yl, carboxy-(C1-C4)-alkyl, phenoxy, phenyl, phenylsulfanyl, (C2-C4) -alkenyl, (R6) 2-N-carbonyl- (C1-C4) -alkyl; and Y is selected from S, i SO, SOz; the alkyl moieties in (R6)2N are optionally substituted with halo or R9 wherein R9 is defined as above, and the alkyl moieties in RS and R50 are optionally substituted with halo, (C2-C4)alkanoyloxy, HOC(=O), phenyl, R60, C6HSY, CN or R9 wherein R9 and R6 are defined as above, and wherein the resulting groups are optionally substituted with halo or R9 with the proviso that a nitrogen, oxygen or sulfur atom and another heteroatom cannot be attached to the same carbon atom, and with the further proviso that no more than three "R9" units may comprise R1;
or each R1 is independently selected from RS-sulfonylamino, phthalimido-(C1-C4)-alkylsulfonylamino, benzamido, benzenesulfonylamino, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, and R1°-(C2-C4)-alkanoylamino wherein R1° is selected from halo, R60, (C2-C4) -alkanoyloxy, R7C(=O), (R6)2N and carboxyl; and wherein the benzamido or benzenesulfonylamino or phenyl or phenoxy or anilino or phenylsulfanyl substituent in R1 may optionally bear one or two halogens, (C1-C4)alkyl, cyano, methansulfonyl or (C1-C4) -alkoxy substituents;
or any two Rls taken together with the carbons to which they are attached form a 5-8 membered ring comprising one or two heteroatoms selected from oxygen, sulfur and nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if ~I
Although the anti-cancer compounds described above make a significant contribution to the art there is a continuing search in this field of art for improved anti-cancer pharmaceuticals.
Summary of the Invention This invention is directed to 4-(substituted phenylamino)quinazoline derivatives of the formula RZ ~R3~n N (I) ~~N
~Rl~m ~ Ra N
and pharmaceutically acceptable salts and prodrugs thereof, wherein m is 1, 2, or 3;
each R1 is independently selected from hydrogen, halo, hydroxy, amino, hydroxyamino, carboxy, (C1-C4)alkoxycarbonyl, nitro, guanidino, ureido, carbamoyl, cyano, i 2a trifluoromethyl, (R6)2N-carbonyl, and phenyl-W-alkyl wherein W
is selected from a single bond, O, S and NH;
or each R1 is independently selected from aminocarbonylmethyl, aminocarbonylethyl, cyano-(C1-C4)-alkyl and R9 wherein R9 is selected from the group consisting of R5, R50, (R6) 2N, R7C (=O) , RSONH, A and RSY; R5 is (C1-C4) alkyl; R6 is hydrogen or RS wherein the Rss are the same or different; R' is R5, R50 or (R6) 2N; A is selected from piperidino, morpholino, pyrrolidino and 4-R6-piperazin-1-yl, imidazol-1-y1, 4-pyridon-1-yl, carboxy-(C1-C4)-alkyl, phenoxy, phenyl, phenylsulfanyl, (C2-C4) -alkenyl, (R6) 2-N-carbonyl- (C1-C4) -alkyl; and Y is selected from S, i SO, SOz; the alkyl moieties in (R6)2N are optionally substituted with halo or R9 wherein R9 is defined as above, and the alkyl moieties in RS and R50 are optionally substituted with halo, (C2-C4)alkanoyloxy, HOC(=O), phenyl, R60, C6HSY, CN or R9 wherein R9 and R6 are defined as above, and wherein the resulting groups are optionally substituted with halo or R9 with the proviso that a nitrogen, oxygen or sulfur atom and another heteroatom cannot be attached to the same carbon atom, and with the further proviso that no more than three "R9" units may comprise R1;
or each R1 is independently selected from RS-sulfonylamino, phthalimido-(C1-C4)-alkylsulfonylamino, benzamido, benzenesulfonylamino, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, and R1°-(C2-C4)-alkanoylamino wherein R1° is selected from halo, R60, (C2-C4) -alkanoyloxy, R7C(=O), (R6)2N and carboxyl; and wherein the benzamido or benzenesulfonylamino or phenyl or phenoxy or anilino or phenylsulfanyl substituent in R1 may optionally bear one or two halogens, (C1-C4)alkyl, cyano, methansulfonyl or (C1-C4) -alkoxy substituents;
or any two Rls taken together with the carbons to which they are attached form a 5-8 membered ring comprising one or two heteroatoms selected from oxygen, sulfur and nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if ~I
comprised of at least three carbons may be branched or cyclic;
R2 is selected from hydrogen and optionally substituted (C1-C6) -alkyl;
n is 1 or 2;
each R3 is independently selected from hydrogen, optionally substituted (C1-C6)-alkyl, optionally substituted amino, halo, hydroxy, optionally substituted hydroxy; and R4 is azido or R11-ethynyl wherein Rll is selected from hydrogen, optionally substituted (Cl-C6)alkyl wherein the substituents are selected from hydrogen, amino, hydroxy, R50, RSNH and ( RS ) 2N .
More particularly the invention relates to compounds of formula I wherein m, n, R1 and R3 are as defined above; R2 is hydrogen; and R4 is R11-ethynyl wherein R11 is selected from hydrogen, optionally substituted (Cl-C6)-alkyl wherein the substituents are selected from hydrogen, amino, hydroxyl, R50, RSNH and (RS) 2N or R4 is azido.
The invention also relates to compounds of formula I wherein n is defined above and m is 1 or 2, each R1 is independently selected from hydrogen, hydroxyl, amino, hydroxyamino, carboxy, vitro, carbamoyl, ureido;
RS optionally substituted with halo, R60, HOC(=O), (R6) ZNC (=O) , A or (R6) 2 N;
4a 8120, wherein R12 is HK and K is (CZ-C9) alkyl, optionally substituted with halo, R60, (CZ-C9) -alkanoyloxy, HOC (=O) , A, (R6) ZN, R60K0, R50KNH, CN or phenyl; RSNH
optionally substituted halo, (C2-C9) -alkanoyloxy, R60, R'C (=0) , (R6) 2N, A, R60K0, R60KNH, C6H5Y or CN;
(R6) 2N (C=0) , R50NH, RSS, (C1-C9) -alkylsulfonylamino, phthalimido-(C1-C4)-alkylsulfonylamino, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, halo-(CZ-C9)-alkanoylamino, hydroxy- (CZ-C4) -alkanoylamino, (C2-C4) -alkanoyloxy- (CZ-C9) -alkanoylamino, (C1-C4) -alkoxy- (C2-CQ) -alkanoylamino, carboxy- (CZ-C4) -alkanoylamino, (C1-C4) -alkoxycarbonyl- (C2-C4) -alkanoylamino, carbamoyl- (C2-C4) -alkanoylamino, N-(C1-C4)alkylcarbamoyl-(CZ-C4)-alkanoylamino, N, N-di [ (C1-C4) -alkyl] carbamoyl- (CZ-C4) -alkanoylamino, amino-(CZ-C4) -alkanoylamino, (C1-CQ) -alkyl-amino- (CZ-CQ) -alkanoylamino, di- (C1-C9) -alkyl-amino- (CZ-C9) -alkanoylamino, and wherein the phenyl or phenoxy or anilino substituent in R1 may optionally bear one or two halogens, (Cl-C4)-alkyl or (C1-C4)alkoxy substituents; or any two Rls taken together with the carbons to which they are attached comprise a 5-8 membered ring comprising at least one or two heteroatoms selected from oxygen, sulfur or nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic;
4b each R3 is independently selected from hydrogen, methyl, ethyl, amino, halo and hydroxy;
R9 is R11-ethynyl wherein R11 is hydrogen Most particularly the invention relates to compounds of formula I wherein m, n, R1, RZ and R3 are as defined above and each R1 is independently selected from hydrogen, hydroxy, amino, hydroxyamino, nitro, carbamoyl, ureido, RS optionally substituted with halo, R60, HOC(=0), H2NC (=O) ;
R50 optionally substituted with halo, R60, (CZ-C4) -alkanoyloxy, HOC(=0), (R6)ZN, A, phenyl;
RSNH, ( RS ) 2N, RSNH2. ( RS ) zNH. R5NHC ( =0 ) , ( RS ) zNC ( =O ) , RSS, phenyl-(C2-C4)-alkoxy, and wherein said phenyl substituent in R1 may optionally bear one or two halo, R5 or R50 substituents; or any two Rls taken together with the carbons to which they are attached comprise a 5-8 membered ring comprising at least one or two heteroatoms selected from oxygen, sulfur or nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic.
Particularly preferred compounds are those in which R1 is each independently selected from the group consisting of methoxy, ethoxy, propoxy, isopropoxy, butoxy, nitro, amino, methenesulfonylamino, 4-toluenesulfonylamino, 4c 2-phthalimidoeth-1-ylsulfonylamino guanidino, carbomethoxy, 2-methoxyethoxy, methanesulfonyl, ethanesulfonyl, 2-chloroethoxy, 2-acetoxyethoxy, 2-hydroxyethoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 2-(4-morpholin-4-yl)ethoxy, aminomethyl, aminocarbonylmethyl, and aminocarbonylethyl; or two Rls together form methylenedioxy.
A group of particularly preferred compounds include: (6,7-dipropoxyquinazolin-4-yl)-(3-ethynyl-phenyl)-amore;
(6,7-diethoxyquinazolin-4-yl)-(3-ethynyl-5-fluoro-phenyl)-amine;
(6,7-diethoxyquinazolin-4-y1)-(3-ethynyl-4-fluoro-phenyl)-amine;
(6,7-diethoxyquinazolin-4-yl)-(5-ethynyl-2-methyl-phenyl)-amine;
(6,7-diethoxyquinazolin-4-y1)-(3-ethynyl-4-methyl-phenyl)-amine;
(6-aminomethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminomethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-ethoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
4d (6-aminocarbonylethyl-7-ethoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-isopropoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-propoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylethyl-7-isopropoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; and (6-aminocarbonylethyl-7-propoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine.
R2 is selected from hydrogen and optionally substituted (C1-C6) -alkyl;
n is 1 or 2;
each R3 is independently selected from hydrogen, optionally substituted (C1-C6)-alkyl, optionally substituted amino, halo, hydroxy, optionally substituted hydroxy; and R4 is azido or R11-ethynyl wherein Rll is selected from hydrogen, optionally substituted (Cl-C6)alkyl wherein the substituents are selected from hydrogen, amino, hydroxy, R50, RSNH and ( RS ) 2N .
More particularly the invention relates to compounds of formula I wherein m, n, R1 and R3 are as defined above; R2 is hydrogen; and R4 is R11-ethynyl wherein R11 is selected from hydrogen, optionally substituted (Cl-C6)-alkyl wherein the substituents are selected from hydrogen, amino, hydroxyl, R50, RSNH and (RS) 2N or R4 is azido.
The invention also relates to compounds of formula I wherein n is defined above and m is 1 or 2, each R1 is independently selected from hydrogen, hydroxyl, amino, hydroxyamino, carboxy, vitro, carbamoyl, ureido;
RS optionally substituted with halo, R60, HOC(=O), (R6) ZNC (=O) , A or (R6) 2 N;
4a 8120, wherein R12 is HK and K is (CZ-C9) alkyl, optionally substituted with halo, R60, (CZ-C9) -alkanoyloxy, HOC (=O) , A, (R6) ZN, R60K0, R50KNH, CN or phenyl; RSNH
optionally substituted halo, (C2-C9) -alkanoyloxy, R60, R'C (=0) , (R6) 2N, A, R60K0, R60KNH, C6H5Y or CN;
(R6) 2N (C=0) , R50NH, RSS, (C1-C9) -alkylsulfonylamino, phthalimido-(C1-C4)-alkylsulfonylamino, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, halo-(CZ-C9)-alkanoylamino, hydroxy- (CZ-C4) -alkanoylamino, (C2-C4) -alkanoyloxy- (CZ-C9) -alkanoylamino, (C1-C4) -alkoxy- (C2-CQ) -alkanoylamino, carboxy- (CZ-C4) -alkanoylamino, (C1-C4) -alkoxycarbonyl- (C2-C4) -alkanoylamino, carbamoyl- (C2-C4) -alkanoylamino, N-(C1-C4)alkylcarbamoyl-(CZ-C4)-alkanoylamino, N, N-di [ (C1-C4) -alkyl] carbamoyl- (CZ-C4) -alkanoylamino, amino-(CZ-C4) -alkanoylamino, (C1-CQ) -alkyl-amino- (CZ-CQ) -alkanoylamino, di- (C1-C9) -alkyl-amino- (CZ-C9) -alkanoylamino, and wherein the phenyl or phenoxy or anilino substituent in R1 may optionally bear one or two halogens, (Cl-C4)-alkyl or (C1-C4)alkoxy substituents; or any two Rls taken together with the carbons to which they are attached comprise a 5-8 membered ring comprising at least one or two heteroatoms selected from oxygen, sulfur or nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic;
4b each R3 is independently selected from hydrogen, methyl, ethyl, amino, halo and hydroxy;
R9 is R11-ethynyl wherein R11 is hydrogen Most particularly the invention relates to compounds of formula I wherein m, n, R1, RZ and R3 are as defined above and each R1 is independently selected from hydrogen, hydroxy, amino, hydroxyamino, nitro, carbamoyl, ureido, RS optionally substituted with halo, R60, HOC(=0), H2NC (=O) ;
R50 optionally substituted with halo, R60, (CZ-C4) -alkanoyloxy, HOC(=0), (R6)ZN, A, phenyl;
RSNH, ( RS ) 2N, RSNH2. ( RS ) zNH. R5NHC ( =0 ) , ( RS ) zNC ( =O ) , RSS, phenyl-(C2-C4)-alkoxy, and wherein said phenyl substituent in R1 may optionally bear one or two halo, R5 or R50 substituents; or any two Rls taken together with the carbons to which they are attached comprise a 5-8 membered ring comprising at least one or two heteroatoms selected from oxygen, sulfur or nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic.
Particularly preferred compounds are those in which R1 is each independently selected from the group consisting of methoxy, ethoxy, propoxy, isopropoxy, butoxy, nitro, amino, methenesulfonylamino, 4-toluenesulfonylamino, 4c 2-phthalimidoeth-1-ylsulfonylamino guanidino, carbomethoxy, 2-methoxyethoxy, methanesulfonyl, ethanesulfonyl, 2-chloroethoxy, 2-acetoxyethoxy, 2-hydroxyethoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 2-(4-morpholin-4-yl)ethoxy, aminomethyl, aminocarbonylmethyl, and aminocarbonylethyl; or two Rls together form methylenedioxy.
A group of particularly preferred compounds include: (6,7-dipropoxyquinazolin-4-yl)-(3-ethynyl-phenyl)-amore;
(6,7-diethoxyquinazolin-4-yl)-(3-ethynyl-5-fluoro-phenyl)-amine;
(6,7-diethoxyquinazolin-4-y1)-(3-ethynyl-4-fluoro-phenyl)-amine;
(6,7-diethoxyquinazolin-4-yl)-(5-ethynyl-2-methyl-phenyl)-amine;
(6,7-diethoxyquinazolin-4-y1)-(3-ethynyl-4-methyl-phenyl)-amine;
(6-aminomethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminomethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-ethoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
4d (6-aminocarbonylethyl-7-ethoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-isopropoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-propoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylethyl-7-isopropoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; and (6-aminocarbonylethyl-7-propoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine.
The invention most particularly relates to compounds of the formula I selected from the group consisting of (6,7-dimethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6,7-dimethoxyquinazolin-4.-yl)-[3-(3'-hydroxypropyn-1-yl)phenyl]-amine;
5, (6,7-dimethoxyquinazolin-4.-yf)-j(3-(2'-(aminomethyl)-ethynyl)phenyl]-amine;
[(3-ethynylpheny!)-(6-nitroquinazolin-4-yl)-amine;
(6,7-dimethoxyquinazolin-4-yl)-(4-ethynylphenyl)-amine;
(6,7-dimethoxyquinazolin-4-yl)-(3-ethyny!-2-methylphenyl)-amine;
(6-aminoquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(3-ethynylphenyl)-(6-methanesulfonylaminoquinazolin-4-yl)-amine;
(3-ethynylphenyl)-(6,7-methylenedioxyquinazolin-4-yl)-amine;
(6,7-dimethoxyquinazolin-4-yl)-(3-ethynyl-6-methylphenyl)-amine;
(3-ethynylphenyl)-(7-nitroquinazolin-4-yl)-amine;
(3-ethynylphenyl)-[6-(4'-toluenesulfonylamino)-quinazolin-4-yl]-amine;
(3-ethynylphenyl)-{6-[2'-phthalimido-ethan-1'-yl-sulfonylamino]quinazolin-4-yl}-amine;
(3-ethynylphenyl)-(6-guanidinoquinazolin-4-yl)-amine;
(7-aminoquinazolin-4-yl}-(3-ethynylphenyl)-amine;
(3-ethynylphenyl)-(7-methox yquinazolin-4.-yl)-amine;
(6-carbomethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(7-carbomethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine;
[6,7-bis{2-methoxyethoxy)quinazofin-4-ylJ-(3-ethynylphenyf)amine;
(3-azidophenyl)-(6,7-dimethoxyquinazolin-4-yl)amine;
(4-aZidophenyl)-(6,7-dimethoxyquinazolin-4-yl)amine;
(3-azido-5-chlorophenyl)-(6,7-dimethoxyquinazolin-4-yl)amine;
(3-ethynylphenyl)-(6-methansulfc;~yl-quinazolin-4-yl)-amine;
(6-ethansulfanyl-quinazolin-4-yl)-(3-ethynylphenyl)-amine (6,7-dimethoxy-quinazolin-4-yl)-(3-ethynyl-4-fluoro-phenyl)-amine;
(6,7-dimethoxy-quinazolin-4-yl)-[3-propyn-1-yl-phenyl]-amine.
[6,7-bis-(2-methoxy-ethoxy}-quinazolin-4-yl]-(5-ethynyl-2-methyl-phenyl)-amine;
[6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-~-fluoro-phenyl)-amine;
[6,7-bis-(2-chloro-ethoxy)-quinazofin-4-yl]-(3-ethynyl-phenyl)-amine;
WO 96!30347 PCT/IB95/00436 amine;
[6-(2-chloro-ethoxy)-7-{2-methoxy-ethoxy)-quinazoiin-4-yl]-(3-ethynyl-phenyl)-[6,7-bis-(2-acetoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
2-[4-{3-ethynyl-phenylamino)-7-(2-hydroxy-ethoxy)-quinazolin-6-yloxy]-ethanol;
[6-(2-acetoxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
amine;
amine;
amine;
[7-(2-chloro-ethoxy)-6-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-[7-(2-acetoxy-ethoxy)-6-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-2-[4-(3-ethynyl-phenylamino)-6-(2-hydroxy-ethoxy)-quinazolin-7-yloxy]-ethanol;
2-[4-(3-ethynyl-phenylamino)-7-(2-methoxy-ethoxy)-quinazolin-6-yloxy]-ethanol;
2-[4-(3-ethynyl-phenylamino)-6-(2-methoxy-ethoxy)-quinazolin-7-yloxy]-ethanol;
j6-(2-acetoxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-(3-ethynyl-phenyl)-{6-(2-methoxy-ethoxy)-7-[2-(4-methyl-piperazin-1-yl)-ethoxy]-quinazolin-4-yl}-amine;
{3-ethynyl-phenyl)-[7-(2-methoxy-ethoxy)-6-(2-morpholin-4-yl)-ethoxy)-quinazolin-4-yl]-amine;
(6,7-diethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(6,7-dibutoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(6,7-diisopropoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(6,7-diethoxyquinazolin-1-yl)-(3-ethynyl-2-methyl-phenyl)-amine;
j6,7-bis-(2-methoxy-ethoxy)-quinazolin-1-yl]-(3-ethynyl-2-methyl-phenyl)-amine;
(3-ethynylphenyl)-[6-(2-hydroxy-ethoxy)-7-(2-methoxy-ethoxy)-quirrazolin-1-yl]-amine;
and [6,7-bis-(2-hydroxy-ethoxy)-quinazoiin-1-yl]-(3-ethynyl-2-methyl-phenyl)-amine;
2-[4-(3-ethynyl-phenylamino)-6-(2-methoxy-ethoxy)-quinazolin-7-yloxy]-ethanol.
Another aspect of the invention provides a process for preparing a compound of the formula Replacement Qage _7_ CR3>n R
I
~~ N
CR1)m N
wherein misl,2,or3;
each R' is independently selected from hydrogen, halo, hydroxy, amino, hydroxyamino, carboxy, (C,-C4)alkoxycarbonyl, vitro, guanidino, ureido, carbamoyi, cyano, trifluoromethyl, (Re)ZN-carbonyl, and phenyl-W-alkyl wherein W is selected from a single bond, O, S and NH;
or each R' is independently selected from cyano-(C,-C4)-alkyl and R9 wherein R9 is selected from the group consisting of R5, R50, (Re)ZN, R'C(=O), R50NH, A
and RSY; wherein R5 is (C,-C4)alkyl; Re is hydrogen or R5 wherein the R5s are the same or different; R' is R5, R50 or (RB)ZN; A is selected from piperidino-, morpholino, pyrrolidino and 4-Re-piperazin-1-yl, imidazol-1-yl, 4-pyridon-1-yl, carboxy-(C,-C4)-alkyl, phenoxy, phenyl, phenylsulfanyl, (CZ C4)-alkenyi, (Re)2 N-carbonyl-(C,-C4)-alkyl; and Y
is selected from S, SO, SOZ; the alkyl moieties in (RB)zN are optionally substituted with halo or R9 wherein R9 is defined as above, and the alkyl moieties in R~ and R50 are optionally substituted with halo, R80 or R9 wherein R9 and Re are defined as above, and wherein the resulting groups are optionally substituted with halo or R9 with the proviso that a nitrogen, oxygen or sulfur atom and another heteroatom can not be attached to the same carbon atom, and with the further proviso that no more than three "R9"
units may comprise R' ;
or each R' is independently selected from R5-sulfonylamino, phthalimido-(C,-C4)-alkylsulfonylamino, benzamido, benzenesulfonylamino, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, and R' °-(Cz C4)-alkanoylamino wherein R' ° is selected from halo, R80, (CZ C4)-alkanoyloxy, R'C(=O), and (Re)ZN; and wherein said benzamido or benzenesulfonylamino or phenyl or phenoxy or anilino or phenylsulfanyl substituent in AMENDED SHEET
or any two Rls taken together with the carbons to which they are attached comprise a 5-8 membered ring comprising at least one or two heteroatoms selected from oxygen, sulfur or nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic;
R2 is selected from hydrogen and optionally substituted (C1-C6) -alkyl;
n is 1 or 2 and each R3 is independently selected from hydrogen, optionally substituted (C1-C6)-alkyl, optionally substituted amino, halo, hydroxy, optionally substituted hydroxy;
R4 is azido or R11-ethynyl wherein R11 is selected from hydrogen, optionally substituted (C1-C6)-alkyl wherein the substituents are selected from hydrogen, amino, hydroxy, R50 , RSNH and ( RS ) 2N , which comprises:
a) treating a compound of the formula aH o ~~N ~R1) ~NH
NJ or N
wherein R1 and m are as defined above, with CC14 and an optionally substituted triarylphosphine, 8a optionally supported on an inert polymer, of the formula Ar3P
wherein each Ar is an optionally substituted (C6-Clo)aryl group and each of the substituents is independently selected from (C1-C6) alkyl; and b) treating the product of step a) with a compound of the formula Rz ~R~n HN
J
(6,7-dimethoxyquinazolin-4.-yl)-[3-(3'-hydroxypropyn-1-yl)phenyl]-amine;
5, (6,7-dimethoxyquinazolin-4.-yf)-j(3-(2'-(aminomethyl)-ethynyl)phenyl]-amine;
[(3-ethynylpheny!)-(6-nitroquinazolin-4-yl)-amine;
(6,7-dimethoxyquinazolin-4-yl)-(4-ethynylphenyl)-amine;
(6,7-dimethoxyquinazolin-4-yl)-(3-ethyny!-2-methylphenyl)-amine;
(6-aminoquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(3-ethynylphenyl)-(6-methanesulfonylaminoquinazolin-4-yl)-amine;
(3-ethynylphenyl)-(6,7-methylenedioxyquinazolin-4-yl)-amine;
(6,7-dimethoxyquinazolin-4-yl)-(3-ethynyl-6-methylphenyl)-amine;
(3-ethynylphenyl)-(7-nitroquinazolin-4-yl)-amine;
(3-ethynylphenyl)-[6-(4'-toluenesulfonylamino)-quinazolin-4-yl]-amine;
(3-ethynylphenyl)-{6-[2'-phthalimido-ethan-1'-yl-sulfonylamino]quinazolin-4-yl}-amine;
(3-ethynylphenyl)-(6-guanidinoquinazolin-4-yl)-amine;
(7-aminoquinazolin-4-yl}-(3-ethynylphenyl)-amine;
(3-ethynylphenyl)-(7-methox yquinazolin-4.-yl)-amine;
(6-carbomethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(7-carbomethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine;
[6,7-bis{2-methoxyethoxy)quinazofin-4-ylJ-(3-ethynylphenyf)amine;
(3-azidophenyl)-(6,7-dimethoxyquinazolin-4-yl)amine;
(4-aZidophenyl)-(6,7-dimethoxyquinazolin-4-yl)amine;
(3-azido-5-chlorophenyl)-(6,7-dimethoxyquinazolin-4-yl)amine;
(3-ethynylphenyl)-(6-methansulfc;~yl-quinazolin-4-yl)-amine;
(6-ethansulfanyl-quinazolin-4-yl)-(3-ethynylphenyl)-amine (6,7-dimethoxy-quinazolin-4-yl)-(3-ethynyl-4-fluoro-phenyl)-amine;
(6,7-dimethoxy-quinazolin-4-yl)-[3-propyn-1-yl-phenyl]-amine.
[6,7-bis-(2-methoxy-ethoxy}-quinazolin-4-yl]-(5-ethynyl-2-methyl-phenyl)-amine;
[6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-~-fluoro-phenyl)-amine;
[6,7-bis-(2-chloro-ethoxy)-quinazofin-4-yl]-(3-ethynyl-phenyl)-amine;
WO 96!30347 PCT/IB95/00436 amine;
[6-(2-chloro-ethoxy)-7-{2-methoxy-ethoxy)-quinazoiin-4-yl]-(3-ethynyl-phenyl)-[6,7-bis-(2-acetoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
2-[4-{3-ethynyl-phenylamino)-7-(2-hydroxy-ethoxy)-quinazolin-6-yloxy]-ethanol;
[6-(2-acetoxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
amine;
amine;
amine;
[7-(2-chloro-ethoxy)-6-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-[7-(2-acetoxy-ethoxy)-6-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-2-[4-(3-ethynyl-phenylamino)-6-(2-hydroxy-ethoxy)-quinazolin-7-yloxy]-ethanol;
2-[4-(3-ethynyl-phenylamino)-7-(2-methoxy-ethoxy)-quinazolin-6-yloxy]-ethanol;
2-[4-(3-ethynyl-phenylamino)-6-(2-methoxy-ethoxy)-quinazolin-7-yloxy]-ethanol;
j6-(2-acetoxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-(3-ethynyl-phenyl)-{6-(2-methoxy-ethoxy)-7-[2-(4-methyl-piperazin-1-yl)-ethoxy]-quinazolin-4-yl}-amine;
{3-ethynyl-phenyl)-[7-(2-methoxy-ethoxy)-6-(2-morpholin-4-yl)-ethoxy)-quinazolin-4-yl]-amine;
(6,7-diethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(6,7-dibutoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(6,7-diisopropoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(6,7-diethoxyquinazolin-1-yl)-(3-ethynyl-2-methyl-phenyl)-amine;
j6,7-bis-(2-methoxy-ethoxy)-quinazolin-1-yl]-(3-ethynyl-2-methyl-phenyl)-amine;
(3-ethynylphenyl)-[6-(2-hydroxy-ethoxy)-7-(2-methoxy-ethoxy)-quirrazolin-1-yl]-amine;
and [6,7-bis-(2-hydroxy-ethoxy)-quinazoiin-1-yl]-(3-ethynyl-2-methyl-phenyl)-amine;
2-[4-(3-ethynyl-phenylamino)-6-(2-methoxy-ethoxy)-quinazolin-7-yloxy]-ethanol.
Another aspect of the invention provides a process for preparing a compound of the formula Replacement Qage _7_ CR3>n R
I
~~ N
CR1)m N
wherein misl,2,or3;
each R' is independently selected from hydrogen, halo, hydroxy, amino, hydroxyamino, carboxy, (C,-C4)alkoxycarbonyl, vitro, guanidino, ureido, carbamoyi, cyano, trifluoromethyl, (Re)ZN-carbonyl, and phenyl-W-alkyl wherein W is selected from a single bond, O, S and NH;
or each R' is independently selected from cyano-(C,-C4)-alkyl and R9 wherein R9 is selected from the group consisting of R5, R50, (Re)ZN, R'C(=O), R50NH, A
and RSY; wherein R5 is (C,-C4)alkyl; Re is hydrogen or R5 wherein the R5s are the same or different; R' is R5, R50 or (RB)ZN; A is selected from piperidino-, morpholino, pyrrolidino and 4-Re-piperazin-1-yl, imidazol-1-yl, 4-pyridon-1-yl, carboxy-(C,-C4)-alkyl, phenoxy, phenyl, phenylsulfanyl, (CZ C4)-alkenyi, (Re)2 N-carbonyl-(C,-C4)-alkyl; and Y
is selected from S, SO, SOZ; the alkyl moieties in (RB)zN are optionally substituted with halo or R9 wherein R9 is defined as above, and the alkyl moieties in R~ and R50 are optionally substituted with halo, R80 or R9 wherein R9 and Re are defined as above, and wherein the resulting groups are optionally substituted with halo or R9 with the proviso that a nitrogen, oxygen or sulfur atom and another heteroatom can not be attached to the same carbon atom, and with the further proviso that no more than three "R9"
units may comprise R' ;
or each R' is independently selected from R5-sulfonylamino, phthalimido-(C,-C4)-alkylsulfonylamino, benzamido, benzenesulfonylamino, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, and R' °-(Cz C4)-alkanoylamino wherein R' ° is selected from halo, R80, (CZ C4)-alkanoyloxy, R'C(=O), and (Re)ZN; and wherein said benzamido or benzenesulfonylamino or phenyl or phenoxy or anilino or phenylsulfanyl substituent in AMENDED SHEET
or any two Rls taken together with the carbons to which they are attached comprise a 5-8 membered ring comprising at least one or two heteroatoms selected from oxygen, sulfur or nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic;
R2 is selected from hydrogen and optionally substituted (C1-C6) -alkyl;
n is 1 or 2 and each R3 is independently selected from hydrogen, optionally substituted (C1-C6)-alkyl, optionally substituted amino, halo, hydroxy, optionally substituted hydroxy;
R4 is azido or R11-ethynyl wherein R11 is selected from hydrogen, optionally substituted (C1-C6)-alkyl wherein the substituents are selected from hydrogen, amino, hydroxy, R50 , RSNH and ( RS ) 2N , which comprises:
a) treating a compound of the formula aH o ~~N ~R1) ~NH
NJ or N
wherein R1 and m are as defined above, with CC14 and an optionally substituted triarylphosphine, 8a optionally supported on an inert polymer, of the formula Ar3P
wherein each Ar is an optionally substituted (C6-Clo)aryl group and each of the substituents is independently selected from (C1-C6) alkyl; and b) treating the product of step a) with a compound of the formula Rz ~R~n HN
J
_g_ wherein RZ, R' and n are as defined above, and J is Y or R4, wherein R°
is as defined above, with the proviso that when J is Y then the product of step b) must further be treated with an alkyne.
Yet another aspect of this invention is directed to a method for treating a hyperproliferative disease in a mammal by administering to. a mammal suffering from a hyperproliferative disease, a hyperproliferative disease treating amount of a Formula I
compound.
This invention is also directed to pharmaceutical compositions for the treatment of a hyperproliferative disease in mammals vrhich comprise a hyperproliferative disease treating amount of a compound of the Formula I and a pharmaceutically acceptable carrier.' By halo is meant chloro, bromo, iodo, or fluoro.
By alkyl is meant straight chain, cyclic or branched saturated or unsaturated hydrocarbyl moiety with the proviso that said alkyl must comprise three or more carbon atoms if it is branched or cyclic.
As used herein, the expression "reaction-inert solvent" refers to a solvent which does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.
Other features and advantages will be apparent from the specification and claims which describe the invention.
WO .96/30347 PCT/IS95/00436 SCHEME
X
\
/ / <R3)n <R1)m ' R2 H C~ \ + Y / N/
N H
15 \
<R3)n 2 / /R
N
Y
~ <R1)m HC\N \
_y y _ SCHEME (continued <R3)n 2 / /R
i /
~R1)m H CAN
X
\ i /
CR3)" , / /R2 + HC\ \ <R1)m ~N N
R H
WO 96/30347 PC'T/IB95/00436 _ 12_ Detailed Description of the Invention The Formula I compounds, pharmaceutically acceptable salts and prodrugs thereof (hereafter the active compounds) may be prepared by any process known to be applicable to the preparation of chemically-related compounds. , In general the active compounds may be made from the appropriately substituted quinazoline using the appropriately substituted amine.
As shown in the Scheme the appropriate 4-substituted quinazoline 2 wherein X
is a suitable displaceable leaving group such as halo, aryloxy, alkylsulfinyl, alkylsulfonyl such as trifluoromethanesulfonyloxy, arylsulfinyl, arylsulfonyl, siloxy, cyano, pyrazolo, triazolo or tetrazolo, preferably a 4-chloroquinazoline, is reacted with the appropriate amine or amine hydrochloride 4 or 5, wherein R' is as described above and Y is Br, I, or trifluoromethane-sulfonyloxy in a solvent such as a (C,-Cs)alcohol, dimethylformamide (DMF), N-methylpyrrolidin-2-one, chloroform, acetonitrile, tetrahydrofuran (THF), 1-4 dioxane, pyridine or other aprotic solvent. The reaction may be effected in the presence of a base, preferably an alkali or alkaline earth metal carbonate or hydroxide or a tertiary amine base, such as pyridine, 2,6-lutidine, collidine, N-methyl-morpholine, triethylamine, 4-dimethylamino-pyridine or N,N-dimethylaniline.
These bases are hereinafter refered to as suitable bases. The reaction mixture is maintained at a temperature from about ambient to about the reflux temperature of the solvent, preferably from about 35°C to about reflux, until substantially no remaining 4-haloquinazoline can be detected, typically about 2 to about 24 hours.
Preferably, the reaction is performed under an inert atmosphere such as dry nitrogen.
Generally the reactants are combined stoichiometrically. When an amine base is used for those compounds where a salt (typically the HCI salt) of an amine 4 or 5 is used, it is preferable to use excess amine base, generally an extra equivalent of amine base. (Alternatively, if an amine base is not used an excess of the amine 4 or 5 may be used).
For those compounds whEre a sterically hindered amine 4 (such as a 2-alkyl-3-ethynylaniline) or very reactive 4-haloquinazoline is used it is preferable to use t-butyl ' alcohol or a polar aprotic solvent such as DMF or N-methylpyrrolidin-2-one as the solvent.
Alternatively, a 4-substituted quinazoline 2 wherein X is hydroxyl or oxo (and the 2- nitrogen is hydrogenated) is reacted with carbon tetrachloride and an optionally substituted triarylphosphine which is optionally supported on an inert polymer (e.g.
triphenylphosphine, polymer supported, Aldrich Cat. No. 36,645-5, which is a 29'0 divinylbenzene cross-linked polystyrene containing 3 mmol phosphorous per gram . . resin) in a solvent such as carbon tetrachloride, chloroform, dichloroethane, tetrahydrofuran, acetonitrile or other aprotic solvent or mixtures thereof.
The reaction mixture is maintained at a temperature from about ambient to reflex, preferably from about 35°C to reflex, for 2 to 24 hours. This mixture is reacted with the appropriate amine or amine hydrochloride 4 or 5 either directly or after removal of solvent, for example by vacuum evaporation, and addition of a suitable alternative solvent such as a (C,-C6) alcohol, DMF, N-methylpyrrolidin-2-one, pyridine or 1-4 dioxane.
Then, the reaction mixture is maintained at a temperature from about ambient to the reflex temperature of the solvent preferably from about 35° C to about reflex, until substantially complete formation of product is acheived, typically from about 2 to about 24 hours.
Preferably the reaction is performed under an inert atmosphere such as dry nitrogen.
When compound 4, wherein Y is Br, I, or trifluoromethanesulfonyloxy, is used as starting material in the reaction with quinazoline 2, a compound of formula 3 is formed wherein R', R2, R3, and Y are as described above. Compound 3 is converted to compounds of formula 1 wherein R4 is R"ethynyl, and R" is as defined above, by reaction with a suitable palladium reagent such as tetrakis(triphenylphosphine)palladium or bis(triphenylphosphine)palladium dichloride in the presence of a suitable Lewis acid such as cuprous chloride and a suitable alkyne such as trimethylsilylacetylene , propargyl alcohol or 3-(N,N-dimethylamino)-propyne in a solvent such as diethylamine or triethylamine. Compounds 3, wherein Y is NH2, may be converted to compounds 1 wherein R4 is azide by treatment of compound 3 with a diazotizing agent, such as an acid and a nitrite (e.g., acetic acid and NaN02) followed by treatment of the resulting product with an azide, such as NaN3.
For the production of those compounds of Formula l wherein an R' is an amino or hydroxyamino C roup the reduction of the corresponding Formula I compound wherein R' is nitre is employed.
The reduction may corn~~=niently be carried out by any of the many procedures known for such transformations. The reduction may be carried out, for example, by hydrogenation of the vitro compound in a reaction-inert solvent in the presence of a suitable metal catalyst such as palladium, platinum or nickel. A further suitable reducing agent is, for example, an activated metal such as activated iron (produced by washing iron powder with a dilute solution of an acid such as hydrochloric acid). Thus, for example, the reduction may be carried out by heating a mixture of the vitro compound and the activated metal with concentrated hydrochloric acid in a solvent such as a mixture of water and an alcohol, for example, methanol or ethanol, to a temperature in the range, for example, 50 to 150°C, conveniently at or near 70°C.
Another suitable class of reducing agents are the alkali metal dithionites, such as sodium dithionite, which may be used in (C1-C4)alkanoic acids, (C,-C6)alkanols, water or mixtures thereof.
For the production of those compounds of Formula I wherein Rz or R3 incorpcrates a primary or secondary amino moiety (other than the amino group intended to react with the quinazoline), such free amino group is preferably protected prior to the above described reaction followed by deprotection, subsequent to the above described reaction with 4-(substituted)quinazoline 2.
Several well known nitrogen protecting groups can be used. Such groups include (C,-C6)alkoxycarbonyl, optionally substituted benzyloxycarbonyl, aryloxycarbonyl, trityl, vinyloxycarbonyl, O-nitrophenylsulfonyl, diphenylphosphinyl, p-toluenesulfonyl, and benzyl. The addition of the nitrogen protecting group may be carried out in a chlorinated hydrocarbon solvent such as methylene chloride or 1,2-dichloroethane, or an ethereal solvent such as glyme, diglyme or THF, in the presence or absence of a tertiary amine base such as triethylamine, diisopropylethylamine or pyridine, preferably triethylamine, at a temperature from about 0°C to about 50°C, preferably about ambient temperature. Alternatively, the protecting groups are conveniently attached using Schotten-Baumann conditions.
Subsequent to the above described coupling reaction, of compounds 2 and 5, the protecting group may be removed by deprotecting methods known to those skilled in the arf such as treatment with trifluoroacetic acid in methylene chloride for the tert-butaxycarbonyl protected products.
For a description of protecting groups and their use, see T.W. Greene and P.G.t~l. Wuts, "Protective Groups in Orvanic Synthesis" Second Ed., John Wiley & Sons, New York, 1991. ' For the production of compounds of Formula ! wherein R' or Rz is hydroxy, cleavage of a Formula I compound wherein R' or RZ is (C,-Ca)alkoxy is preferred.
The cleavage reaction may conveniently be carried out by any of the many procedures known for such a transformation. Treatment of the protected formula I
derivative with molten pyridine hydrochloride (20-30 eq.) at 150 to 175°C may be employed for O-dealkylations. Alternatively, the cleavage reaction may be carried out, for example, by treatment of the protected quinazoline derivative with an alkali metal (C,-C4)alkylsulphide, such as sodium ethanethiolate or by treatment with an alkali metal diarylphosphide such as lithium diphenylphosphide. The cleavage reaction may also, conveniently, be carried out by treatment of the protected quinazoline derivative with a boron or aluminum trihalide such as boron tribromide. Such reactions are preferably carried out in the presence of a reaction-inert solvent at a suitable temperature.
Compounds of formula I, wherein R' or RZ is a (C,-C,)alkylsulphinyl or (C,-C4)alkylsulphonyl group are preferably prepared by oxidation of a formula I
compound wherein R' or R2 is a (C,-C4)alkylsulfanyl group. Suitable oxidizing agents are known in the art for the oxidation of sulfanyl to sulphinyl and/or sulphonyl, e. g., hydrogen peroxide, a peracid (such as 3-chloroperoxybenzoic or peroxyacetic acid), an alkali metal peroxysulphate (such as potassium peroxymonosulphate), chromium trioxide or gaseous oxygen in the presence of platinum. The oxidation is generally carried out under as mild conditions as possible using the stoichiometric amount of oxidizing agent in order to reduce the risk of over oxidation and damage to other functional groups.
In general, the reaction is carried out in a suitable solvent such as methylene chloride, chloroform, acetone, tetrahydrofuran or tert-butyl methyl ether and at a temperature from about -25 to 50°C, preferably at or near ambient temperature, i.
e., in the range of 15 to 35°C. When a compound carrying a sulphinyl group is desired a milder oxidizing agents should be used such as sodium or potassium metaperiodate, conveniently in a polar solvent such as acetic acid or ethanol. The compounds of formula I containing a (C,-CQ)alkylsulphonyl group may be obtained by oxidation of the corresponding (C,-CQ)alkylsulphinyl compound as well as of the corresponding (C,-CQ)alkylsulfanyl compound.
Compounds of formula I wherein R' is optionally substituted (C2 C4)alkanoylamino, ureido, 3-phenylureido, benzamido or sulfonamido can be prepared by acylation or sulfonylation of a corresponding compound wherein R' is amino.
Suitable acylating agents are any agents known in the art for the acylation of amino to acylamino, for example, acyl halides, e.g., a (Cz-CQ)alkanoyl chloride or bromide or a _16_ benzoyl chloride or bromide, alkanoic acid anhydrides or mixed anhydrides (e.g., acetic anhydride or the mixed anhydride formed by the reaction of an alkanoic acid and a (C,-C4)alkoxycarbonyl halide, for example (C,-C4)alkoxycarbonyl chloride, in the presence of a suitable base. For the production of those compounds of Formula I wherein R' is ureido or 3-phenylureido, a suitable acyfating agent is, for example, a cyanate, e.g., an alkali metal cyanate such as sodium cyanate, or an isocyanate such as phenyl isocyanate. N-sulfonylations may be carried out with suitable sulfonyl halides or sulfonylanhydrides in the presence of a tertiary amine base. In general the acylation or sulfonylation is carried out in a reaction-inert solvent and at a temperature in the range of about -30 to 120°C, conveniently at or near ambient temperature.
Compounds of Formula I wherein R' is (C,-C~)alkoxy or substituted (C,-C~)alkoxy or R' is (C,-CQ)alkylamino or substituted mono-N- or di-N,N-(C,-C4)alkylamino, are prepared by the alkylation, preferably in the presence of a suitable base, of a corresponding compound wherein R' is hydroxy or amino, respectively.
Suitable alkylating agents include alkyl or substituted alkyl halides, for example, an optionally substituted (C,-C4)alkyl chloride, bromide or iodide, in the presence of a suitable base in a reaction-inert solvent and at a temperature in the range of about 10 to 140°C, conveniently at or near ambient temperature.
For the production of those compounds of Formula I wherein R' is an amino-, oxy- or cyano-substituted (C,-CQ)alkyl substituent, a corresponding compound wherein R' is a (C,-C4)alkyl substituent bearing a group which is displacable by an amino-, alkoxy-, or cyano group is reacted with an appropriate amine, alcohol or cyanide, preferably in the presence of a suitable base. The reaction is preferably carried out in a reaction-inert solvent or diluent and at a temperature in the range of about 10 to 100°C, preferably at or near ambient temperature.
Compounds of Formula I, wherein R' is a carboxy substituent or a substituent which includes a carboxy group are prepared by hydrolysis of a corresponding compound wherein R' is a (C,-C4)alkoxycarbonyl substituent or a substituent which includes a (C,-C4)alkoxycarbonyl group. The hydrolysis may conveniently be performed, for example, under basic conditions, e.g., in the presence of alkali metal hydroxide as illustrated in the accompanying Examples.
Compounds of Formula I wherein R' is amino, (C,-C4)alkylamino, di-[(C,-C4)alkyl]amino, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, 4-(C,-R'~ 96/30347 PCT/IB95/00436 C4)alkylpiperazin-1-yl or (C,-C4)alkysulfanyl, may be prepared by the reaction, in the presence of a suitable base, of a corresponding compound wherein R' is an amine or thiol displaceable group with an appropriate amine or thiol. The reaction is preferably carried out in a reaction-inert solvent or diluent and at a temperature in the range of about 10 to 180°C, conveniently in the range 100 to 150°C.
Compounds of Formula I wherein R' is 2-oxopyrrolidin-1-yl or 2-oxopiperidin-1-yl are prepared by the cyclisation, in the presence of a suitable base, of a corresponding compound wherein R' is a halo-(C2-CQ)alkanoylamino group. The reaction is preferably carried out in a reaction-inert solvent or diluent and at a temperature in the range of about 10 to 100°C, conveniently at or near ambient temperature.
For the production of compounds of Formula I in which R' is carbamoyl, substituted carbamoyl, alkanoyloxy or substituted alkanoyloxy, the carbamoylation or acylation of a corresponding compound wherein R' is hydroxy is convenient.
Suitable acylating agents known in the art for acylation of hydroxyaryl moieties to alkanoyloxyaryl groups include, far example, (CZ-C4)alkanoyl halides, (CZ-C4)alkanoyl anhydrides and mixed anhydrides as described above, and suitable substituted derivatives thereof may be employed, typically in the presence of a suitable base.
Alternatively, (CZ-CQ)alkanoic acids or suitably substituted derivatives thereof may be coupled with a Formula I compound wherein R' is hydroxy with the aid of a condensing agent such as a carbodiimide. For the production of those compounds of Formula in which R' is carbamoyl or substituted carbamoyl, suitable carbamoylating agents are, for example, cyanates or alkyl or arylisocyanates, typically in the presence of a suitable base. Alternatively, suitable intermediates such as the chloroformate or carbonylimidazolyl derivative of a compound of Formula I in which R' is hydroxy may be generated, for example, by treatment of said derivative with phosgene (or a phosgene equivalent) or carbonyldiimidazale. The resulting intermediate may then be reacted v.~ith an appropriate amine ar substituted amine to produce the desired carbamoyl derivatives.
Compounds of formula I wherein R' is aminocarbonyl or a substituted aminocarbonyl can be prepared by the aminolysis of a suitable intermediate in v;hich R' is carboxy.
The activation and coupling of formula I compounds wherein R' is carboxy may be performed by a variety of methods known to those skilled in the art.
Suitable _ 18_ methods include activation of the carboxyl as an acid halide, azide, symmetric or mixed anhydride, or active ester of appropriate reactivity for coupling with the desired amine.
Examples of such types of intermediates and their production and use in couplings with amines may be found extensively in the literature; for example M. Bodansky and A. , Bodansky, "The Practice of Peptide Synthesis", Springer,-Verlag, New York, 1984. The resulting formula I compounds may be isolated and purified by standard methods, such as solvent removal and recrystallization or chromatography.
The starting materials for the above described reaction schemes (e.g., amines, quinazolines and amine protecting groups) are readily available or can be easily synthesized by those skilled in the art using conventional methods of organic synthesis.
For example, the preparation of 2,3-dihydro-1,4-benzoxazine derivatives are described in R. C. Elderfield, W.H. Todd, S. Gerber, Ch. 12 in "Heterocyclic Compounds"
, Vol. 6, R. C. Elderfield ed., John Wiley and Sons, Inc., N.Y., 1957. Substituted 2,3-dihydro benzothiazinyl compounds are described by R.C. Elderfield and E.E. Harris in Ch. 13 of Volume 6 of the Elderfield "Heterocyclic Compounds" book.
Certain Formula I quinazolines can exist in solvated, as well as unsolvated forms, such as the hydrated forms. It is to be understood that the invention encompasses all such solvated, as well as unsolvated forms, which possess activity against hyperproliferative diseases.
A suitable pharmaceutically-acceptable salt of a compound of formula I is, for example, an acid-addition salt of a corresponding compound which is sufficiently basic, e.g., an acid-addition salt with, for example, an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric, phosphoric, methanesulfonic, benzenesulfonic, trifluoroacetic, citric, lactic or malefic acid. A suitable pharmaceutically-acceptable hase-addition salt of a compound of formula I vdhich is acidic is an alkali metal salt, for example, a lithium, sodium or potassium salt; an alkaline earth metal salt, for exG~ople, a calcium or magnesium salt; an ammonium salt; or a salt with an organic base which affords a physiologically-acceptable cation for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyefhyl)amine.
All such salts are within the scope of this invention and they can be prepared by conventional metf iods. For example, they can be prepared simply by contacting the acidic and basic entities, usually in a stoichiometric ratio, in either an aqueous, non-aqueous or partially aqueous medium, as appropriate. The salts are recovered by WO 96/30347 PCTlIB95/00436 _19_ filtration; by precipitation with a non-solvent, preferably an etheral or hydrocarbon solvent, followed by filtration and by evaporation of a solvent, or, in the case of aqueous solutions, by lyophilization.
. Some of the compounds of Formula I have asymmetric carbon atoms. Such diasteromeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known er se., for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiotners. All such isomers, including diastereomers mixtures and pure enantiomers are considered as part of the invention.
The active compounds of this invention are potent inhibitors of the erbB
family of oncogenic and protooncogenic protein tyrosine kinases such as epidermal growth factor receptor (EGFR), erbB2, HER3, or HER4 and thus are all adapted to therapeutic use as antiproliferative agents (e.g., anticancer) in mammals, particularly humans. In particular, the compounds of this invention are therapeutants or prophylactics for the treatment of a variety of human tumors (renal, liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblastomas, various head and neck tumors), and other hyperplastic conditions such as benign hyperplasia of the skin (e.g., psoriasis) or prostate (e.g., BPH). It is, in addition, expected that a quinazoline of the present invention may possess activity against a range of leukemias and lymphoid malignancies.
The active compounds may also be expected to be useful in the treatment of additional disorders in which aberrant expression ligand/receptor interactions, activation or signalling events related to various protein tyrosine kinases, whose activity is inhibited by the agents of Formula I, are involved.
Such disorders may include those of neuronal, glial, astrocytal, hypothalamic, and other glandular, macrophagal, epithelial, stromal, and blactocoelic nature in which aberrant function, expression, activation or signalling of the erbB tyrosine kinases may be involved. In addition, compounds of Formula I may have therapeutic utility in inflammatory, angiogenic and immunologic disorders involving both identified and as yet unidentified tyrosine kinases which are inhibited by compounds of Formula I.
The in vitro activity of the active compounds in inhibiting the receptor tyrosine kinase (and thus subsequent proliferative response, e.g., cancer) may be determined by the procedure detailed below.
Activity of the active compunds, in vitro, can be determined by the amount of inhibition of the phosphorylation of an exogenous substrate (e.g., Lys, -Gastrin or polyGluTyr (4:1 ) random copolymer (I. Posner et. al., J. Biol. Chem. 267 (29), 20638-47 (1992)) on tyrosine by epidermal growth factor receptor kinase by a test compound relative to a control. Affinity purified, soluble human EGF receptor (96 ngj is obtained according to the procedure in G. N. Gill, W. Weber, Methods in Enzymolo~c y 146, 82-88 (1987) from A431 cells (American Type Culture Collection, Rockville, MD) and preincubated in a microfuge tube with EGF (2Ng/ml) in phosphorylation buffer +
vanadate (PBV: 50 mM HEPES, pH 7.4; 125 mM NaCI; 24 mM MgCll; 100 NM sodium orthovanadate), in a total volume of 10 NI, for 20-30 minutes at room temperature. The test compound, dissolved in dimethylsulfoxide (DMSO), is diluted in PBV, and 10 NI is mixed with the EGF receptor /EGF mix, and incubated for 10-30 minutes at 30°C. The phosphorylation reaction is initiated by addition of 20 NI "P-ATP/ substrate mix (120 NM
Lys3-Gastrin (sequence in single letter code for ammo acids, KKKGPWLEEEEEAYGWLDF), 50 mM Hepes pH 7.4, 40 NM ATP, 2 uCi y-[''P]-ATP) to the EGFr/EGF mix and incubated for 20 minutes at room temperature. The reaction is stopped by addition of 10 NI stop solution (0.5 M EDTA, pH 8; 2mM ATP) and 6 NI ZN
HCI. The tubes are centrifuged at 14,000 RPM, 4°C, for 10 minutes. 35 ,u1 of supernatant from each tube is pipetted onto a 2.5 cm circle of Whatman P81 paper, bulk washed four times in 5°o acetic acid, 1 liter per wash, and then air dried. This results in the binding of substrate to the paper with loss of free ATP on washing. The [3'P] incorporated is meas;.~red by liquid scintillation counting.
Incorporation in the absence of substrate (e.g., lys~-gastrin) is subtracted from all values as a background and percent inhibition is calculated relative to controls without test compound present.
Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate ICSO value for the in vitro inhibition of EGFR
kinase activity. Although the inhibitory properties of the compounds of Formula I
vary with structural change as expected, the activity generally exhibited by these agents, determined in the manner described above, is in the range of ICS°=0.0001-30 uM.
*Trade-mark Activity of the active compounds, in vivo, can be determined by the amount of inhibition of tumor growth by a test compound relative to a control. The tumor growth inhibitory effects of various compounds are measured according to the methods of Corbett T. H., et al. "Tumor Induction Relationships in Developri~ent of Transplantable Cancers of the Colon in Mice for Chemotherapy Assays, with a Note on Carcinogen Structure", Cancer Res., 35, 2434-2439 (1975) and Corbett, T. H., et al., "A
Mouse Colon-tumor Model for Experimental Therapy", Cancer Chemother. Rep. Part 2~, 5, 169-186 (1975), with slight modifications. Tumors are induced in the left flank by s.c.
injection of 1 X 10B fog phase cultured tumor cells (human MDA-MB-468 breast or human HN5 head and neck carcinoma cells) suspended in 0.10 ml RPM/ 1640. After sufficient time has elapsed for the tumors to become palpable (2-3 mm in diameter) the test animals (athymic mice) are treated with active compound (formulated by dissolution in DMSO typically at a concentration of 50 to 100 mg/mL followed by 1:9 dilution into saline or, alternatively, 1:9 dilution into 0.1% Pluronic P105 in 0.9°.6 saline) by the intraperitoneal (ip) or oral (po) routes of administration twice daily (i.e., every 12 hours) for 5 consecutive days. In order to determine an anti-tumor effect, the tumor is measured in millimeters with Vernier calipers across two diameters and the tumor size (mg) is calculated using the formula: Tumor weight = (length x jwidth]2)/2, according to the methods of Geran, R.1., et al. "Protocols for Screening Chemical Agents and Natural Products Against Animal Tumors and Other Biological Systems", Third Edition, Cancer Chemother. Rep., 3, 1-104 (1972). . Results are expressed as percent inhibition, according to the formula: Inhibition (%) _ (TuW~o"t,o~ -TuW,as,)/TuW~o"t,a~ x 100. The flank site of tumor implantation provides reproducible dose/response effects for a variety of chemotherapeutic agents, and the method of measurement (tumor diameter) is a reliable method for assessing tumor growth rates.
Administration of the active compounds can be effected by any method which enables delivery of the compounds to the site of action (e.g., cancer cells).
These methods include oral routes, intraduodenal rou'...s, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical administration, etc.
The amount of active compound administered will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgement of the prescribing physician. However an effective dosage is in the range of approximately 0.001-100 mg/kg, preferably 1 to 35 mg/kg in single or divided doses. For an average 70kg human, this would amount to 0.05 to 7 g/day, preferably 0.2 to 2.5 g/day.
The composition may, for example, be in a form suitable for oral administration , 5. as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parentera! injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
Pharmaceutical compositions according to the invention may contain 0.1 %-959'0 of the compound, preferably 1 %-70%. In any event, the composition or formulation to be administered will contain a quantity of active compound in an amount effective to alleviate or reduce the signs in the subject being treated, i.e., hyperproliferative diseases, over the course of the treatment.
Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.
Suitable pharmaceutical carriers include inert diluents orfillers, water and various organic solvents. The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the tike. Thus for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia.
Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Preferred materials, therefor, include lactose or milk sugar and high molecular weight polyethylene glycols.
When aqueous suspensions or elixirs are desired for oral administration the active compound therein may be combined with various sweetening or flavoring agents, coloring matters R'O 96/30347 PCT/IB95/00436 or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.
Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent, to those skilled in this art.
For examples, see Remington's Pharmaceutical Sciences., Mack Publishing Company, Easter, Pa., 15th Edition (1975).
The hyperprotiferative disease treatment described above may be applied as a sole therapy or may involve, in addition to the active compound, one or more other antitumor substances. Such conjoint treatment may be achieved by way of the simultaneous, sequential, cyclic or separate dosing of the individual components of the treatment.
High pressure liquid chromatography (HPLC) used in the following examples and preparations was effected according to the following method unless modified in specific examples. Perkin-Elmer Pecosphere 3X3C cartridge column (3mm X 3cm, C18;
available from Perkin Elmer Corp., Norwalk, CT 06859) with a Brownlee (trademark) RP-8 Newguard precolumn (7 micron, 3.2mm X l5mm, available from Applied Biosystems inc. San Jose, CA 95134) which was previously equilibrated in pH 4.50, 200 mM
ammonium acetate buffer. Samples were eluted using a linear gradient of 0-100%
acetonitrile/pH4.50, 200 mM NHQ acetate over 10 minutes with a flow rate of 3.0 ml.~min. Chromatograms were generated over the range 240-400nm using a diode array detector.
It should be understood that the invention is not limited to the particular embodiments shown and described herein, but that various changes and modifications may be made without departing from the spirit and scope of the invention as defined by the claims.
(4-Azidophenyl)-(6.7-dimethoxyqu_inazolin-4-ylLamine hydrochloride ~;-Chloro-6,7-dimethoxyquinazoline (250 mg, 1.12 mmol) and 4-azidoaniline ' hydrochloride (200 mg, 1.11 mmol) were refluxed in 10 mL of isopropyl alcohol for 0.5 hour, cooled and filtered to afford solid title product which was vrashed with 10 ml_ of isopropyl alcohol and dried in vacuo, at 70°C, 392 mg (98%); mp 200-205°C (dec).
WO 96/30347 PCT/IB95/004.36 (6.7-Dimethoxyquinazolin-4-yl}-(3-ethynylphenyll-amine hydrochloride 4-Chloro-6,7-dimethoxyquinazoline (250 mg, 1.12 mmol) and 3-ethynyl-aniline (137 mg, 1.17 mmol) were refluxed in 10 mL of isopropyl alcohol for 0.5 hour, cooled and filtered to afford solid title product which was washed with 10 mL of isopropyl alcohol and dried in vacuo, at 70 ° C, 338 mg (99%); mp 269-270 ° C.
,(6 7-Dimethox rLguinazolin-4-yl)-(3-(3'-hydroxypropynl-yl)phenyll-amine A mixture of (3'-bromophanyl)-(6,7-dimethoxyquinazolin-4-yl)-amine hydrochloride (250 mg, 0.591 mmol), tetrakis(triphenylphosphine)palladium (100 mg), propargyl alcohol (600~L), 7 mL of dry, nitrogen purged diethylamine and cuprous iodide (10 mg) was refluxed for 5 hours, cooled and filtered to afford solid title product which was washed two times with 2mL of 50°~ diethylamine: methanol; 136 mg. The solid was recrystallized from methanol to give pure title product after drying, in vacuo" at 70°C, 73 mg (37~); mp 267-268°C.
j(3-(2'-Aminomethyl-ethyn rLl)phenyll-(6 7-dimethoxyguinazolin-4-yl)-amine hydrochloride The title product of Example 3 (50 mg, 0.149 mmol}, triphenylphosphine (60 mg, 0.225 mmol)), phthalimide (165 mg, 1.12 mmol) and diethyl azodicarboxylate (36 iuL, 0.228 mmol) were stirred at room temperature in 3 mL of dry tetrahydrofuran for 16 hours. The reaction mixture was concentrated to a solid and flash chromatographed on silica gel eluted with 15% acetone:methylene chloride to afford pure solid j3-(2' {phthalimidomethyl}-ethynyl)phenyl]-(6,7-dimethoxyquinazoline-4-yl)amine which was converted to its hydrochloride salt by addition of 1 mL of anhydrous 1 M HCI
in methanol followed by 3 mL of isapropyi alcohol. The salt was collected by filtration, dried and used immediately in the next step; 15 mg. This 15 mg, 0.0323 mmol was treated with 0.5 ml of hydrazine hydrate and 1 mL of methanol for 0.5 hours.
The reaction mixture was evaporated, in vacuo, and the product isolated by flash chromatography eluted with 10% methanol in rnethylene chloride. Pure title product Was isolated after conversion to its hydrochloride salt with 1 mL of i M HCI
in methanol, precipitation with isopropyl alcohol and diethyl ether and drying , in vacuo,;
5.6 mg (47°~) mp 275 ° C dec.
~3-Ethynylphenyl)-(6-nitroquinazolin-4-yl)-amine hydrochloride 4-Chloro-6-nitroquinazoline (1.06 g, 5.00 mmol) and 3-ethynylaniline (1.00 g, 5.30 mmol) were refluxed in 10 mL of isopropyl alcohol for 3 hours,' cooled and, after 16 hours at room temperature, filtered to afford solid title product which was washed with mL of isopropyl alcohol and dried iri vacuo, at 70°C, 1.27 g (78%); mp 255-256°C.
(6,7-Dimethoxyquinazolin-4 ~y~4-ethynylphenyl)-amine The title product was prepared in the following three step sequence without 10 purification of the intermediates. 4-Chloro-6,7-dimethoxyquinazoline (250 mg, 1.113 mmol) and 4-iodoaniline (268 mg, 1.224 mmol) were refluxed in 10 mL of isopropyl alcohol for 3 hours, cooled to room temperature and filtered to afford solid (4 iodophenyl)-(6,7-dimethoxyquinazoline-4.-yl)aminehydrochloridewhichwaswashedwith 10 mL of isopropyl alcohol and dried in vacuo at 70°C, 396 mg (76°.6). A mixture consisting of (4'-iodophenyl)-(6,7-dimethoxyquinazoline-4-yl)amine hydrochloride (250 mg, 0.564 mmol), tetrakis(triphenylphosphine)palladium (50 mg), trimethylsilylacetylene (160NL, 1.13 mmol), 4 mL of dry, nitrogen purged diethylamine and cuprous iodide (10 mg) was refluxed for 2 hours, cooled and concentrated in vacuo, to afford a residue which was partitioned between chloroform and 1 N HCL. Solid [4-(2'-{trimethylsilyl}-ethynyl)phenyl]-(6,7-dimethoxyquinazoline-4-yl)amine formed at the interface of the two liquid phases and was filtered and dried in vacuo; 170 mg (80%).
[4-(2'-{Trimethylsilyl} ethynyl)phenyl]-(6,7-dimethoxyquinazoline-4-yl)amine (100 mg, 0.265 mmol) and anhydrous potassium carbonate (125 mg, 0.906 mmol) were stirred in 3 mL of methanol and 1 mL of vrater at room temperature for 2.5 hours. The reaction mixture was concentrated in vacuo, and partitioned betGVeen 20 mL of chloroform and 20 mL of 1 N hydrochloric acid. The organic layer was dried with magnesium sulfate, filtered and vacuum evaporated to give the title product which was triturated with diethyl ether and dried in vacuo at 70°C; 81 mg (90%) mp 239°G dec.
L6,7-Dimethoxyquinazolin-4-yl',~3-ethy ~I-2-methylphenyl)-amine The title product was prepared in the following three step sequence with out purification of the intermediates. A mixture consisting of 3-bromo-2-methylaniline (1.00 g, 5.37 mmol), tetrakis(triphenylphosphine)palladium (200 mg), trimethylsilylacetylene (1.053 g, 10.75 mmol), lOmL of dry, nitrogen purged diethylamine and cuprous iodide 910 mg) was refluxed for 16 hours, cooled and concentrated, in vacuo, to afford a residue which was partitioned between chloroform and 1 N HCL. The organic layer was washed with brine, dried with magnesium sulfate and vacuum evaporated to yield a residue, 3-[2'-(trimethylsilyl)ethynyl]-2-methylaniline which was purified by flash chromatography on silica gel eluted with 1:1 hexanes: methylene chloride; 200 mg (18~).
4-Chloro-6,7-dimethoxyquinazoline (104 mg, 0.466 mmol) and 3-[2'-(trimethylsilyl)ethinyl]-2-methylaniline (100 mg, 0.491 mmol) were refluxed in 3 mL of isopropyl alcohol for 16 hour, cooled to room temperature and filtered to afford a residue of solid ~3-(2'-(trimethylsilyl)ethynyl]-2'-methylphenyl]}-(6,7-dimethoxyquinazoline-4-yl)amine hydrochloride which was washed with 10 mL of isopropyl alcohol and triturated for 16 hours with diethyl ether. Thin layer chromatography on silica gel eluted with 9:1 chloroform: methanol indicated that the residue was impure product. The residue was purified by flash chromatography on silica gel eluted with 9:1 methylene chloride: methanol to afford after concentration and drying , in vacuo, pure product, 64 mg (33%). The product was dissolved in 3 mL of methanol and treated with 64 mg of anhydrous potassium carbonate at room temperature for 3 hours. The reaction mixture was concentrated in vacuo and partitioned between 1 N HCI and chloroform. Solid title product formed at the interface of the two liquid phases and was filtered and dried, in vacuo,; 40 mg (84%) mp 225°C
dec.
16-Amino-quinazolin-4-yy ~3-ethynylphenyl)-amine (3-Ethynyl-phenyl)-(6-nitro-quinazolin-4-yl)-amine hydrochloride (500 mg, 1.50 mmol) was dissolved in 10 mL of formic acid and treated portion-wise with sodium 5, dithionite (1.10 g, 6.28 mmol) at room temperature. After 2 hours the mixture was quenched with 120 mL of water and filtered. The filtrate was evaporated in vacuo to a residue which was dissolved in 100 mL of 1:1 methanol:chloroform, filtered and evaporated in vacuo to a second residue. This was triturated with 200 mL of 5%
sodium bicarbonate for 30 minutes, filtered,washed with water and dried in vacuo for 16 hours.
Flash chromatography on silica gel eluted with ethyl acetate afforded pure (6-amino-quinazoiin-4-yl)-(3-ethynylphenyl)-amine ; 140 mg (34%); mp 165 °C dec.
13-Ethynylphenyl)-(6-methanesulfor~laminoguinazolin-4-y~-amine The title product of Example 8 (100 mg, 0.384 mmol), pyridine (140 frL, 1.68 mmol) and methanesulfonyl chloride (99 NL, 1.26 mmol) were refluxed in 10 mL
of 1,2-dichloroethane for 7 hours. The reaction mixture was cooled and evaporated in a vacuo to a residue which was triturated in 10 mL of 1 N HCI, filtered and dried in vacuo toyield(3-ethynylphenyl)-(6-methanesulfonylaminoquinazoline-4-yl)amine;102mg(78%) mp 248°C dec.
~3-Ethynylphenyl)-(6.7-methylenedioxyquinazolin-4-yl)-amine hydrochloride 4-Chloro-6,7-methylenedioxyquinazoline (200 mg, 1.04 mmol) and 3 ethynyianiline (127 mg, 1.09 mmol) were refluxed in 5 mL of isopropyl alcohol for 16 hour, cooled and filtered to afford solid title product which was washed with 10 mL of isopropyl alcohol and dried in vacuo at 70°C, 266 mg (79%); mp >350°C.
~(6,7-Dimethoxyguinazolin-4-yl)-3-ethynyl-6-n~~thviphenvl)-amine hydrochloride The title product was prepared in the follov;ring three step sequence v,~ifhout ' purification of the intermediates. A mixture consisting of 4-bromo-2-nitrotoluene (1.50 g, 6.94 mmol) tetrakis(triphenylphosphine)palladium (750 mg), trimethylsilylacetylene (3.00 mL, 21.21 mmol) and cuprous iodide (20 mg) in 20 mL of nitrogen purged, dry diethylamine was refluxed for 2 hours, cooled and concentrated, in vacuo, to afford a residue which was partitioned between 100 mL of ethyl acetate and 100 mL of 1 N HCI.
WO 96/30347 PC'T/IB95/00436 The organic layer was washed two times with 50 mL of 1 N HCI followed by brine, dried with magnesium sulfate and vacuum evaporated to a residue. The residue was dissolved in 10 mL of ethyl acetate and diluted with 200 mL of petroleum ether. The solids were filtered off. and the oil, obtained upon vacuum evaporation of the filtrate, , solidified to give 4-[2'-(trimethylsilyl)ethinyl]-2-nitrotoluene. This product was reduced to the amino product by treatment with iron powder (1.76 g, 98.5 mmot) in 30 mL of methanol and 5 mL of concentrated hydrochloric acid at 80°C for 2 hours. The cooled reaction mixture was filtered through Celite' and the filtrate was evaporated in vacuum.
The residue was partitioned between ethyl acetate and 5% aaueous sodium bicarbonate. The organic layer was washed with brine, dried with magnesium sulfate, filtered and vacuum evaporated to yield an oil, 5-[2'-(trimethylsilyl)ethynyl)-methylaniline which solidified upon standing: 1.37 g.
The above product (185 mg, 0.909 mmol) and 4-chloro-6,7-dimethoxy quinazoline (200 mg, 0.890 mmol) were refluxed in tent-butyl alcohol for 16 hours. After cooling the reaction mixture was filtered to yield pure [2-methyl-5-(2' {trimethylsilyl}ethynyl)-phenyl]-(6,7-dimethoxyquinazofine-4-yl-amin~ydrochlorideafter washing with ether and drying in vacuum; 326 mg (85%). The trimethylsilyl group was removed by dissolving the above product in 5 mL of methanol and 1 mL of water and treatment with potassium carbonate (320 mg). After stirring for 1 hour the mixture was filtered and concentrated in vacuo. The residue thus obtained was partitioned between 100 mL of methylene chloride and 100 mL of 1 N HCI. The aqueous layer was extracted with an additional 100 mL of methylene chloride. The pooled organic layers were dried with magnesium sulfate, filtered and vacuum evaporated to a residue which was dissolved in anhydrous 1 N HCI in methanol, concentrated and precipitated with ether.
The solid title product was collected by filtration and washed with diethyl ether then dried in vacuo at 70 ° C; 236 mg (88%) mp 266-267 ° C.
j3-Ethyn~phenyl)-(7-nitroc,~uinazolin-4-y~-amine hydrochloride 4-Chloro-7-nitroquina: olive (7.97 g, 38.0 mmol) and 3-ethynylaniline (4.54 g, 38.8 mmol) were refluxed in 125 mL of iert-butyl alcohol for 3 hours, cooled to room temperature and filtered to afford the title product as a solid which was washed with 10 mL of isopropyl alcohol and dried in vacuo at 70°C, 9.95g (80%); mp 209-210°C dec.
(3-Ethynylphenyl)-f6-(4'-toluenesulfonylamino)-quinazolin-4~r11-amine hydrochloride The title product of example 8 (0.201 mg, 0.774 mmol) and 4-toluenesulfonyl chloride (0.441 mg, 2.31 mmol) were refluxed in 3 mL of 1,2-dichloroethane and 0.5 mL
5, of pyridine for 5 minutes. The reaction mixture was cooled to room temperature, diluted with 75 mL of ethyl acetate and washed two times with 75 mL of water once with 75 mL of 3% sodium bicarbonate and once with 75 mL of brine. The organic layer was dried with magnesium sulfate, filtered and vacuum evaporated to a residue which was purified by chromatography using a Chromatotron (trademark) eluted with ethyl acetate, to afford solid title product; 86.7 mg (27%) mp 220-222 ° C.
j3-Ethynylphenyl)-f 6-f2'-phthalimido-ethan-1'-ylsulfonylarninolauinazofin-4-vl~-amine hydrochloride The title product of example 8 (0.20 mg, 0.768 mmol) and 2-phthalimido-1-ethanesulfonyl chloride (0.615 mg, 2.25 mmol) were refluxed in 2 mL of 1,2-dichloroethane and 0.5 mL of pyridine for 16 hours, cooled to room temperature, diluted with 100 mL of chloroform and washed with 50 mL of 3% sodium bicarbonate and 50 mL of brine. The organic layer was dried with magnesium sulfate, filtered and vacuum evaporated to a residue which was dissolved in minimal methylene chloride and precipitated with petroleum ether, 188 mg. The precipitate was purified by chromatography using Chromatotron@ eluted with ethyl acetate, to afford the title product as a solid ; 53.4 mg (14%) mp 197 - 200°C.
j3-Ethyny(phenyl)-(6-auanidinoquinazolin-4_yl)-amine h~rdrochloride The title product of example 8, (0.302 mg, 1.16 mmol} and 3,5-dimethylpyrazole-1-carboxamidine (0.328 mg, 2.36 mmol) were ref(uxed in 10 mL of 1,2-dichloroethane and 0.97 mL of acetic acid for 24 hours, cooled to room temperature and filtered to yield the crude acetate of the title product. The product was ~!issolved in 35 mL of ' methanol and treated with 15 mL of anhydrous 1 N HCI in methanol for 15 minutes and then precipitated vrith 75 mL of diethyl ether. Solid title product was collected by filtration and dried in vacuo at 70°C; 91.2 mg (23%) mp>400°C.
WO 96/30347 PC'T/IS95/00436 j7-Aminoquinazolin-4.-yl)-(3-ethynylpheny~-amine The title product of example 12 (1.039 g, 3.18 mmol) was dissolved in 50 mL of tetrahydrofuran, 10 mL of methanol and 5 mL of chloroform at 50°C.
Sodium 5, dihydrogen phosphite (NaH2P02, 3.822 g, 36 mmol) and 10% palladium on carbon (0.19 g) were added followed by dropwise addition of 10 mL of water. When 3 mL
of water had been added the mixture became noticeably more homogeneous. After 1 hour the mixture was filtered through Celite. The Celite was washed thoroughly with methanol and chloroform. The combined organic solutions were vacuum evaporated to a residue which was triturated with water, 3% aqueous sodium bicarbonate and filtered. The solid title product was washed with water then diethyl ether and dried in vacuo, 1.054 gm (127%, wet). A portion of the above product was recrystallized from a minimum amount of hot ethanol and water to give, after removal of a small first crop of impure material, pure title product, (43%), mp 180°C (dec).
13-Ethynylphenyll-(7-methoxyquinazolin-4-yl)-amine hydrochloride 4-Chloro-7-methoxyquinazoline (274 mg, 3.72 mmol) and 3-ethynylaniline (436 mg, 3.72 mmol) were refluxed in 15 mL of tert-butyl alcohol for 3 hours, cooled and filtered to afford solid title product which was washed with 10 mL of isopropyl alcohol and dried in vacuo at 70°C, 977 mg (84%); mp 229-231 °C.
16-Carbomethoxyctuinazolin-4-yl)-f3-ethynylphenyl -amine hydrochloride 4-Chloro-6-carbomethoxyquinazoline (100 mg, 0.450 mmol) and 3-ethynylaniline hydrochloride (53.4 mg, 0.456 mmol) were refluxed in 2 mL of tert-butyl alcohol for 2 hours, cooled, diluted with 2 mL of isopropyl alcohol and filtered to afford solid title product which u~as washed with 10 mL of diethyl ether and dried , in vacuo, at 70°C, 122 mg (80%); mp 232-233°C (dec).
R'O 96/30347 PCT/IB95/00436 (7-Carbomethoxyquinazolin-4-yIL~3-ethynylphenyl)-amine hydrochloride 4-Chloro-7-carbomethoxyquinazoline (202 mg, 0.907 mmol) and 3-ethynylaniline (110 mg, 0.939 mmol) were refluxed in 4 mL of tert-butyl alcohol for 2 hours, cooled, diluted with 4 mL of isopropyl alcohol and filtered to afford solid title product which was washed with 10 mL of diethyl ether and dried , in vacuo, at 70°C, 248 mg (8096); mp 219.5-221 ° C.
j6-,7-Bis-(2-methoxyethoxy)-quinazolin-4y11-(3-ethyn~,rphenyl)amine hydrochloride 3-Ethynylaniline (37 mg, 0.32 mmol.), and 4-chloro-6,7-bis-(2-methoxy-ethoxy)-quinazoline (90 mg, 0.29 mmol) were added to isopropanol (1.5 mL) containing pyridine (25 ~rL, 0.32 mmol) and the mixture was refluxed 4 hours under an atomospher of dry nitrogen. The solvent was removed , in vacuo, and the residue partitioned between 109'° methanol in CHCI3 and saturated aqueous NaHC03. The organic phase was dried over Na2S04, filtered and concentrated in vacuo. The residue was flash chromatographed on silica using 30% acetone in hexanes to afford 81 mg of the free base of the title product as a pale yellow solid. The free-base was dissolved in a minimum volume of CHCI3, diluted with several volumes of ether, and titrated with 1 M
HCI in ether to precipitate the title product as its hydrochloride salt; 90 mg; 71 %; mp 228-230 ° C.
(3-Azido~henyl~~6,7-dimethox rLQUinazolin-4=y)amine 4-Chloro-6,7-dimethoxyquinazoline (5.01 g, 22.3 mmol) was added in portions, over 1.5 hours, to m-phenylenediamine (2.66 g, 24.6 mmol) in refluxing isopropanol (100 mL} under an atmosphere of dry nitrogen. After the addition was complete the mixture was heated at reflux for 4 hours. The mixture was cooled to 20°C, and the precipitate was filtered, washed trt~ith chilled isopropanol and dried in vacuo to aficrd 6.97 g (93%) of (3-aminophenyl)-(6,7-dimsthoxyquinazolin-4-yl)amine hydrochloride (LC-a MS: 297 (MH+}. To a solution of the above product (50 mg, 0.169 mmol) in 8090 acetic acid/H20 (2 mL), at 0°C, was added a solution of NaN02 (18.4 mg, 0.186 mmol) in Hz0 (i00 ~rL). After stirring 10 minutes at 0°C a solution of NaN3 (12 mg, 0.185 rnmol) io H20 (100~L) was added. The mixture was allowed to warm to 20°C and stirred for 1.5 hours. The reaction mixture was lyophilized and the residue partitioned between ethyl WO 96/30347 PCT/1895/004~6 acetate and saturated aqueous NaHC03. The organic phase was wahsed further with brine, dried over Na2S04, filtered, and concentrated , in vacuo,.
Recrystallization from , CHCI3/hexanes afforded 36 mg of the title product as a white solid; mp 110-113°C.
5. (3-Azido-5-chlorophenyl)=(6 7-dimethoxyQUinazolin-4-yl)amine 4-Chloro-6,7-dimethoxyquinazoline (200 mg, 0.89 mmol) and 5-amino-3-chloroaniline (253 mg, 1.78 mmol) were combined in isopropanol (3 mL) and heated to reflux for 16 hours under an atmosphere of dry nitrogen. After cooling to 20°C the mixture was diluted with methanol (5 mL} and the resulting precipitate was filtered and dried, in vacuo, to afford 252 mg (77%) of (3-amino-5-chlorophenyl}-(6,7-dimethoxyquinazolin-4-yl)amine hydrochloride (mp. 298-301 °C; LC-MS:
331 (MH+)).
A portion of this product (175 mg, 0.476 mmol) was dissolved in 80% acetic acid/Hz0 (12 mL), cooled to 0°C, and a solution of NaN02 (36 mg, 0.516 mmol) in HZO (300 /rL) was added. The solution was stirred for 10 minutes at 0°C and NaN3 (33 mg, 0.50 mmol) in HZO (300 ~rL) was added. The reaction mixture was allowed to warm to 20 ° C
and stirred 16 hours. The resulting precipitate was filtered and dissolved in 10%
methanol in CHCI3 and the solution was washed with saturated aqueous NaHC03, and brine, dried over Na2S04, filtered and concentrated in vacuo to yield 59 mg (35~°) of the title product as a yellow solid; mp 205-206°C.
L3-Ethynylphenyl)-t6-methanesulfonyl-quinazolin-4-yl)-amine hydrochloride 6-Methanesulfonyl-quinazolin-4-one (200 mg, 0.89 mmol}, triphenyl phosphine (566 mg, 2.15 mmol) and carbon tetrachloride (815 NL, 8.92 mmol} were refluxed in 3 mL of chloroform for 3.5 hours. The solvent was vacuum evaporated to afford a residue.
This was dissolved in 5 mL of isopropyl alcohol and 3-ethynylaniline (156 mg, 1.33 mmol) and heated at reflux for 16 hours. The cooled reaction mixture was filtered,washed with a minimum of cold isopropyl alcohol and dried in vacuo at 70 °C
for 16 hours to afford pure title product; 63 mg (20%) rnp 281-282 °C.
WO 96/30347 PCTlIB95/00436 (6-Ethansulfanyl-quinazolin-4-y~y3-eth r~nypheny,-amine hydrochloride 6-Ethanesulfanyl-quinazolin-4-one (100 mg, 0.48 mmol), triphenyl phosphine (305 mg, 1.16 mural) and 3 mL of carbon tetrachloride were refluxed for 16 hours. The solvent was vacuum evaporated to afford a residue. This was dissolved in 5 mL
of isopropyl alcohol and 3-ethynylaniline (68 mg, 0.58 mmol) and heated at reflux for 1 hour. The cooled reaction mixture was filtered, washed with a minimum of cold isopropyl alcohol and dried in vacuo at 70°C for 16 hours to afford pure title product;
70 mg (42%) mp 239-40°C.
56.7=Dimethoxy-guinazolin-4=yl)-(3-ethynyl-4-fluoro-phenyl)-amine hydrochloride 4-Chloro-6,7-dimethoxyquinazoline (500 mg, 2.23 mmol) and 3-(2'-trimethylsilyl-ethynyl)-4-fluoroaniline (507 mg, 2.44 mmol) were refluxed in 5 mL of tert-butyl alcohol for 16 hours, cooled and filtered to afford solid (6,7-dimethoxy-quinazolin-4-yl)-(3'-ethynyl-phenyl)-amine hydrochloride which was washed with 10 mL of isopropyl alcohol and dried in vacuo at 70 °C, 832 mg (83%). This was reacted in 10 mL of methanol and 1 drop of water containing 250 mg of potassium carbonate for 3 hours. The mixture was filtered and the filtrate vacuum evaoprated. This residue was triturated for 1 hour with 1 N hydrochloric acid, filtered and washed with a minimum amount of water then methanol and dried in vacuo; 506 mg (63%) mp 229°C dec.
3-(2'-Trimethylsilyl-ethynyl)-4-fluoroaniline, used above, was prepared from 3-bromo-4.-fluoroaniline (7.0 gm, 36.8 mural) tetrakis(triphenylphosphine)palladium (1.4 gm), trimethylsilyl-acetylene (7.2 gm, 74 mmol) and cuprous iodide (40 mg) in 140 mL
of nitrogen purged dry diethylamine at reflux for 16 hours. The cooled reaction mixture was filtered through Celite and the Celite washed with ether. The combined filtrates were vacuum evaporated to a residue which was purified by clash chromatography on silica gel eluted with 35% hexanes in methylene chloride. Fractions containing the pure 3-(2'-trimethylsilyl-ethynyl)-4-fiuoroaniline vrere vacuum evaporated to a residue and used without further purification.
16,7-Dimethoxy-guinazolin-4-yl)-!3-hropyn-1-yl)phenyl)-amine hydrochloride 4-Chloro-6,7-dimethoxyquinazoline (585 mg, 2.60 mmol) and 3-(propyn-1 yl)aniline (361 mg, 2.74 mmol) were refluxed in 5 mL of tert-butyl alcohol for 16 hours, cooled and filtered to afford solid (6,7-dimethoxy-quinazolin-4-yl)-[3-(propyn-yl)phenyl)J-amine hydrochloride which was washed with 5 mL of isopropyl alcohol and 25 mL of ether then dried in vacuo at 70 °C, 869 mg (94'x); mp 260-261 °C.
3-(Propyn-1-yl)aniline, used above, was prepared from 3-bromo-nitrobenzene in four steps. 3-Bromo-nitrobenzene (5.0 gm, 24.7 mmol), tetrakis(triphenylphosphine)palladium (1.0 gm), trimethylsilyl-acetylene (3.6 gm, 37 mmol) and cuprous iodide (20 mg) in 20 mL of nitrogen purged, dry diethylamine at reflux for 16 hours. The cooled reaction mixture was vacuum evaporated, diluted with 50 mL of methylene chloride and 50 mL of 1 N hydrochloric acid and filtered.
The organic layer was collected and dried with magnesium sulfate filtered and vacuum evaporated to a residue. The 3-trimethylsilylethynylnitrobenzene was purified by flash chromatography on silica gel eluted with 2:1 hexanes:methylene chloride.
Fractions containing the pure material were vacuum evaporated to afford pure 3-trimethylsilyl-ethynyl nitrobenzene (4.6 gm). 4.0 gm of this were dissolved in 30 mL of methanol and 1 drop of water containing 1.16 gm of potassium carbonate. After one hour the mixture was vacuum evaporated and diluted with 100 mL of methylene chloride. The organic layer was washed with 100 mL of 1 N hydrochloric acid, dried with magnesium sulfate, filtered and vacuum evaporated to a residue (2.96 gm). 790 mg of this was dissolved in 10 mL of benzene and treated with finely pulverized 87% potassium hydroxide (377 mg, 5.91 mmol), methyl iodide (2 mL) and 10 mg of 18-Crown-6 (Aldrich) at reflux for 16 hours. An additional 0.5 mL of methyl iodide were added and the reflux continued for an additional 2 hours. The cooled reaction mixture was vacuum evaporated to a residue which was diluted with 100 mL of methylene chloride and washed with i 00 mL
of 1 N hydrochloric acid, dried with magnesium sulf te, filtered and vacuum evaporated to an oil. This was purified by flash chromatography on silica gel eluted with 1:1 ' hexanes:methylene chloride. Fractions containing pure 3-(propyn-1-yl)-nitrobenzene v~ere vacuum evaporated to an oil which was used without further purification;
530 mg (61%). 3-(Propyn-1-yl)-nitrobenzene (530 mg, 3.3 mmol), iron powder (400 mg, 7.27 mmol), 3 mL of concentrated hydrochloric acid and 10 mL of methanol were refluxed WO .96/30347 PCT/IB95/00436 for 1 hour. The reaction mixture was filtered and vacuum evaporated to a solid which was partitioned between 100 mL of methylene chloride and 100 mL of 1 N sodium hydroxide. The two phases were filtered and then the organic phase was separated, dried with magnesium sulfate, filtered and vacuum evaporated to an oil which was used 5, directly in the preparation of the title product; 321 mg (78~).
I6.7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yll-(3-ethynyl-4-fluoro phenyl)-amine hydrochloride 4-Chloro-6,7-bis-(2-methoxy-ethoxy)-quinazoline (140 mg, 0.446 mmol) and 3 ethynyt-4-fluoroaniline (66 mg, 0.452 mmol) were reacted in refluxing isopropanol (3 mL) under an atmosphere of NZ for 16 hours. The solvent was removed in vacuo and the residue was partitioned between CHCI3 and saturated aqueous NaHC03. The organic extracts were washed with brine, dried over Na2S04, filtered and concentrated in vacuo.
The crude product was chromatographed on silica using 40% acetone/CHZCIZ to provide 116 mg of the pure title product as its free base. This oil was dissolved in a minimum volume of CHCI3, diluted with several volumes of ether and titrated with 1 M
HCI in ether to precipitate the title product as a white solid (99 mg; 50%;
M.P. 170-190 °C (dec); LC-MS: 412 (MH+); anal. RP18-HPLC RT: 4.33 min.).
I6,7-Bis-(2-methoxy-ethoxyl-quinazolin-4=yll-(5-ethynyl-2-methyl-phenyl-amine hydrochloride 4-Chtoro-6,7-bis-(2-methoxy-ethoxy)-quinazoline (153 mg, 0.49 mmol), pyridine (40 NL) and 3-ethynyl-6-methylaniline (71 mg, 0.54 mmol) were reacted in DMF
(3 mL) at 110 °C under an atmosphere of NZ for 36 hours. The solvent was removed in vacuo and the residue was partitioned between CHCI3 and saturated aqueous NaHC03.
The organic extracts were washed with brine, dried over NazS04, filtered and concentrated in vacuo. The crude product was chromatographed on silica using 40%
acetone/CH2C12 to provide 40 mg (19%) of pure product as its free base. This oil was ' dissolved in a minimum volume of CHCI3, diluted with several volumes of ether, and triturated with 1 M HCI in ether to precipitate the title product as a white solid (M.P. 170 185 °C (dec); LC-MS: 408 (MH+); anal. RP18-HPLC RT: 3.93 min.).
WU 96/30347 PC'T/IB95/00436 (6.7-Bis-(2-chloro-ethoxy)-auinazotin~-y1113-ethvnvf-phenyl)-amine hydrochloride 4-Chloro-6,7-bis-(2-chloro-ethoxy)-quinazoline (600 mg, 1.87 mmol) and 3-ethynyl-aniline (219 mg, 1.87 mmol) were reacted in refluxing isopropanol (15 mL) under an atmosphere of NZ for 2.5 hours. The mixture was cooled to 20 °C and the precipitated product was filtered, washed with isopropanol and ether and dried in vacuo. (707 mg; 86~; M.P. 230-240°C (dec); LC-MS: 402 (MH+); anal. RP18-HPLC RT:
5.35 min.).
j6~2-Chloro-ethoxy)-7-(2-methoxy-ethoxv)-quinazolin-4-vtl-(3-ethvnvl-ahenvll-amine hydrochloride The title product was prepared from 4-chloro-6-(2-chloro-ethoxy)-7-(2-methoxy ethoxy)-quinazoline (399 mg, 1.26 mmol) and 3-ethynyl-aniline (147 mg, 1.26 mmol) as described for Example 29. (515 mg; 94%; M.P. 215-225°C (dec); LC-MS:
398 (MH+);
anal. RP18-HPLC RT: 4.85 min.).
6,7-Bis(2-acetoxV-ethoxyl-4-(3-ethynyl phen lamino)- quinazoline The title product of Example 29 (200 mg, 0.456 mmol) was treated with cesuim acetate (1.75 g, 9.12 mmol) in DMF (3 mL) at 120°C under an atmosphere of NZ for 16 hours. The reaction mixture was partitioned between brine and CHCI3, and the organic extract was washed with brine, dried over NazS04, filtered and concentrated in vacuo to afford an oil (277 mg) which was recrystallized from CH2CI2 J hexane. (184 mg; 90~°;
M.P. 137-138 °C; LC-MS: 450 (MH+); anal. RPiB-HPLC RT: 4.64 min.).
2-j4~3-EthynYl--phenVlamino)-7~2-hydrox -ethoxy)-quinazolin-6-yloxyl-ethanol hydrochloride 6,7-6is-(2-acetoxy-ethoxy)-4-(3-ethynyl-phenyl-amino)-quinazoline (199 mg, 0.443 mmol) in methanol (3 mL) was treated with 7M aqueous KOt-i (0.25 mL). Tt~e mixture was stirred at 20°C for 2 hours, before removing the solvent in vacuo.
The solid ' residue was washed with water to remove salts, and dried azeotropically by dissolution two times in acetonitrile and concentration in vacuo to afford 116 mg of title product as its free base. This material was converted to its HCI salt according to the method used in Example 28 (115 mg; 65~; M.P.215-218°C (dec); LC-MS: 366 (MH+);
anal. RP18-HPLC RT: 3.08 min.).
. ~2-Acetoxy-ethoxy)~-(3-ethynyl-phenylamino)-7-(2-methoxy-ethoxy)-quinazoline 5. The title product of Example 30 (160 mg, 0.368 mmol); was treated with cesium acetate (707 mg, 3.68 mmol) in DMF (3 mL) at 120°C under an atmosphere of NZ for 16 hours. The reaction mixture was partitioned between brine and CHCI3, and the organic extract was washed with brine, dried over Na2S04, filtered and concentrated in vacuo to afford a residue (285 mg) which was recrystallized from ethylacetate / hexane.
(134 mg; M.P.84-87°C; LC-MS: 422 (MH+); anal. RP18-HPLC RT: 4.38 min.).
f7-(2-Chloro-ethoxy)-~2-methoxy-ethoxy~guinazolin-4.-yll-(3-ethynyl_ phenyl-amine hydrochloride This product was prepared from 4-chloro-7-(2-chloro-ethoxy)-6-(2-methoxy ethoxy)-quinazoline (600 mg, 1.89 mmol) and 3-ethynyl-aniline (147 mg, 1.26 mmol) as described for Example 29. (737 mg; 90%; M.P. 225-235°C (dec); LC-MS:
398 (MH*);
anal. RP18-HPLC RT: 4.89 min.).
7-(2-Acetoxv-ethoxy)-4-(3-ethvnyl-phenvlamino)-6-(2-methoxv-ethoxv)-auinazoline The title product of Example 34 (160 mg, 0.368 mmol); was treated with cesium acetate (707 mg, 3.68 mmol) in DMF (3 mL) at 120 °C under an atmosphere of N2 for 16 hours. The reaction mixture was partitioned between brine and CHCI3, and the organic extract was washed with brine, dried over NazS04, filtered and concentrated in vacuo to afford a residue (288 mg) which was recrystallized from ethyl acetate /
hexanes. (134 mg; t~l.P.134-135 °C; LC-MS: 422 (MH+); anal. RP18-HPLC
RT: 4.43 min.).
2- 4- 3-Eth ~_~ nyl-pt~enylamino -6-(2-methox)r-etho~~ uinazolin-7- i-oxyl-c-thanol ' hydrochloride The title product of Example 35 (149 mg, 0.354 mmol) in methanol (3 mL) was treated with 5M aqueous KOH (0.25 mL). The mixture was stirred at 20°C
for 30 minutes before removing the solvent in vacuo. The solid residue was washed with water to remove salts, and dried azeotropically by dissolution two times in acetonitrile and concentration in vacuo to afford 100 mg of title product as its free base.
This material was converted to its HCI salt according to the method used in Example 28 (87 mg; 59 96; M.P.230-235 °C (dec); LC-MS: 380 (MH+); anal. RP18-HPLC RT:
3.42 min.).
j3-Ethynyl-phenyl)-~6-(2-methoxy-ethoxy)-7-f2-(4-methyl-piperazin-1-yl -ethoxyl-quinazolin-4. y~-amine dihydrochloride The title product of Example 34 (110 mg, 0.253 mmol) in DMF (2 mL) was treated with N-methyl-piperazine (281 ~rL, 2.53 mmol) at 110 °C for 16 hours. The reaction mixture was partitioned between CHCI3 and saturated aqueous NaHC03.
The organic extracts were washed with brine, dried over NaZS04, filtered and concentrated in vacuo. The crude product was chromatographed on silica using 15°~
methanol/CHZCIZ to provide 56 mg of pure product as its free base. This white solid was dissolved in a minimum volume of CHCI3, and titrated with 2 equivalents of in ether to precipitate the title product as a white solid (65 mg; 48 %; M.P.
130-142 °C
(dec); LC-MS: 462 (MH+); anal. RP18-HPLC RT: 3.69 min.).
!3-Ethynyl-phenyl-f7-(2-imidazol-1-yl-ethoxy)-~2-methoxy-ethoxy}quinazolin-4-yl]-amine di~drochloride The title product from Example 34 (110 mg, 0.253 mmol) in DMF (2 mL) was treated with imidazole (172 mg, 2.53 mmol) at 110 °C for 48 hours. The reaction mixture was partitioned between CHCI3 and saturated aqueous NaHC03. The organic extracts were washed with brine, dried over NaZS04, filtered and concentrated in vacuo.
The crude product (119 mg) was chromatographed on silica using 10%
methanol/CH2CIz to provide 85 mg of pure title product as its free base. This white solid was dissolved in a minimum volume of CHCl3, and titrated with 2 equivalents of 1 M HCI in ether to precipitate the title product as a white solid (95 mg; 75 %; M.P. 220-227 °C (dec); LC-MS: 430 (MH+); anal. RP18-HPLC RT: 3.75 min.).
(3-Ethynyl-phenyl)-f6-(2-imidazol-1-yl-ethoxy~-7-(2-methox -ethoxrLquinazolin~-yll-amine dihydrochloride The title product of Example 30 (110 mg, 0.253 mmol) in DMF (2 mL) was , treated with imidazole (172 mg, 2.53 mmol) at 110 ° C for 48 hours.
The reaction mixture was partitioned between CHCI3 and saturated aqueous NaHC03. The organic extracts were washed with brine, dried over NazS04, filtered and concentrated in vacuo.
The crude product (125 mg) was chromatographed on silica using 1096 methanol/CHzCl2 to provide 86 mg of pure title product as its free base. This white solid was dissolved in a minimum volume of CHCI3, and titrated with 2 equivalents of 1 M HCI in ether to precipitate the title product as a white solid dihydrochloride salt (95 mg; 78 96; M.P. 85-100 °C (dec); LC-MS: 430 (MH+); anal. RP18-HPLC RT:
4.13 min.).
f 3-Ethynyf-phenyl)-f7-(2-methoxy-ethoxy)-6-(2-morpholin-4-vl-ethoxv)-auinazolin-4-yll-amine dihydrochloride The title product from Example 30 (107 mg, 0.245 mmol) in DMF (2 mL) was treated with morpholine (214 NL, 2.45 mmol) at 80°C for 24 hours. The reaction mixture was partitioned between CHCl3 and saturated aqueous NaHC03. The organic extracts were washed with brine, dried over NaZS04, filtered and concentrated in vacuo.
The crude product (168 mg) was chromatographed on silica using 7.5~
methanol/CHZCIZ to provide 65 mg of pure title product as its free base. This white solid was dissolved in a minimum volume of CHCI3, and titrated with 2 equivalents of 1 M HCI in ether to precipitate the title product as a white solid (88 mg; 59 %; M.P. 115-130 °C (dec); LC-MS: 449 (MH+); anal. RP18-HPLC RT: 4.00 min.).
2-(4-(3-Et~nyl-phen5rlamino~2-methoxy-ethoxy)-- quinazolin-6-yloxyl-ethanol hydrochloride The title product from Example 33 (149 mg, 0.354 mmol) in methanol (3 mL) was ' treated with 5M aqueous KOH (0.25 mL). The mi>aure was stirred at 20°C for 30 minutes before removing the solvent in vacuo. The solid residue was washed with water to remove salts, and dried aze-__otropically by dissolution two times in acetonitrile and concentration in vacuo to afford 95 mg of title product as its free base.
This material was converted to its HCI salt according to the method used in Example 28 (89 mg; 61 96; M.P.190-215 °C (dec); LC-MS: 380 (MH+); anal. RP18-HPLC RT:
3.66 min.).
X6,7-Diethoxy-quinazo(in-4-yl) ~3-ethyny!-ahen~rl)-amine hydrochloride , 5. 6,7-Diethoxyquinazolin-4-one (120 mg, 0.512 mmol), triphenylphosphine (295 mg, 1.126 mmol) and 3 mL of carbon tetrachloride were refluxed for 16 hours.
the reaction mixture was concentrated in vacuo to a residue which was diluted with 3 mL
of isopropyl alcohol and 3-ethynylaniline (66 mg, 0.563 mmol) and refluxed for 3 hours.
The cooled reaction mixture was filtered to afford solid title product which was washed with 10 mL of isopropyl alcohol and dried in vacuo at 70°C, 140 mg (75%); mp 269-270 ° C.
~6,7-Diethoxy-auinazolin-4-y1)-L3-ethynyl-2-methyl-phe~~-amine hydrochloride 4-Chloro-6,7-diethoxyquinazoline (200 mg, 0.792 mmol) and 3-(2'-trimethylsilylethynyl-2-methyl-aniline (168 mg, 0.871 mmol) in 4 mL of tert-butyl alcohol was refluxed for 16 hours. The cooled reaction mixture was diluted with 5 mL
of ethyl ether and filtered to afford solid (6,7-diethoxy-quinazolin-4-yl)-(3-(2'-trimethylsilyl-ethynyl)-2-methyl-phenyl)-amine hydrochloride which was washed with 10 mL of ethyl ether and dried in vacuo at 70°C. This material was desilated directly by treatment with 2 mL of methanol containing 1 drop of water and 100 mg of potassium carbonate for 0.5 hours.
The heterogeneous reaction mixture was filtered through Celite and vacuum evaporated to a residue which was dissolved in excess 1 N HCI in methanol, precipitated with ethyl ether, filtered and dried in vacuo at 70°C to afford the title product;
160 mg (75%); mp 258-259.5 ° C.
(3-Eth~~phenyl)-(6-methyl-auinazolin-4-yl)-zmine hydrochloride 6-Methyl-quina~olir,-4-one (350 mg, 2.18 mmol) was added to a suspension of polymer-supported triphenylphosphine (from Ffuka, 3.63 g of about 3 mmol P/g resin;
10.9 mmol) in a mixture of CCl4 (3.35 g, 21.80 mmol) and 1,2 dichloroethane (10 mL). ' The mixture was heated to 60°C for 2 hours and then the polymer rrdas removed by filtration and washed with dichloroethane. The filtrate was collected in a f ask containing 3-ethynyl-aniline (0.644 g, 2.18 mmol) and concentrated to 5 mL by evaporation. After 4 hours reflux under N2, followed by cooling to 20°C, the title product was collected by filtration (551 mg; 86%; M.P. 256-257°C; LC-MS: 260 (MH+); anal. RP-HPLC RT: 4.41 min).
2-~2-f4-(3-Ethynyl-phenylamino}-6-(2-methoxy-ethoxyl-auinazolin-7-yloxy]!-ethylsulfanyl}-propionic acid ammonium salt The title product of Example 34 (150 mg, 0.34 mmol) was added to a solution of thiolactic acid (100 NL, 1.14 mmol) and KOH (150 mg, 2.7 mmol) in degassed DMF
(5 mL)/ H20 (0.5 mL). The reaction mixture was stirred at 50°C under an atmosphere of NZ for 72 hours and then cooled to room temperature. The pH of the mixture was adjusted to about 4.0 with acetic acid and then partitioned between CHCI3 and brine.
The organic extracts were washed with brine, dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by preparative RP18 HPLC
utilizing a gradient of 15% to 100% CH3CN/pH 4.5, 50 mM ammonium acetate followed by lyophilization of the appropriate pure fractions to afford the title product (28 mg;
18°~; M.P. 95-103°C (dec}; LC-MS: 468 (MH+); anal. RP-HPLC RT:
3.57 min).
~2-(4-(3-Ethyn)rl-phenylamino)-6-(2-methoxy-etho~y-auinazolin-7-yloxyl-ethylsulfan~rl~-acetic acid ammonium salt The title product was prepared from the title product of Example34 and mercaptoacetic acid according to the method of Example45. (3%; LC-MS: 454 (MH+);
anal. RP-HPLC RT: 3.37 min).
4-(3-Ethynyl-phenylaminoZ-6~2-methox~r-ethoxY)-quinazolin-7-of This product was isolated as a more lipophilic product (by preparative RP18 HPLC) from the reaction used to generate the title product of Example46 (5%;
LC-MS:
336 (MH+); anal. RP-HPLC RT: 3.60 min).
~3-eth~n~rlphenyl}-[~2-methoxy-ethoxYL-vinyloxy-guinazolin-4-ylamine and I~2-ethoxy-ethoxy}-7-(2-methoxy-ethoxY~-ctuinazolin-4-yll-(3-eth~nyl-phen~rl -amine hydrochloride The title product of Example 30 (107 mg, 0.245 mmol) was treated with sodium ethoxide (0.582 mmol) in refluxing ethanol (3 mL) for 24 hours. The solvent was removed in vacuo and the product vdas isolated by flash chromatography on silica using 1096 acetone/CHZCI2 to provide 30 mg of the 6-vinyloxy product (33~°; M.P. 113-114°C; LC-MS: 362 (MH+); anal. RP-HPLC RT: 4.84 min). The 6-(2-ethoxy-ethoxy) derivative eluted as a more polar product (45 mg) and was converted to its HCI
salt according to the procedure described for Example28 (4396; M.P. 220-225°C (dec); LC- .
MS: 408 (MH+); anal. RP-HPLC RT: 4.35 min).
4-(3-Ethynyl-phenylamino)-7-(2-methoxy-ethoxy}-guinazofin-6-of hydrochloride (3-Ethynyl-phenyl)-[7-(2-methoxy-ethoxy)-6-vinyloxy-quinazolin-4-yl]-amine (20 mg; from Example 48) was hydrolyzed by treatment with 6M HCI / methanol (30:70; 3 mL) at 50°C for 5 days. The solution was concentrated in vacuo, and the residue was partitioned between CHCI3 and brine at a pH of about 7. The organic extracts were washed with brine, dried over NaZS04, filtered and concentrated in vacuo to afford the title product as its free base (15 mg), which was converted to its HCI salt according to the procedure described for Example 28 (M.P. 135-150°C (dec); LC-MS:
336 (MH+);
anal. RP-HPLC RT: 3.77 min).
1 ~2-f4-!3-Ethynyl-phenyfamino)-6-(2-m ethoxy-ethoxy)-quinazol in-7 yloxyl-ethyl~-1 H-pyridin-4-one hydrochloride NaH (30 mg of 60% in mineral oil, 0.77 mmol) was added to anhydrous DMF
(2.0 mL) followed by pyrid-4-one (79 mg, 0.83 mmol). The mixture was stirred minutes at 22°C until all solids dissolved and the evolution of Hz ceased. The title product of Example 34 (120 mg, 0.28 mmol) and fetrabutylammonium iodide (15 mg) were added and the reaction mixture was stirred at 22°C for 7 days under N2.
Additional pyrid-4-one (79 mg) and NaH (30 mg of 60%) were dissolved in DMF (2 mL) .
and the solution was added to the reaction mixture. After another 4 days stirring the mixture vras partitioned between CHCI3 and brine. The organic extracts were dried over NazS04, filtered and concentrated in vacuo. The crude product was purified by flash chromatography on silica utilizing 10% methanol/ CH2C12 to afford 65 mg of the free base of the title product which was ccnverted to the mono-hydrochloride salt according ' to the procedure described for Example 28 (66 mg; M.P. 240-248°C (dec);
LC-MS: 457 (MH+); anal. RP-HPLC RT: 3.23 min) -4.3-1-d2-f4-3-EthYnyl,~henylamino)-7-(2-methox~-e~ thoxyLquinazolin-6-yloxy]-ethr~l -1 H-pyridin-4-one hydrochloride - ~ The free base of this product was prepared from the title product of Example30 . and the sodium salt of pyrid-4-one as described for Example 50. The free base was isolated by flash chromatography with 15% methanol/CHCI3 and converted to the title product according to the procedure described for Example 28 (32%; M.P. 155-168°C
(dec); LC-MS: 457 (MH+); anal. RP-HPLC RT: 3.45 min).
(3-Ethynyl-phenyls-~6-methoxy-guinazolin-4~r1)-amine hydrochloride A 25 mM solution of 6-methoxy-3H-quinazolin-4-one in 1,2-dichloroethane was added to polymer-supported triphenylphosphine (from Fluka, about 3 mmol P/g polymer; 2.5 mol equiv) and carbon tetrachloride (100 mole equiv). The reaction mixture was heated, with shaking, at 60°C for 21 hours, cooled to 22°C, and a 30 mM solution of the 3-ethynylaniline (1.5 mole equiv) in t-butanoi was added. The resulting mixture was then heated, with shaking, at 60°C for 18 hours followed by cooling to 22°C. The polymer was filtered off and washed twice with methanol. The methanol washes were added to the filtrate and the solution was concentrated in vacuo to afford the title product (73°~; LC-MS: 276 (MH+); anal. RP18-HPLC RT: 5.82 min). For these cases the analytical RP18-HPLC system consisted of a Waters 717 (trademark) autosampler, Waters 996 Photodiode Array Detector (trademark), and Waters 600 quarternary solvent delivery system, and was controlled by Millennium (trademark) software. The aliquots of samples were chromatographed using a linear gradient of 0% to 100°~
acetonitrile/
0.2 M ammonium acetate buffer (pH 4.5) over ten minutes at a flow rate of 3 ml/min.
using a Perkin-Elmer Pecosphere (trademark) (3mm X 3cm) C18 column.
The compounds of Examples 53-94, as their hydrochloride salts, were prepared in an analogous manner to that of Example 52 from the appropriate 3H-quinazolin-4-one derivative and 3-ethynyl-aniline:
LC-MS HPLC RT
Exam;aleProduct % Yield(MH+) (mires}
53 (6-Chloro-quinazolin-4-yl)-(3-ethynyl-60 280, 6.44 phenyl)-amine WO 96130347 PCT/IB95l00436 LC-MS HPLC RT
ExampleProduct 96 Yield(MH+) (mins) 54 [7-Chloro-6-(2,5-dichloro-phenylsulfanyl)-51 456, 8.74 quinazolin-4-ylj-(3-ethynyl-phenyl)-amine 55 7-Chloro-4-(3-ethynyl-phenylamino)-12 305, 6.51 quinazoiine-6-carbonitrile 56 [6-Bromo-7-(4-chloro-phenoxy)-quinazolin-28 450, 8.05 4-ylj-(3-ethynyl-phenyl)-amine 57 [6-(4-Bromo-benzylsulfanyl)-quinazolin-4-50 446, 7.99 ylj-(3-ethynyl-phenyl)-amine 58 (7-Bromo-6-methylsulfanyl-quinazolin-4-yl)-46 370, 6.99 (3-ethynyl-phenyl)-amine 59 {7-Chloro-6-[4-(4-chloro-phenylsulfanyl)-82 514, 9.45 phenoxyj-quinazolin-4-yl }-(3-ethynyl-phenyl)-amine 60 (3-Ethynyl-phenyl)-(7-phenylsulfanyl-88 354 7.40 quinazolin-4-yl)-amine 61 (3-Ethynyl-phenyl)-(6-iodo-quinazolin-4-yl)-64 372 6.81 amine 62 (3-Ethynyl-phenyl)-(6-trifluoromethyl-53 314 6.73 quinazolin-4-yl)-amine 63 [7-Chloro-6-(4-chloro-phenoxy)-quinazolin-78 406, 8.06 4-ylj-(3-ethynyl-phenyl)-amine 64 [7-Chloro-6-(4-chloro-phenylsulfanyl)-68 422, 8.45 quinazolin-4-ylj-(3-ethynyl -phenyl)-amine 65 [7-Chloro-6-(4-methoxy-phenoxy)-88 402, 7.55 quinazolin-4-ylj-(3-ethynyl-phenyl)-amine 66 (7-Chloro-6-(4-ffuoro=phenoxy)-quinazolin-80 390 7.61 4-ylj-(3-ethynyl-phenyl)-amine 67 [6-(4-Ghloro-phenoxy)-quinazolin-4-ylj-(3-79 372, 7.66 ethynyl-phenyl)-amine 68 7-Bromo-4-(3-ethynyl-phenylamino)-61 431, 6.44 quinazoline-6-sulfonic acid 69 ( 6-Bromo-7-chloro-quinazolin-4-~-I)-(3-80 358, 7.17 ethynyl-phenyl)-amine 70 4-(3-Ethynyl-phenylamino)-quinazoline-6-72 271 5.84 carbonitrile LC-MS HPLC RT
Example Product 96 Yield(MH+) (mins) 71 [6-(4-Bromo-phenylsulfany!)-7-chloro-70 466, 8.56 quinazolin-4-yl]-(3-ethynyl-phenyl)-amine 72 {6-[2-(4-Bromo-phenoxy)-ethylsulfanyl]-79 476, 8.11 quinazolin-4-yl}-(3-ethynyl-phenyl)-amine 73 4-[7-Chloro-4-(3-ethynyl-phenylamino)-85 427, 7.56 quinazolin-6-ylsulfanyl-methyl]-benzonitrile 74 [7-Chloro-6-(3-chloro-phenoxy)-quinazolin-80 406, 8.10 4-yl]-(3-ethynyl-phenyl)-amine 75 [6-(3-Bromo-phenoxy)-7-chloro-quinazolin-82 450, 8.22 4-yl]-(3-ethynyl-phenyl)- amine 76 (7-Chloro-6-phenoxy-quinazolin-4-yl)-(3-83 372, 7.59 ethynyl-phenyl)-amine 77 [7-Chloro-6-(4-methylsulfanyl-phenoxy)-86 418, 8.02 quinazoiin-4-yl]-(3-ethynyl-phenyl)-amine 78 [7-Chloro-6-(4-methanesulfonyl-phenoxy)-73 450, 6.73 quinazolin-4-yl]-(3-ethynyl-phenyl)-amine 79 (7-Chloro-6-p-tolyloxy-quinazolin-4-yl)-(3-85 386, 7.95 ethynyl-phenyl)-amine 80 (3-Ethynyl-phenyl)-[6-(4-phenoxy-81 430 8.29 phenoxy)-quinazolin-4-yl]-amine 81 (7-Chloro-6-phenylsulfanyl-quinazolin-4-yl)-80 388, 7.96 (3-ethynyl-phenyl)-amine 82 [6-(3-Chloro-phenoxy)-quinazolin-4-yl]-(3-77 372, 7.71 ethynyl-phenyl)-amine 83 [6-(3,5-Dichloro-phenoxy)-quinazolin-4-yl]-61 406, 8.30 (3-ethynyl-phenyl)-amine 84 [6-(2-Chloro-phenoxy)-quinazolin-4-yl]-(3-70 372, 7.38 ethynyl-phenyl)-amine 85 (7-Chlo~o-6-metharcsulfonyl-quinazolin-4-74 358, 5.74 yl)-(3-efhynyl-phenyl)-amine 86 [6-(3,4-Dichloro-phenoxy)-quinazolin-4-yl]-62 406, 8.14 (3-ethynyl-phenyl)-amine 87 [6-(4-Bromo-phenoxy)-quinazo(in-4-yl]-(3-68 416, 7.81 ethynyl-phenyl)-amine WO 96!30347 PCT/IB95/00436 LC-MS HPLC RT
ExampleProduct 96 Yield(MH+) (mans) 88 [6-(4-Chloro-2-methyl-phenoxy)-quinazolin-73 386, 8.02 4-yl]-(3-ethynyl-phenyl)-amine 89 [7-Chloro-4-(3-ethynyl-phenylamino)-70 351 6.44 ' quinazolin-6-ylsulfanyl]-acetonitrile **
90 (6-Allylsulfanyl-quinazolin-4-yl)-(3-ethynyl-72 318 6.93 phenyl)-amine 91 (7-Chloro-6-propylsulfanyl-quinazolin-4-yl)-69 354, 7.79 (3-ethynyl-phenyl)-amine 92 (7-Chloro-6-methyl-sulfanyl-quinazoiin-4-72 326, 6.94 yl)-(3-ethynyl-phenyl)-amine 93 [7-Chloro-6-(2-methyl-sulfanyl-71 386, 7.56 ethylsulfanyl)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine 94 (6-Chloro-7-methoxy-quinazolin-4.-yl)-(3-87 310, 6.fi5 ethynyl-phenyl)-amine ** [7-Chloro-4-(3-ethynyl-phenylamino)-quinazo(in-6-ylsulfanyl]-acetonitrife was obtained from 2-(7-chloro-4--oxo-3,4-dihydro-quinazolin-6-ylsulfanyl)-acetamide under these conditions.
(6.7-Dibutoxy-quinazolin-4-y~~3-ethynyl-phen r~l -amine hydrochloride 6,7-Dibutoxyquinazolin-4-one (105 mg, 0.362 mmol), triphenylphosphine (208 mg, 0.796 mmol) and 5 mL of carbon tetrachloride were refluxed for 16 hours and the reaction mixture was concentrated in vacuo to a residue which was diluted with 3 mL
of isopropyl alcohol and 3-ethynylaniline (47 mg, 0.398 mmol) and refluxed for 3 hours.
The cooled reaction mixture was filtered to afford solid (6,7-dibutoxy-quinazolin-4-yl)-(3-ethynyl-pha-:~y1)-amine hydrochloride which vYas washed with 10 mL of iscpropyl alcohol and dried in vacuo at 70°C, 92 mg (60%); mp 247-248°C.
~ 6.7-Diisopropox~quinazolin-4-yf)-~3-eth~nyl-phen~rl)-amine hydrochloride 6,7-Diisopropoxyquinazo(in-4-one (55 mg, 0.210 mmo!), triphenyfphosphine (121 mg, 0.462 mma!) and 3 rnL of carbon tetrachloride were refluxed for 16 hours and the reaction mixture was concentrated in vacuo to a residue which was diluted with 3 mL
of isopropyl alcohol and 3-ethynylaniline (30 mg, 0.257 mmol) and refluxed for 3 hours.
The cooled reaction mixture was vacuum evaporated to afford the solid title product which was column chromatographed on silica gel eluted with 5% acetone in methylene chloride containing 0.25% triethylamine. Fractions containing the pure product were concentrated in vacuo to a solid which was dissolved in 2 mL of 1 N HCI in methanol, precipitated with ethyl ether, filtered and dried in vacuo at 70°C to afford the title product; 140 mg (75~); mp 241-242 ° C.
L6-Chloro-7-(2-methoxyethylsulfanyl~guinazolin-4~IL(3-ethynyl-phenyl -amine ~drochloride 6-Chloro-7-(2-methoxyethylsutfanyl)-quinazolin-4-one (200 mg, 0.739 mmol), triphenylphosphine (427 mg, 1.63 mmol) and 0.7 mL of carbon tetrachloride were refluxed in 4 ml of 1,2-dichloroethane for 4 hours, concentrated in vacuo to a residue, diluted with 4 mL of isopropyl alcohol and 3-ethynylaniline (129 mg, 1.104 mmol) and refluxed for 16 hours. The hot reaction mixture was filtered to isolate crude product which was column chromatographed on silica gel eluted with 5°~ methanol in chloroform. Fractions containing the pure product were concentrated in vacuo to afford the title product as a solid; 23 mg (8.4%); mp 230-232°C.
j6.7-Bis-f2-methoxyethoxyl-cLuinazolin-4-yl)-(3-ethynyl-2-methyl-phenyl -amine 6,7-Bis-[2-methoxyethoxy]-4-chloro-quinazoline (90 mg, 0.288 mmol) and 3-(2'-trimethylsilylethynyl-2-methyl-aniline (62 mg, 0.317 mmol) were refluxed in 4 mL of tert-butyl alcohol for 16 hours. The cooled reaction mixture was diluted with 1 mL
of isopropyl alcohol and filtered to afford solid (6,7-bis-(methoxyethoxy)-quinazolin-4-yl)-(3-(2'-trimethylsilyl-ethyn-1yl)-2-methyl-phenyl)-amine hydrochloridewhichwaswashedwith 10 mL of ethyl ether and dried in vacuo at 70°C; 70 mg. Of this material 51 mg was desilated by treatment with in 3 mL of methanol containing 1 drop of water and 50 mg of potassium carbonate for 0.5 hours at room temperature. The heterogeneous ' reaction mixture was filtered through celite and vacuum evaporated to a residue which was dried in vacuo at 70°C to afford the title product as a dry foam;
38 mg (75°i°); mp 232 ° C.
~6,7-Bis-f2-methoxyethoxyl-quinazolin-4-y~-(3-ethyn~il-5'-fluoro-phenyl's-amine hydrochloride 6,7-Bis[2-methoxyethoxyJ-4-chioro-quinazoline (90 mg, 0.288 mmol) and 3-(2'-5, trimethylsilylethynyl-5-fluoro-aniline (69 mg, 0.317 mmol) were refluxed in 3 mL of tert-butyl alcohol for 5 hours. The cooled reaction mixture was diluted with 2 mL
of isopropyl alcohol and filtered to afford solid (6,7-bis-methoxyethoxy-quinazolin-4-yf)-(3-(2'-trimethylsilyl-ethynyl)-5'-fiuoro-phenyl)-amine hydrochloride which was washed with mL of ethyl ether and dried in vacuo at 70°C; 131 mg. All of this material was 10 desilated by dissolution in 3 mL of methanol containing 1 drop of water and 35 mg of potassium carbonate for 0.5 hours at room temperature. The reaction mixture was adjusted to pH 2.5 with aqueous 1 N hydrochloric acid and filtered. The solid was dried in vacuo at 70°C to afford the title product; 92 mg (78%); mp 249-250°C.
~7-Propylsulfanyl-guinazolin-4-yl)-(3-ethyl-phen~rly-amine hydrochloride 7-Propylsulfanyl-quinazolin-4-one (300 mg, 1.36 mmol), triphenylphosphine (785 mg, 2.99 mmol), 1.31 mL of carbon tetrachloride and 5 mL of chloroform were refluxed for 16 hours and the reaction mixture was concentrated in vacuo to a residue which was diluted with 5 mL of isopropyl alcohol and 3-ethynylaniline (175 mg, 1.49 mmol) and refluxed for 3 hours. The cooled reaction mixture was concentrated in vacuo and the residue purified by column chromatography on silica gel eluted with 10%
methanol in chloroform. Fractions containing the pure title product, as the frree amine, were concentrated in vacuo to afford solid which was added to 3 mL of 1 N HCI in methanol.
This solution was evaporated in vacuo to a residue which eras triturated with 4 mL of hot isopropyl alcohol cooled and filtered. The solid thus obtained was dried in vacuo at 70°C to aftord pure title product; 239 mg (55%); mp 2?_9-230°C.
~7-,'2-Methoxyethylsulfan-yl)-c~uirazolin-4=y~(3-eihy~l-phenyl)-amine hydrochloride In the same manner as Example 42 [7-(2-methoxyethylsulfanyl)-quinazolin-4-yl~-(3-ethynyl-phenyl)-amine hydrochloride was prepared from 7-(2-methoxyethylsulfanyl)-quinazolin-4-one (200 mg, 0.847 mmol), triphenylphosphine (533 mg, 2.03 mmol) cnd 3 mL of carbon tetrachloride in 74 % yield; 233 mg; mp 208-?09°C.
j7-Chloro-6-vitro-auinazolin-4 y1-(3-ethynyl-phenyls amine hydrochloride 7-Chloro-6-vitro-quinazolin-4-one(1.002g,4.44mmol),phosphorousoxychloride (11.5 g, 7.51 mmol) and phosphorous pentachloride (1.62 g, 7.74 mmol) were refluxed for 2 hours and the reaction mixture was concentrated in vacuo to a residue which was triturated with toluene and then again with chloroform and dried in vacuo to afford crude 4,7-dichloro-6-vitro-quinazoline. This was dissolved in 35 mL of isopropyl alcohol and 3-ethynylaniline (639 mg, 5.45 mmol) and refluxed for 3 hours. The cooled reaction mixture was filtered to afford the title product as a solid which was washed with 10 mL
of isopropyl alcohol and dried in vacuo at 70°C, 1.055 g (66%); mp 230.8-232.6°C.
~6-Amino-7-chloro-quinazolin-4-yl)-(3-eth~nyl-phenyl-amine hydrochloride (7-Chloro-6-vitro-quinazolin-4-yl)-(3-ethynyl-phenyl)-amine hydrochloride (166 mg, 0.295 mmol} and sodium dithionite (207 mg, 1.19 mmol) were stirred in 1.5 mL
of formic acid for 4 hours at room temperature. 45 mL of methanol were added to the reaction mixture which was set aside for 16 hours at room temperature. The precipitate thus obtained was filtered, triturated with 3% sodium bicarbonate for 0.5 hours and refiltered. The solid was dissolved in 20 mL of 1 N HCI in methanol and precipitated with 200 mL of ethyl ether. This was filtered and dried in vacuo at 70°C to afford the title product, 72 mg (83%); mp 260-265°C.
(3-Ethyl-phenyl~7-methoxy-6-vitro-c~uinazolin-4-~ -amine (7-Chloro-6-vitro-quinazolin-4.-yl)-(3-ethynyl-phenyl)-amine hydrochloride (100 mg, 0.306 mmol and dry sodium methoxide (7 20 mg, 2.22 mmol) ~;~ere stirred in 2 mL of dry 2-methylpyrrolidin-1-one for 8 hours at 30°C. To the cooled reaction mixture 0.93 mL
of 3 N and 1 mL of water were added. Tlje mixture v;~as diluted with 60 mL of water and extracted with two time 60 mL of ethyl acetate. T! ~e pooled crganic layers were vjashed with three times 50 mL of water and 50 mL of brine, dried with magnesium sulfate, filtered and vacuum evaporated to afford the title pr~~duct as a solid; 80 mg (82%); mp 213-218°C dec.
WO 96!30347 PCT/IB95/00436 ~2-f4- 3-Eth~nyl-phenylamino-7-~2-methoxy-ethoxy)-4uinazolin-6-yloxyl-ethylsulfan~i}-acetic acid ammonium salt This product was prepared from the title product of Example 30 and mercaptoacetic acid at 22°C over 10 days according to the method outlined in Example 45. (16%; M.P. 98-113°C (dec); LC-MS 454 (MH+); anal. RP-HPLC
3.24 min.) 6,7-Bis~2-methoxy-ethoxy~-quinazolone To ethyl 3,4-dihydroxybenzoate (36.4 g, 0.200 mol), K~C03 (60.8 g, 0.44 mol) and tetrabutylammonium iodide (750 mg) in degassed acetone (400 mL) was added 2-bromoethyl methyl ether (69.5 g, 47 mL). The mixture was stirred under NZ at reflux for 64 hours. Ether (600 mL) was added to the mixture and after stirring 30 minutes at ° C the precipitated salts were removed by filtration. The filtrate was concentrated in vacuo and the residue was triturated with hexane (500 mL) for 30 minutes and the 15 white solid ethyl 3,4-bis(2-methoxy-ethoxy)benzoate was filtered and dried in vacuo (55.5 g; 93%; M.P. 50-51 °C). A portion of this product (45.7 g, 0.158 mol) in acetic acid (150 mL) was treated dropwise with cone. HN03 (40 mL) at 5°C and the solution stirred 24 hours before pouring into cold H20 (1.6 L). The mixture was extracted with ethyl acetate (1.1 L), and the organic phase was washed three times with 200 mL HzO, 20 and brine, dried over Na2S04, filtered and concentrated in vacuo to afford ethyl 4,5-bis-(2-methoxy-ethoxy)-2-vitro-benzoate (54.3 g) as a brown oil. This vitro product (52.0 g, 0.15 mol) was dissolved in ethanol (1000 mL) containing 1 equivalent of HCI
(generated in the ethanol by prior addition of 11 mL acetyl chloride), PtO2sH20 (1.0 g) was added, and the mixture was hydrogenated under 45 psi HZ for 6 hours. The catalyst was removed by filtration through Celite, and the filtrate was concentrated in vacuo to a thick slurry which was diluted with ether (400 mL). The solid white hydrochloride salt of ethyl 2-amir:o-4,5-Lis-(2-methoxy-ethoxy)benzoate vdas filtered and dried in vscuo (4~.7 g; 88%). A portion of this rnaterial (42 g, 0.12 mcl) and ammonium for~r~ate (7.6 g, O.i2 mol) were disssolved in formamide (63 mL) and the stirred mixture was heated to 160-165 °C under an atmosphere of NZ for 3 hours. H20 (200 mL) vras added and after cooli~-~c the precipitated crude title product was recovered by filtration, washed with cold HzO, and dried in vacuo. The filtrate was extracted five times with CHCI3, and the pooled organic extracts were washed with brine, dried over Na2S04, and concentrated in vacuo . The residue and crude quinazolone precipitate were combined, triturated in hot acetonitrile (250 mL) for 30 minutes, cooled to 20 °C and treated with ether (250 mL). After cooling to 4 °C the white solid was filtered and dried in vacuo (30.4 g, 86~; GC-MS m/z 294 (M+)).
4-Chloro-6.7-bis-(2-methoxy-ethoxy)-quinazoline To 6,7-bis(2-methoxy-ethoxy)-quinazolone (500 mg, 1.7 mmol), from Preparation 1, in CHCI3 (10 mL) containing one drop of DMF was added oxalylchloride (490VL, 5.6 mmol) in several portions over 5 minutes. Once foaming ceased the solution was refluxed 1.5 hours. The solvent was removed in vacuo and the residue was dissolved in 1,2-dichloroethane (20 mL) and washed two times with 80 mL saturated aqueous NaZC03. The organic phase was dried over NaZS04, and concentrated in vacuo to afford solid title product (520 mg, 92%; M.P. 108-109 °C).
4-Chloro-6.7-bis-(2-chloro-ethoxyl-cluinazoline.4-chloro-6-(2-chloro-ethoxy)-7-(2-methoxy-ethoxy,L uinazoline and 4-chloro-6,7-bis-(2-methoxy-ethoxy)-quinazoline and 4-chloro-7-(2-chloro-ethoxy)-6-f2-methoxy-ethoxyZ quinazoline 6,7-Bis(2-methoxy-ethoxy}-quinazolone (5.4 g, 18.3 mmol), from Preparation 1, and pyridine (3.0 mL, 37 mmol) were heated in refluxing POCI3 (22 mL) under an atmosphere of dry nitrogen for 2.5 hours. Following concentration of the mixture in vacuo at 60°C the residue was dissolved in CHCI3 (150 mL) and carefully added in portions with stirring to cold saturated aqueous NaHC03 (100 mL}. The mixture was stirred 10 min. after the addition was complete and the organic phase was separated, washed with brine, dried over Na2S04, and concentrated in vacuo. The residue was filash chromatographed on silica using a gradient of 20% to 60% ethyl acetate/hexanes to afford 3.41 g of 4-chloro-6,7-bis-(2-methoxy-ethoxy)-quinazoline, 234 mg of ~-chloro 6-(2-chloro-ethaxy)-7-(2-meitaoxy-ethoxy)-quinazoline, 532 mg of 4-chloro-7-(2-chloro ethoxy}-6-(2-methoxy-ethoxy}-quinazoline, and 330 mg of 4-chloro-6,7-bis-(2-chloro ' ethoxy}-quinazoline.
is as defined above, with the proviso that when J is Y then the product of step b) must further be treated with an alkyne.
Yet another aspect of this invention is directed to a method for treating a hyperproliferative disease in a mammal by administering to. a mammal suffering from a hyperproliferative disease, a hyperproliferative disease treating amount of a Formula I
compound.
This invention is also directed to pharmaceutical compositions for the treatment of a hyperproliferative disease in mammals vrhich comprise a hyperproliferative disease treating amount of a compound of the Formula I and a pharmaceutically acceptable carrier.' By halo is meant chloro, bromo, iodo, or fluoro.
By alkyl is meant straight chain, cyclic or branched saturated or unsaturated hydrocarbyl moiety with the proviso that said alkyl must comprise three or more carbon atoms if it is branched or cyclic.
As used herein, the expression "reaction-inert solvent" refers to a solvent which does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.
Other features and advantages will be apparent from the specification and claims which describe the invention.
WO .96/30347 PCT/IS95/00436 SCHEME
X
\
/ / <R3)n <R1)m ' R2 H C~ \ + Y / N/
N H
15 \
<R3)n 2 / /R
N
Y
~ <R1)m HC\N \
_y y _ SCHEME (continued <R3)n 2 / /R
i /
~R1)m H CAN
X
\ i /
CR3)" , / /R2 + HC\ \ <R1)m ~N N
R H
WO 96/30347 PC'T/IB95/00436 _ 12_ Detailed Description of the Invention The Formula I compounds, pharmaceutically acceptable salts and prodrugs thereof (hereafter the active compounds) may be prepared by any process known to be applicable to the preparation of chemically-related compounds. , In general the active compounds may be made from the appropriately substituted quinazoline using the appropriately substituted amine.
As shown in the Scheme the appropriate 4-substituted quinazoline 2 wherein X
is a suitable displaceable leaving group such as halo, aryloxy, alkylsulfinyl, alkylsulfonyl such as trifluoromethanesulfonyloxy, arylsulfinyl, arylsulfonyl, siloxy, cyano, pyrazolo, triazolo or tetrazolo, preferably a 4-chloroquinazoline, is reacted with the appropriate amine or amine hydrochloride 4 or 5, wherein R' is as described above and Y is Br, I, or trifluoromethane-sulfonyloxy in a solvent such as a (C,-Cs)alcohol, dimethylformamide (DMF), N-methylpyrrolidin-2-one, chloroform, acetonitrile, tetrahydrofuran (THF), 1-4 dioxane, pyridine or other aprotic solvent. The reaction may be effected in the presence of a base, preferably an alkali or alkaline earth metal carbonate or hydroxide or a tertiary amine base, such as pyridine, 2,6-lutidine, collidine, N-methyl-morpholine, triethylamine, 4-dimethylamino-pyridine or N,N-dimethylaniline.
These bases are hereinafter refered to as suitable bases. The reaction mixture is maintained at a temperature from about ambient to about the reflux temperature of the solvent, preferably from about 35°C to about reflux, until substantially no remaining 4-haloquinazoline can be detected, typically about 2 to about 24 hours.
Preferably, the reaction is performed under an inert atmosphere such as dry nitrogen.
Generally the reactants are combined stoichiometrically. When an amine base is used for those compounds where a salt (typically the HCI salt) of an amine 4 or 5 is used, it is preferable to use excess amine base, generally an extra equivalent of amine base. (Alternatively, if an amine base is not used an excess of the amine 4 or 5 may be used).
For those compounds whEre a sterically hindered amine 4 (such as a 2-alkyl-3-ethynylaniline) or very reactive 4-haloquinazoline is used it is preferable to use t-butyl ' alcohol or a polar aprotic solvent such as DMF or N-methylpyrrolidin-2-one as the solvent.
Alternatively, a 4-substituted quinazoline 2 wherein X is hydroxyl or oxo (and the 2- nitrogen is hydrogenated) is reacted with carbon tetrachloride and an optionally substituted triarylphosphine which is optionally supported on an inert polymer (e.g.
triphenylphosphine, polymer supported, Aldrich Cat. No. 36,645-5, which is a 29'0 divinylbenzene cross-linked polystyrene containing 3 mmol phosphorous per gram . . resin) in a solvent such as carbon tetrachloride, chloroform, dichloroethane, tetrahydrofuran, acetonitrile or other aprotic solvent or mixtures thereof.
The reaction mixture is maintained at a temperature from about ambient to reflex, preferably from about 35°C to reflex, for 2 to 24 hours. This mixture is reacted with the appropriate amine or amine hydrochloride 4 or 5 either directly or after removal of solvent, for example by vacuum evaporation, and addition of a suitable alternative solvent such as a (C,-C6) alcohol, DMF, N-methylpyrrolidin-2-one, pyridine or 1-4 dioxane.
Then, the reaction mixture is maintained at a temperature from about ambient to the reflex temperature of the solvent preferably from about 35° C to about reflex, until substantially complete formation of product is acheived, typically from about 2 to about 24 hours.
Preferably the reaction is performed under an inert atmosphere such as dry nitrogen.
When compound 4, wherein Y is Br, I, or trifluoromethanesulfonyloxy, is used as starting material in the reaction with quinazoline 2, a compound of formula 3 is formed wherein R', R2, R3, and Y are as described above. Compound 3 is converted to compounds of formula 1 wherein R4 is R"ethynyl, and R" is as defined above, by reaction with a suitable palladium reagent such as tetrakis(triphenylphosphine)palladium or bis(triphenylphosphine)palladium dichloride in the presence of a suitable Lewis acid such as cuprous chloride and a suitable alkyne such as trimethylsilylacetylene , propargyl alcohol or 3-(N,N-dimethylamino)-propyne in a solvent such as diethylamine or triethylamine. Compounds 3, wherein Y is NH2, may be converted to compounds 1 wherein R4 is azide by treatment of compound 3 with a diazotizing agent, such as an acid and a nitrite (e.g., acetic acid and NaN02) followed by treatment of the resulting product with an azide, such as NaN3.
For the production of those compounds of Formula l wherein an R' is an amino or hydroxyamino C roup the reduction of the corresponding Formula I compound wherein R' is nitre is employed.
The reduction may corn~~=niently be carried out by any of the many procedures known for such transformations. The reduction may be carried out, for example, by hydrogenation of the vitro compound in a reaction-inert solvent in the presence of a suitable metal catalyst such as palladium, platinum or nickel. A further suitable reducing agent is, for example, an activated metal such as activated iron (produced by washing iron powder with a dilute solution of an acid such as hydrochloric acid). Thus, for example, the reduction may be carried out by heating a mixture of the vitro compound and the activated metal with concentrated hydrochloric acid in a solvent such as a mixture of water and an alcohol, for example, methanol or ethanol, to a temperature in the range, for example, 50 to 150°C, conveniently at or near 70°C.
Another suitable class of reducing agents are the alkali metal dithionites, such as sodium dithionite, which may be used in (C1-C4)alkanoic acids, (C,-C6)alkanols, water or mixtures thereof.
For the production of those compounds of Formula I wherein Rz or R3 incorpcrates a primary or secondary amino moiety (other than the amino group intended to react with the quinazoline), such free amino group is preferably protected prior to the above described reaction followed by deprotection, subsequent to the above described reaction with 4-(substituted)quinazoline 2.
Several well known nitrogen protecting groups can be used. Such groups include (C,-C6)alkoxycarbonyl, optionally substituted benzyloxycarbonyl, aryloxycarbonyl, trityl, vinyloxycarbonyl, O-nitrophenylsulfonyl, diphenylphosphinyl, p-toluenesulfonyl, and benzyl. The addition of the nitrogen protecting group may be carried out in a chlorinated hydrocarbon solvent such as methylene chloride or 1,2-dichloroethane, or an ethereal solvent such as glyme, diglyme or THF, in the presence or absence of a tertiary amine base such as triethylamine, diisopropylethylamine or pyridine, preferably triethylamine, at a temperature from about 0°C to about 50°C, preferably about ambient temperature. Alternatively, the protecting groups are conveniently attached using Schotten-Baumann conditions.
Subsequent to the above described coupling reaction, of compounds 2 and 5, the protecting group may be removed by deprotecting methods known to those skilled in the arf such as treatment with trifluoroacetic acid in methylene chloride for the tert-butaxycarbonyl protected products.
For a description of protecting groups and their use, see T.W. Greene and P.G.t~l. Wuts, "Protective Groups in Orvanic Synthesis" Second Ed., John Wiley & Sons, New York, 1991. ' For the production of compounds of Formula ! wherein R' or Rz is hydroxy, cleavage of a Formula I compound wherein R' or RZ is (C,-Ca)alkoxy is preferred.
The cleavage reaction may conveniently be carried out by any of the many procedures known for such a transformation. Treatment of the protected formula I
derivative with molten pyridine hydrochloride (20-30 eq.) at 150 to 175°C may be employed for O-dealkylations. Alternatively, the cleavage reaction may be carried out, for example, by treatment of the protected quinazoline derivative with an alkali metal (C,-C4)alkylsulphide, such as sodium ethanethiolate or by treatment with an alkali metal diarylphosphide such as lithium diphenylphosphide. The cleavage reaction may also, conveniently, be carried out by treatment of the protected quinazoline derivative with a boron or aluminum trihalide such as boron tribromide. Such reactions are preferably carried out in the presence of a reaction-inert solvent at a suitable temperature.
Compounds of formula I, wherein R' or RZ is a (C,-C,)alkylsulphinyl or (C,-C4)alkylsulphonyl group are preferably prepared by oxidation of a formula I
compound wherein R' or R2 is a (C,-C4)alkylsulfanyl group. Suitable oxidizing agents are known in the art for the oxidation of sulfanyl to sulphinyl and/or sulphonyl, e. g., hydrogen peroxide, a peracid (such as 3-chloroperoxybenzoic or peroxyacetic acid), an alkali metal peroxysulphate (such as potassium peroxymonosulphate), chromium trioxide or gaseous oxygen in the presence of platinum. The oxidation is generally carried out under as mild conditions as possible using the stoichiometric amount of oxidizing agent in order to reduce the risk of over oxidation and damage to other functional groups.
In general, the reaction is carried out in a suitable solvent such as methylene chloride, chloroform, acetone, tetrahydrofuran or tert-butyl methyl ether and at a temperature from about -25 to 50°C, preferably at or near ambient temperature, i.
e., in the range of 15 to 35°C. When a compound carrying a sulphinyl group is desired a milder oxidizing agents should be used such as sodium or potassium metaperiodate, conveniently in a polar solvent such as acetic acid or ethanol. The compounds of formula I containing a (C,-CQ)alkylsulphonyl group may be obtained by oxidation of the corresponding (C,-CQ)alkylsulphinyl compound as well as of the corresponding (C,-CQ)alkylsulfanyl compound.
Compounds of formula I wherein R' is optionally substituted (C2 C4)alkanoylamino, ureido, 3-phenylureido, benzamido or sulfonamido can be prepared by acylation or sulfonylation of a corresponding compound wherein R' is amino.
Suitable acylating agents are any agents known in the art for the acylation of amino to acylamino, for example, acyl halides, e.g., a (Cz-CQ)alkanoyl chloride or bromide or a _16_ benzoyl chloride or bromide, alkanoic acid anhydrides or mixed anhydrides (e.g., acetic anhydride or the mixed anhydride formed by the reaction of an alkanoic acid and a (C,-C4)alkoxycarbonyl halide, for example (C,-C4)alkoxycarbonyl chloride, in the presence of a suitable base. For the production of those compounds of Formula I wherein R' is ureido or 3-phenylureido, a suitable acyfating agent is, for example, a cyanate, e.g., an alkali metal cyanate such as sodium cyanate, or an isocyanate such as phenyl isocyanate. N-sulfonylations may be carried out with suitable sulfonyl halides or sulfonylanhydrides in the presence of a tertiary amine base. In general the acylation or sulfonylation is carried out in a reaction-inert solvent and at a temperature in the range of about -30 to 120°C, conveniently at or near ambient temperature.
Compounds of Formula I wherein R' is (C,-C~)alkoxy or substituted (C,-C~)alkoxy or R' is (C,-CQ)alkylamino or substituted mono-N- or di-N,N-(C,-C4)alkylamino, are prepared by the alkylation, preferably in the presence of a suitable base, of a corresponding compound wherein R' is hydroxy or amino, respectively.
Suitable alkylating agents include alkyl or substituted alkyl halides, for example, an optionally substituted (C,-C4)alkyl chloride, bromide or iodide, in the presence of a suitable base in a reaction-inert solvent and at a temperature in the range of about 10 to 140°C, conveniently at or near ambient temperature.
For the production of those compounds of Formula I wherein R' is an amino-, oxy- or cyano-substituted (C,-CQ)alkyl substituent, a corresponding compound wherein R' is a (C,-C4)alkyl substituent bearing a group which is displacable by an amino-, alkoxy-, or cyano group is reacted with an appropriate amine, alcohol or cyanide, preferably in the presence of a suitable base. The reaction is preferably carried out in a reaction-inert solvent or diluent and at a temperature in the range of about 10 to 100°C, preferably at or near ambient temperature.
Compounds of Formula I, wherein R' is a carboxy substituent or a substituent which includes a carboxy group are prepared by hydrolysis of a corresponding compound wherein R' is a (C,-C4)alkoxycarbonyl substituent or a substituent which includes a (C,-C4)alkoxycarbonyl group. The hydrolysis may conveniently be performed, for example, under basic conditions, e.g., in the presence of alkali metal hydroxide as illustrated in the accompanying Examples.
Compounds of Formula I wherein R' is amino, (C,-C4)alkylamino, di-[(C,-C4)alkyl]amino, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, 4-(C,-R'~ 96/30347 PCT/IB95/00436 C4)alkylpiperazin-1-yl or (C,-C4)alkysulfanyl, may be prepared by the reaction, in the presence of a suitable base, of a corresponding compound wherein R' is an amine or thiol displaceable group with an appropriate amine or thiol. The reaction is preferably carried out in a reaction-inert solvent or diluent and at a temperature in the range of about 10 to 180°C, conveniently in the range 100 to 150°C.
Compounds of Formula I wherein R' is 2-oxopyrrolidin-1-yl or 2-oxopiperidin-1-yl are prepared by the cyclisation, in the presence of a suitable base, of a corresponding compound wherein R' is a halo-(C2-CQ)alkanoylamino group. The reaction is preferably carried out in a reaction-inert solvent or diluent and at a temperature in the range of about 10 to 100°C, conveniently at or near ambient temperature.
For the production of compounds of Formula I in which R' is carbamoyl, substituted carbamoyl, alkanoyloxy or substituted alkanoyloxy, the carbamoylation or acylation of a corresponding compound wherein R' is hydroxy is convenient.
Suitable acylating agents known in the art for acylation of hydroxyaryl moieties to alkanoyloxyaryl groups include, far example, (CZ-C4)alkanoyl halides, (CZ-C4)alkanoyl anhydrides and mixed anhydrides as described above, and suitable substituted derivatives thereof may be employed, typically in the presence of a suitable base.
Alternatively, (CZ-CQ)alkanoic acids or suitably substituted derivatives thereof may be coupled with a Formula I compound wherein R' is hydroxy with the aid of a condensing agent such as a carbodiimide. For the production of those compounds of Formula in which R' is carbamoyl or substituted carbamoyl, suitable carbamoylating agents are, for example, cyanates or alkyl or arylisocyanates, typically in the presence of a suitable base. Alternatively, suitable intermediates such as the chloroformate or carbonylimidazolyl derivative of a compound of Formula I in which R' is hydroxy may be generated, for example, by treatment of said derivative with phosgene (or a phosgene equivalent) or carbonyldiimidazale. The resulting intermediate may then be reacted v.~ith an appropriate amine ar substituted amine to produce the desired carbamoyl derivatives.
Compounds of formula I wherein R' is aminocarbonyl or a substituted aminocarbonyl can be prepared by the aminolysis of a suitable intermediate in v;hich R' is carboxy.
The activation and coupling of formula I compounds wherein R' is carboxy may be performed by a variety of methods known to those skilled in the art.
Suitable _ 18_ methods include activation of the carboxyl as an acid halide, azide, symmetric or mixed anhydride, or active ester of appropriate reactivity for coupling with the desired amine.
Examples of such types of intermediates and their production and use in couplings with amines may be found extensively in the literature; for example M. Bodansky and A. , Bodansky, "The Practice of Peptide Synthesis", Springer,-Verlag, New York, 1984. The resulting formula I compounds may be isolated and purified by standard methods, such as solvent removal and recrystallization or chromatography.
The starting materials for the above described reaction schemes (e.g., amines, quinazolines and amine protecting groups) are readily available or can be easily synthesized by those skilled in the art using conventional methods of organic synthesis.
For example, the preparation of 2,3-dihydro-1,4-benzoxazine derivatives are described in R. C. Elderfield, W.H. Todd, S. Gerber, Ch. 12 in "Heterocyclic Compounds"
, Vol. 6, R. C. Elderfield ed., John Wiley and Sons, Inc., N.Y., 1957. Substituted 2,3-dihydro benzothiazinyl compounds are described by R.C. Elderfield and E.E. Harris in Ch. 13 of Volume 6 of the Elderfield "Heterocyclic Compounds" book.
Certain Formula I quinazolines can exist in solvated, as well as unsolvated forms, such as the hydrated forms. It is to be understood that the invention encompasses all such solvated, as well as unsolvated forms, which possess activity against hyperproliferative diseases.
A suitable pharmaceutically-acceptable salt of a compound of formula I is, for example, an acid-addition salt of a corresponding compound which is sufficiently basic, e.g., an acid-addition salt with, for example, an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric, phosphoric, methanesulfonic, benzenesulfonic, trifluoroacetic, citric, lactic or malefic acid. A suitable pharmaceutically-acceptable hase-addition salt of a compound of formula I vdhich is acidic is an alkali metal salt, for example, a lithium, sodium or potassium salt; an alkaline earth metal salt, for exG~ople, a calcium or magnesium salt; an ammonium salt; or a salt with an organic base which affords a physiologically-acceptable cation for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyefhyl)amine.
All such salts are within the scope of this invention and they can be prepared by conventional metf iods. For example, they can be prepared simply by contacting the acidic and basic entities, usually in a stoichiometric ratio, in either an aqueous, non-aqueous or partially aqueous medium, as appropriate. The salts are recovered by WO 96/30347 PCTlIB95/00436 _19_ filtration; by precipitation with a non-solvent, preferably an etheral or hydrocarbon solvent, followed by filtration and by evaporation of a solvent, or, in the case of aqueous solutions, by lyophilization.
. Some of the compounds of Formula I have asymmetric carbon atoms. Such diasteromeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known er se., for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiotners. All such isomers, including diastereomers mixtures and pure enantiomers are considered as part of the invention.
The active compounds of this invention are potent inhibitors of the erbB
family of oncogenic and protooncogenic protein tyrosine kinases such as epidermal growth factor receptor (EGFR), erbB2, HER3, or HER4 and thus are all adapted to therapeutic use as antiproliferative agents (e.g., anticancer) in mammals, particularly humans. In particular, the compounds of this invention are therapeutants or prophylactics for the treatment of a variety of human tumors (renal, liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblastomas, various head and neck tumors), and other hyperplastic conditions such as benign hyperplasia of the skin (e.g., psoriasis) or prostate (e.g., BPH). It is, in addition, expected that a quinazoline of the present invention may possess activity against a range of leukemias and lymphoid malignancies.
The active compounds may also be expected to be useful in the treatment of additional disorders in which aberrant expression ligand/receptor interactions, activation or signalling events related to various protein tyrosine kinases, whose activity is inhibited by the agents of Formula I, are involved.
Such disorders may include those of neuronal, glial, astrocytal, hypothalamic, and other glandular, macrophagal, epithelial, stromal, and blactocoelic nature in which aberrant function, expression, activation or signalling of the erbB tyrosine kinases may be involved. In addition, compounds of Formula I may have therapeutic utility in inflammatory, angiogenic and immunologic disorders involving both identified and as yet unidentified tyrosine kinases which are inhibited by compounds of Formula I.
The in vitro activity of the active compounds in inhibiting the receptor tyrosine kinase (and thus subsequent proliferative response, e.g., cancer) may be determined by the procedure detailed below.
Activity of the active compunds, in vitro, can be determined by the amount of inhibition of the phosphorylation of an exogenous substrate (e.g., Lys, -Gastrin or polyGluTyr (4:1 ) random copolymer (I. Posner et. al., J. Biol. Chem. 267 (29), 20638-47 (1992)) on tyrosine by epidermal growth factor receptor kinase by a test compound relative to a control. Affinity purified, soluble human EGF receptor (96 ngj is obtained according to the procedure in G. N. Gill, W. Weber, Methods in Enzymolo~c y 146, 82-88 (1987) from A431 cells (American Type Culture Collection, Rockville, MD) and preincubated in a microfuge tube with EGF (2Ng/ml) in phosphorylation buffer +
vanadate (PBV: 50 mM HEPES, pH 7.4; 125 mM NaCI; 24 mM MgCll; 100 NM sodium orthovanadate), in a total volume of 10 NI, for 20-30 minutes at room temperature. The test compound, dissolved in dimethylsulfoxide (DMSO), is diluted in PBV, and 10 NI is mixed with the EGF receptor /EGF mix, and incubated for 10-30 minutes at 30°C. The phosphorylation reaction is initiated by addition of 20 NI "P-ATP/ substrate mix (120 NM
Lys3-Gastrin (sequence in single letter code for ammo acids, KKKGPWLEEEEEAYGWLDF), 50 mM Hepes pH 7.4, 40 NM ATP, 2 uCi y-[''P]-ATP) to the EGFr/EGF mix and incubated for 20 minutes at room temperature. The reaction is stopped by addition of 10 NI stop solution (0.5 M EDTA, pH 8; 2mM ATP) and 6 NI ZN
HCI. The tubes are centrifuged at 14,000 RPM, 4°C, for 10 minutes. 35 ,u1 of supernatant from each tube is pipetted onto a 2.5 cm circle of Whatman P81 paper, bulk washed four times in 5°o acetic acid, 1 liter per wash, and then air dried. This results in the binding of substrate to the paper with loss of free ATP on washing. The [3'P] incorporated is meas;.~red by liquid scintillation counting.
Incorporation in the absence of substrate (e.g., lys~-gastrin) is subtracted from all values as a background and percent inhibition is calculated relative to controls without test compound present.
Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate ICSO value for the in vitro inhibition of EGFR
kinase activity. Although the inhibitory properties of the compounds of Formula I
vary with structural change as expected, the activity generally exhibited by these agents, determined in the manner described above, is in the range of ICS°=0.0001-30 uM.
*Trade-mark Activity of the active compounds, in vivo, can be determined by the amount of inhibition of tumor growth by a test compound relative to a control. The tumor growth inhibitory effects of various compounds are measured according to the methods of Corbett T. H., et al. "Tumor Induction Relationships in Developri~ent of Transplantable Cancers of the Colon in Mice for Chemotherapy Assays, with a Note on Carcinogen Structure", Cancer Res., 35, 2434-2439 (1975) and Corbett, T. H., et al., "A
Mouse Colon-tumor Model for Experimental Therapy", Cancer Chemother. Rep. Part 2~, 5, 169-186 (1975), with slight modifications. Tumors are induced in the left flank by s.c.
injection of 1 X 10B fog phase cultured tumor cells (human MDA-MB-468 breast or human HN5 head and neck carcinoma cells) suspended in 0.10 ml RPM/ 1640. After sufficient time has elapsed for the tumors to become palpable (2-3 mm in diameter) the test animals (athymic mice) are treated with active compound (formulated by dissolution in DMSO typically at a concentration of 50 to 100 mg/mL followed by 1:9 dilution into saline or, alternatively, 1:9 dilution into 0.1% Pluronic P105 in 0.9°.6 saline) by the intraperitoneal (ip) or oral (po) routes of administration twice daily (i.e., every 12 hours) for 5 consecutive days. In order to determine an anti-tumor effect, the tumor is measured in millimeters with Vernier calipers across two diameters and the tumor size (mg) is calculated using the formula: Tumor weight = (length x jwidth]2)/2, according to the methods of Geran, R.1., et al. "Protocols for Screening Chemical Agents and Natural Products Against Animal Tumors and Other Biological Systems", Third Edition, Cancer Chemother. Rep., 3, 1-104 (1972). . Results are expressed as percent inhibition, according to the formula: Inhibition (%) _ (TuW~o"t,o~ -TuW,as,)/TuW~o"t,a~ x 100. The flank site of tumor implantation provides reproducible dose/response effects for a variety of chemotherapeutic agents, and the method of measurement (tumor diameter) is a reliable method for assessing tumor growth rates.
Administration of the active compounds can be effected by any method which enables delivery of the compounds to the site of action (e.g., cancer cells).
These methods include oral routes, intraduodenal rou'...s, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical administration, etc.
The amount of active compound administered will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgement of the prescribing physician. However an effective dosage is in the range of approximately 0.001-100 mg/kg, preferably 1 to 35 mg/kg in single or divided doses. For an average 70kg human, this would amount to 0.05 to 7 g/day, preferably 0.2 to 2.5 g/day.
The composition may, for example, be in a form suitable for oral administration , 5. as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parentera! injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
Pharmaceutical compositions according to the invention may contain 0.1 %-959'0 of the compound, preferably 1 %-70%. In any event, the composition or formulation to be administered will contain a quantity of active compound in an amount effective to alleviate or reduce the signs in the subject being treated, i.e., hyperproliferative diseases, over the course of the treatment.
Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.
Suitable pharmaceutical carriers include inert diluents orfillers, water and various organic solvents. The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the tike. Thus for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia.
Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Preferred materials, therefor, include lactose or milk sugar and high molecular weight polyethylene glycols.
When aqueous suspensions or elixirs are desired for oral administration the active compound therein may be combined with various sweetening or flavoring agents, coloring matters R'O 96/30347 PCT/IB95/00436 or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.
Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent, to those skilled in this art.
For examples, see Remington's Pharmaceutical Sciences., Mack Publishing Company, Easter, Pa., 15th Edition (1975).
The hyperprotiferative disease treatment described above may be applied as a sole therapy or may involve, in addition to the active compound, one or more other antitumor substances. Such conjoint treatment may be achieved by way of the simultaneous, sequential, cyclic or separate dosing of the individual components of the treatment.
High pressure liquid chromatography (HPLC) used in the following examples and preparations was effected according to the following method unless modified in specific examples. Perkin-Elmer Pecosphere 3X3C cartridge column (3mm X 3cm, C18;
available from Perkin Elmer Corp., Norwalk, CT 06859) with a Brownlee (trademark) RP-8 Newguard precolumn (7 micron, 3.2mm X l5mm, available from Applied Biosystems inc. San Jose, CA 95134) which was previously equilibrated in pH 4.50, 200 mM
ammonium acetate buffer. Samples were eluted using a linear gradient of 0-100%
acetonitrile/pH4.50, 200 mM NHQ acetate over 10 minutes with a flow rate of 3.0 ml.~min. Chromatograms were generated over the range 240-400nm using a diode array detector.
It should be understood that the invention is not limited to the particular embodiments shown and described herein, but that various changes and modifications may be made without departing from the spirit and scope of the invention as defined by the claims.
(4-Azidophenyl)-(6.7-dimethoxyqu_inazolin-4-ylLamine hydrochloride ~;-Chloro-6,7-dimethoxyquinazoline (250 mg, 1.12 mmol) and 4-azidoaniline ' hydrochloride (200 mg, 1.11 mmol) were refluxed in 10 mL of isopropyl alcohol for 0.5 hour, cooled and filtered to afford solid title product which was vrashed with 10 ml_ of isopropyl alcohol and dried in vacuo, at 70°C, 392 mg (98%); mp 200-205°C (dec).
WO 96/30347 PCT/IB95/004.36 (6.7-Dimethoxyquinazolin-4-yl}-(3-ethynylphenyll-amine hydrochloride 4-Chloro-6,7-dimethoxyquinazoline (250 mg, 1.12 mmol) and 3-ethynyl-aniline (137 mg, 1.17 mmol) were refluxed in 10 mL of isopropyl alcohol for 0.5 hour, cooled and filtered to afford solid title product which was washed with 10 mL of isopropyl alcohol and dried in vacuo, at 70 ° C, 338 mg (99%); mp 269-270 ° C.
,(6 7-Dimethox rLguinazolin-4-yl)-(3-(3'-hydroxypropynl-yl)phenyll-amine A mixture of (3'-bromophanyl)-(6,7-dimethoxyquinazolin-4-yl)-amine hydrochloride (250 mg, 0.591 mmol), tetrakis(triphenylphosphine)palladium (100 mg), propargyl alcohol (600~L), 7 mL of dry, nitrogen purged diethylamine and cuprous iodide (10 mg) was refluxed for 5 hours, cooled and filtered to afford solid title product which was washed two times with 2mL of 50°~ diethylamine: methanol; 136 mg. The solid was recrystallized from methanol to give pure title product after drying, in vacuo" at 70°C, 73 mg (37~); mp 267-268°C.
j(3-(2'-Aminomethyl-ethyn rLl)phenyll-(6 7-dimethoxyguinazolin-4-yl)-amine hydrochloride The title product of Example 3 (50 mg, 0.149 mmol}, triphenylphosphine (60 mg, 0.225 mmol)), phthalimide (165 mg, 1.12 mmol) and diethyl azodicarboxylate (36 iuL, 0.228 mmol) were stirred at room temperature in 3 mL of dry tetrahydrofuran for 16 hours. The reaction mixture was concentrated to a solid and flash chromatographed on silica gel eluted with 15% acetone:methylene chloride to afford pure solid j3-(2' {phthalimidomethyl}-ethynyl)phenyl]-(6,7-dimethoxyquinazoline-4-yl)amine which was converted to its hydrochloride salt by addition of 1 mL of anhydrous 1 M HCI
in methanol followed by 3 mL of isapropyi alcohol. The salt was collected by filtration, dried and used immediately in the next step; 15 mg. This 15 mg, 0.0323 mmol was treated with 0.5 ml of hydrazine hydrate and 1 mL of methanol for 0.5 hours.
The reaction mixture was evaporated, in vacuo, and the product isolated by flash chromatography eluted with 10% methanol in rnethylene chloride. Pure title product Was isolated after conversion to its hydrochloride salt with 1 mL of i M HCI
in methanol, precipitation with isopropyl alcohol and diethyl ether and drying , in vacuo,;
5.6 mg (47°~) mp 275 ° C dec.
~3-Ethynylphenyl)-(6-nitroquinazolin-4-yl)-amine hydrochloride 4-Chloro-6-nitroquinazoline (1.06 g, 5.00 mmol) and 3-ethynylaniline (1.00 g, 5.30 mmol) were refluxed in 10 mL of isopropyl alcohol for 3 hours,' cooled and, after 16 hours at room temperature, filtered to afford solid title product which was washed with mL of isopropyl alcohol and dried iri vacuo, at 70°C, 1.27 g (78%); mp 255-256°C.
(6,7-Dimethoxyquinazolin-4 ~y~4-ethynylphenyl)-amine The title product was prepared in the following three step sequence without 10 purification of the intermediates. 4-Chloro-6,7-dimethoxyquinazoline (250 mg, 1.113 mmol) and 4-iodoaniline (268 mg, 1.224 mmol) were refluxed in 10 mL of isopropyl alcohol for 3 hours, cooled to room temperature and filtered to afford solid (4 iodophenyl)-(6,7-dimethoxyquinazoline-4.-yl)aminehydrochloridewhichwaswashedwith 10 mL of isopropyl alcohol and dried in vacuo at 70°C, 396 mg (76°.6). A mixture consisting of (4'-iodophenyl)-(6,7-dimethoxyquinazoline-4-yl)amine hydrochloride (250 mg, 0.564 mmol), tetrakis(triphenylphosphine)palladium (50 mg), trimethylsilylacetylene (160NL, 1.13 mmol), 4 mL of dry, nitrogen purged diethylamine and cuprous iodide (10 mg) was refluxed for 2 hours, cooled and concentrated in vacuo, to afford a residue which was partitioned between chloroform and 1 N HCL. Solid [4-(2'-{trimethylsilyl}-ethynyl)phenyl]-(6,7-dimethoxyquinazoline-4-yl)amine formed at the interface of the two liquid phases and was filtered and dried in vacuo; 170 mg (80%).
[4-(2'-{Trimethylsilyl} ethynyl)phenyl]-(6,7-dimethoxyquinazoline-4-yl)amine (100 mg, 0.265 mmol) and anhydrous potassium carbonate (125 mg, 0.906 mmol) were stirred in 3 mL of methanol and 1 mL of vrater at room temperature for 2.5 hours. The reaction mixture was concentrated in vacuo, and partitioned betGVeen 20 mL of chloroform and 20 mL of 1 N hydrochloric acid. The organic layer was dried with magnesium sulfate, filtered and vacuum evaporated to give the title product which was triturated with diethyl ether and dried in vacuo at 70°C; 81 mg (90%) mp 239°G dec.
L6,7-Dimethoxyquinazolin-4-yl',~3-ethy ~I-2-methylphenyl)-amine The title product was prepared in the following three step sequence with out purification of the intermediates. A mixture consisting of 3-bromo-2-methylaniline (1.00 g, 5.37 mmol), tetrakis(triphenylphosphine)palladium (200 mg), trimethylsilylacetylene (1.053 g, 10.75 mmol), lOmL of dry, nitrogen purged diethylamine and cuprous iodide 910 mg) was refluxed for 16 hours, cooled and concentrated, in vacuo, to afford a residue which was partitioned between chloroform and 1 N HCL. The organic layer was washed with brine, dried with magnesium sulfate and vacuum evaporated to yield a residue, 3-[2'-(trimethylsilyl)ethynyl]-2-methylaniline which was purified by flash chromatography on silica gel eluted with 1:1 hexanes: methylene chloride; 200 mg (18~).
4-Chloro-6,7-dimethoxyquinazoline (104 mg, 0.466 mmol) and 3-[2'-(trimethylsilyl)ethinyl]-2-methylaniline (100 mg, 0.491 mmol) were refluxed in 3 mL of isopropyl alcohol for 16 hour, cooled to room temperature and filtered to afford a residue of solid ~3-(2'-(trimethylsilyl)ethynyl]-2'-methylphenyl]}-(6,7-dimethoxyquinazoline-4-yl)amine hydrochloride which was washed with 10 mL of isopropyl alcohol and triturated for 16 hours with diethyl ether. Thin layer chromatography on silica gel eluted with 9:1 chloroform: methanol indicated that the residue was impure product. The residue was purified by flash chromatography on silica gel eluted with 9:1 methylene chloride: methanol to afford after concentration and drying , in vacuo, pure product, 64 mg (33%). The product was dissolved in 3 mL of methanol and treated with 64 mg of anhydrous potassium carbonate at room temperature for 3 hours. The reaction mixture was concentrated in vacuo and partitioned between 1 N HCI and chloroform. Solid title product formed at the interface of the two liquid phases and was filtered and dried, in vacuo,; 40 mg (84%) mp 225°C
dec.
16-Amino-quinazolin-4-yy ~3-ethynylphenyl)-amine (3-Ethynyl-phenyl)-(6-nitro-quinazolin-4-yl)-amine hydrochloride (500 mg, 1.50 mmol) was dissolved in 10 mL of formic acid and treated portion-wise with sodium 5, dithionite (1.10 g, 6.28 mmol) at room temperature. After 2 hours the mixture was quenched with 120 mL of water and filtered. The filtrate was evaporated in vacuo to a residue which was dissolved in 100 mL of 1:1 methanol:chloroform, filtered and evaporated in vacuo to a second residue. This was triturated with 200 mL of 5%
sodium bicarbonate for 30 minutes, filtered,washed with water and dried in vacuo for 16 hours.
Flash chromatography on silica gel eluted with ethyl acetate afforded pure (6-amino-quinazoiin-4-yl)-(3-ethynylphenyl)-amine ; 140 mg (34%); mp 165 °C dec.
13-Ethynylphenyl)-(6-methanesulfor~laminoguinazolin-4-y~-amine The title product of Example 8 (100 mg, 0.384 mmol), pyridine (140 frL, 1.68 mmol) and methanesulfonyl chloride (99 NL, 1.26 mmol) were refluxed in 10 mL
of 1,2-dichloroethane for 7 hours. The reaction mixture was cooled and evaporated in a vacuo to a residue which was triturated in 10 mL of 1 N HCI, filtered and dried in vacuo toyield(3-ethynylphenyl)-(6-methanesulfonylaminoquinazoline-4-yl)amine;102mg(78%) mp 248°C dec.
~3-Ethynylphenyl)-(6.7-methylenedioxyquinazolin-4-yl)-amine hydrochloride 4-Chloro-6,7-methylenedioxyquinazoline (200 mg, 1.04 mmol) and 3 ethynyianiline (127 mg, 1.09 mmol) were refluxed in 5 mL of isopropyl alcohol for 16 hour, cooled and filtered to afford solid title product which was washed with 10 mL of isopropyl alcohol and dried in vacuo at 70°C, 266 mg (79%); mp >350°C.
~(6,7-Dimethoxyguinazolin-4-yl)-3-ethynyl-6-n~~thviphenvl)-amine hydrochloride The title product was prepared in the follov;ring three step sequence v,~ifhout ' purification of the intermediates. A mixture consisting of 4-bromo-2-nitrotoluene (1.50 g, 6.94 mmol) tetrakis(triphenylphosphine)palladium (750 mg), trimethylsilylacetylene (3.00 mL, 21.21 mmol) and cuprous iodide (20 mg) in 20 mL of nitrogen purged, dry diethylamine was refluxed for 2 hours, cooled and concentrated, in vacuo, to afford a residue which was partitioned between 100 mL of ethyl acetate and 100 mL of 1 N HCI.
WO 96/30347 PC'T/IB95/00436 The organic layer was washed two times with 50 mL of 1 N HCI followed by brine, dried with magnesium sulfate and vacuum evaporated to a residue. The residue was dissolved in 10 mL of ethyl acetate and diluted with 200 mL of petroleum ether. The solids were filtered off. and the oil, obtained upon vacuum evaporation of the filtrate, , solidified to give 4-[2'-(trimethylsilyl)ethinyl]-2-nitrotoluene. This product was reduced to the amino product by treatment with iron powder (1.76 g, 98.5 mmot) in 30 mL of methanol and 5 mL of concentrated hydrochloric acid at 80°C for 2 hours. The cooled reaction mixture was filtered through Celite' and the filtrate was evaporated in vacuum.
The residue was partitioned between ethyl acetate and 5% aaueous sodium bicarbonate. The organic layer was washed with brine, dried with magnesium sulfate, filtered and vacuum evaporated to yield an oil, 5-[2'-(trimethylsilyl)ethynyl)-methylaniline which solidified upon standing: 1.37 g.
The above product (185 mg, 0.909 mmol) and 4-chloro-6,7-dimethoxy quinazoline (200 mg, 0.890 mmol) were refluxed in tent-butyl alcohol for 16 hours. After cooling the reaction mixture was filtered to yield pure [2-methyl-5-(2' {trimethylsilyl}ethynyl)-phenyl]-(6,7-dimethoxyquinazofine-4-yl-amin~ydrochlorideafter washing with ether and drying in vacuum; 326 mg (85%). The trimethylsilyl group was removed by dissolving the above product in 5 mL of methanol and 1 mL of water and treatment with potassium carbonate (320 mg). After stirring for 1 hour the mixture was filtered and concentrated in vacuo. The residue thus obtained was partitioned between 100 mL of methylene chloride and 100 mL of 1 N HCI. The aqueous layer was extracted with an additional 100 mL of methylene chloride. The pooled organic layers were dried with magnesium sulfate, filtered and vacuum evaporated to a residue which was dissolved in anhydrous 1 N HCI in methanol, concentrated and precipitated with ether.
The solid title product was collected by filtration and washed with diethyl ether then dried in vacuo at 70 ° C; 236 mg (88%) mp 266-267 ° C.
j3-Ethyn~phenyl)-(7-nitroc,~uinazolin-4-y~-amine hydrochloride 4-Chloro-7-nitroquina: olive (7.97 g, 38.0 mmol) and 3-ethynylaniline (4.54 g, 38.8 mmol) were refluxed in 125 mL of iert-butyl alcohol for 3 hours, cooled to room temperature and filtered to afford the title product as a solid which was washed with 10 mL of isopropyl alcohol and dried in vacuo at 70°C, 9.95g (80%); mp 209-210°C dec.
(3-Ethynylphenyl)-f6-(4'-toluenesulfonylamino)-quinazolin-4~r11-amine hydrochloride The title product of example 8 (0.201 mg, 0.774 mmol) and 4-toluenesulfonyl chloride (0.441 mg, 2.31 mmol) were refluxed in 3 mL of 1,2-dichloroethane and 0.5 mL
5, of pyridine for 5 minutes. The reaction mixture was cooled to room temperature, diluted with 75 mL of ethyl acetate and washed two times with 75 mL of water once with 75 mL of 3% sodium bicarbonate and once with 75 mL of brine. The organic layer was dried with magnesium sulfate, filtered and vacuum evaporated to a residue which was purified by chromatography using a Chromatotron (trademark) eluted with ethyl acetate, to afford solid title product; 86.7 mg (27%) mp 220-222 ° C.
j3-Ethynylphenyl)-f 6-f2'-phthalimido-ethan-1'-ylsulfonylarninolauinazofin-4-vl~-amine hydrochloride The title product of example 8 (0.20 mg, 0.768 mmol) and 2-phthalimido-1-ethanesulfonyl chloride (0.615 mg, 2.25 mmol) were refluxed in 2 mL of 1,2-dichloroethane and 0.5 mL of pyridine for 16 hours, cooled to room temperature, diluted with 100 mL of chloroform and washed with 50 mL of 3% sodium bicarbonate and 50 mL of brine. The organic layer was dried with magnesium sulfate, filtered and vacuum evaporated to a residue which was dissolved in minimal methylene chloride and precipitated with petroleum ether, 188 mg. The precipitate was purified by chromatography using Chromatotron@ eluted with ethyl acetate, to afford the title product as a solid ; 53.4 mg (14%) mp 197 - 200°C.
j3-Ethyny(phenyl)-(6-auanidinoquinazolin-4_yl)-amine h~rdrochloride The title product of example 8, (0.302 mg, 1.16 mmol} and 3,5-dimethylpyrazole-1-carboxamidine (0.328 mg, 2.36 mmol) were ref(uxed in 10 mL of 1,2-dichloroethane and 0.97 mL of acetic acid for 24 hours, cooled to room temperature and filtered to yield the crude acetate of the title product. The product was ~!issolved in 35 mL of ' methanol and treated with 15 mL of anhydrous 1 N HCI in methanol for 15 minutes and then precipitated vrith 75 mL of diethyl ether. Solid title product was collected by filtration and dried in vacuo at 70°C; 91.2 mg (23%) mp>400°C.
WO 96/30347 PC'T/IS95/00436 j7-Aminoquinazolin-4.-yl)-(3-ethynylpheny~-amine The title product of example 12 (1.039 g, 3.18 mmol) was dissolved in 50 mL of tetrahydrofuran, 10 mL of methanol and 5 mL of chloroform at 50°C.
Sodium 5, dihydrogen phosphite (NaH2P02, 3.822 g, 36 mmol) and 10% palladium on carbon (0.19 g) were added followed by dropwise addition of 10 mL of water. When 3 mL
of water had been added the mixture became noticeably more homogeneous. After 1 hour the mixture was filtered through Celite. The Celite was washed thoroughly with methanol and chloroform. The combined organic solutions were vacuum evaporated to a residue which was triturated with water, 3% aqueous sodium bicarbonate and filtered. The solid title product was washed with water then diethyl ether and dried in vacuo, 1.054 gm (127%, wet). A portion of the above product was recrystallized from a minimum amount of hot ethanol and water to give, after removal of a small first crop of impure material, pure title product, (43%), mp 180°C (dec).
13-Ethynylphenyll-(7-methoxyquinazolin-4-yl)-amine hydrochloride 4-Chloro-7-methoxyquinazoline (274 mg, 3.72 mmol) and 3-ethynylaniline (436 mg, 3.72 mmol) were refluxed in 15 mL of tert-butyl alcohol for 3 hours, cooled and filtered to afford solid title product which was washed with 10 mL of isopropyl alcohol and dried in vacuo at 70°C, 977 mg (84%); mp 229-231 °C.
16-Carbomethoxyctuinazolin-4-yl)-f3-ethynylphenyl -amine hydrochloride 4-Chloro-6-carbomethoxyquinazoline (100 mg, 0.450 mmol) and 3-ethynylaniline hydrochloride (53.4 mg, 0.456 mmol) were refluxed in 2 mL of tert-butyl alcohol for 2 hours, cooled, diluted with 2 mL of isopropyl alcohol and filtered to afford solid title product which u~as washed with 10 mL of diethyl ether and dried , in vacuo, at 70°C, 122 mg (80%); mp 232-233°C (dec).
R'O 96/30347 PCT/IB95/00436 (7-Carbomethoxyquinazolin-4-yIL~3-ethynylphenyl)-amine hydrochloride 4-Chloro-7-carbomethoxyquinazoline (202 mg, 0.907 mmol) and 3-ethynylaniline (110 mg, 0.939 mmol) were refluxed in 4 mL of tert-butyl alcohol for 2 hours, cooled, diluted with 4 mL of isopropyl alcohol and filtered to afford solid title product which was washed with 10 mL of diethyl ether and dried , in vacuo, at 70°C, 248 mg (8096); mp 219.5-221 ° C.
j6-,7-Bis-(2-methoxyethoxy)-quinazolin-4y11-(3-ethyn~,rphenyl)amine hydrochloride 3-Ethynylaniline (37 mg, 0.32 mmol.), and 4-chloro-6,7-bis-(2-methoxy-ethoxy)-quinazoline (90 mg, 0.29 mmol) were added to isopropanol (1.5 mL) containing pyridine (25 ~rL, 0.32 mmol) and the mixture was refluxed 4 hours under an atomospher of dry nitrogen. The solvent was removed , in vacuo, and the residue partitioned between 109'° methanol in CHCI3 and saturated aqueous NaHC03. The organic phase was dried over Na2S04, filtered and concentrated in vacuo. The residue was flash chromatographed on silica using 30% acetone in hexanes to afford 81 mg of the free base of the title product as a pale yellow solid. The free-base was dissolved in a minimum volume of CHCI3, diluted with several volumes of ether, and titrated with 1 M
HCI in ether to precipitate the title product as its hydrochloride salt; 90 mg; 71 %; mp 228-230 ° C.
(3-Azido~henyl~~6,7-dimethox rLQUinazolin-4=y)amine 4-Chloro-6,7-dimethoxyquinazoline (5.01 g, 22.3 mmol) was added in portions, over 1.5 hours, to m-phenylenediamine (2.66 g, 24.6 mmol) in refluxing isopropanol (100 mL} under an atmosphere of dry nitrogen. After the addition was complete the mixture was heated at reflux for 4 hours. The mixture was cooled to 20°C, and the precipitate was filtered, washed trt~ith chilled isopropanol and dried in vacuo to aficrd 6.97 g (93%) of (3-aminophenyl)-(6,7-dimsthoxyquinazolin-4-yl)amine hydrochloride (LC-a MS: 297 (MH+}. To a solution of the above product (50 mg, 0.169 mmol) in 8090 acetic acid/H20 (2 mL), at 0°C, was added a solution of NaN02 (18.4 mg, 0.186 mmol) in Hz0 (i00 ~rL). After stirring 10 minutes at 0°C a solution of NaN3 (12 mg, 0.185 rnmol) io H20 (100~L) was added. The mixture was allowed to warm to 20°C and stirred for 1.5 hours. The reaction mixture was lyophilized and the residue partitioned between ethyl WO 96/30347 PCT/1895/004~6 acetate and saturated aqueous NaHC03. The organic phase was wahsed further with brine, dried over Na2S04, filtered, and concentrated , in vacuo,.
Recrystallization from , CHCI3/hexanes afforded 36 mg of the title product as a white solid; mp 110-113°C.
5. (3-Azido-5-chlorophenyl)=(6 7-dimethoxyQUinazolin-4-yl)amine 4-Chloro-6,7-dimethoxyquinazoline (200 mg, 0.89 mmol) and 5-amino-3-chloroaniline (253 mg, 1.78 mmol) were combined in isopropanol (3 mL) and heated to reflux for 16 hours under an atmosphere of dry nitrogen. After cooling to 20°C the mixture was diluted with methanol (5 mL} and the resulting precipitate was filtered and dried, in vacuo, to afford 252 mg (77%) of (3-amino-5-chlorophenyl}-(6,7-dimethoxyquinazolin-4-yl)amine hydrochloride (mp. 298-301 °C; LC-MS:
331 (MH+)).
A portion of this product (175 mg, 0.476 mmol) was dissolved in 80% acetic acid/Hz0 (12 mL), cooled to 0°C, and a solution of NaN02 (36 mg, 0.516 mmol) in HZO (300 /rL) was added. The solution was stirred for 10 minutes at 0°C and NaN3 (33 mg, 0.50 mmol) in HZO (300 ~rL) was added. The reaction mixture was allowed to warm to 20 ° C
and stirred 16 hours. The resulting precipitate was filtered and dissolved in 10%
methanol in CHCI3 and the solution was washed with saturated aqueous NaHC03, and brine, dried over Na2S04, filtered and concentrated in vacuo to yield 59 mg (35~°) of the title product as a yellow solid; mp 205-206°C.
L3-Ethynylphenyl)-t6-methanesulfonyl-quinazolin-4-yl)-amine hydrochloride 6-Methanesulfonyl-quinazolin-4-one (200 mg, 0.89 mmol}, triphenyl phosphine (566 mg, 2.15 mmol) and carbon tetrachloride (815 NL, 8.92 mmol} were refluxed in 3 mL of chloroform for 3.5 hours. The solvent was vacuum evaporated to afford a residue.
This was dissolved in 5 mL of isopropyl alcohol and 3-ethynylaniline (156 mg, 1.33 mmol) and heated at reflux for 16 hours. The cooled reaction mixture was filtered,washed with a minimum of cold isopropyl alcohol and dried in vacuo at 70 °C
for 16 hours to afford pure title product; 63 mg (20%) rnp 281-282 °C.
WO 96/30347 PCTlIB95/00436 (6-Ethansulfanyl-quinazolin-4-y~y3-eth r~nypheny,-amine hydrochloride 6-Ethanesulfanyl-quinazolin-4-one (100 mg, 0.48 mmol), triphenyl phosphine (305 mg, 1.16 mural) and 3 mL of carbon tetrachloride were refluxed for 16 hours. The solvent was vacuum evaporated to afford a residue. This was dissolved in 5 mL
of isopropyl alcohol and 3-ethynylaniline (68 mg, 0.58 mmol) and heated at reflux for 1 hour. The cooled reaction mixture was filtered, washed with a minimum of cold isopropyl alcohol and dried in vacuo at 70°C for 16 hours to afford pure title product;
70 mg (42%) mp 239-40°C.
56.7=Dimethoxy-guinazolin-4=yl)-(3-ethynyl-4-fluoro-phenyl)-amine hydrochloride 4-Chloro-6,7-dimethoxyquinazoline (500 mg, 2.23 mmol) and 3-(2'-trimethylsilyl-ethynyl)-4-fluoroaniline (507 mg, 2.44 mmol) were refluxed in 5 mL of tert-butyl alcohol for 16 hours, cooled and filtered to afford solid (6,7-dimethoxy-quinazolin-4-yl)-(3'-ethynyl-phenyl)-amine hydrochloride which was washed with 10 mL of isopropyl alcohol and dried in vacuo at 70 °C, 832 mg (83%). This was reacted in 10 mL of methanol and 1 drop of water containing 250 mg of potassium carbonate for 3 hours. The mixture was filtered and the filtrate vacuum evaoprated. This residue was triturated for 1 hour with 1 N hydrochloric acid, filtered and washed with a minimum amount of water then methanol and dried in vacuo; 506 mg (63%) mp 229°C dec.
3-(2'-Trimethylsilyl-ethynyl)-4-fluoroaniline, used above, was prepared from 3-bromo-4.-fluoroaniline (7.0 gm, 36.8 mural) tetrakis(triphenylphosphine)palladium (1.4 gm), trimethylsilyl-acetylene (7.2 gm, 74 mmol) and cuprous iodide (40 mg) in 140 mL
of nitrogen purged dry diethylamine at reflux for 16 hours. The cooled reaction mixture was filtered through Celite and the Celite washed with ether. The combined filtrates were vacuum evaporated to a residue which was purified by clash chromatography on silica gel eluted with 35% hexanes in methylene chloride. Fractions containing the pure 3-(2'-trimethylsilyl-ethynyl)-4-fiuoroaniline vrere vacuum evaporated to a residue and used without further purification.
16,7-Dimethoxy-guinazolin-4-yl)-!3-hropyn-1-yl)phenyl)-amine hydrochloride 4-Chloro-6,7-dimethoxyquinazoline (585 mg, 2.60 mmol) and 3-(propyn-1 yl)aniline (361 mg, 2.74 mmol) were refluxed in 5 mL of tert-butyl alcohol for 16 hours, cooled and filtered to afford solid (6,7-dimethoxy-quinazolin-4-yl)-[3-(propyn-yl)phenyl)J-amine hydrochloride which was washed with 5 mL of isopropyl alcohol and 25 mL of ether then dried in vacuo at 70 °C, 869 mg (94'x); mp 260-261 °C.
3-(Propyn-1-yl)aniline, used above, was prepared from 3-bromo-nitrobenzene in four steps. 3-Bromo-nitrobenzene (5.0 gm, 24.7 mmol), tetrakis(triphenylphosphine)palladium (1.0 gm), trimethylsilyl-acetylene (3.6 gm, 37 mmol) and cuprous iodide (20 mg) in 20 mL of nitrogen purged, dry diethylamine at reflux for 16 hours. The cooled reaction mixture was vacuum evaporated, diluted with 50 mL of methylene chloride and 50 mL of 1 N hydrochloric acid and filtered.
The organic layer was collected and dried with magnesium sulfate filtered and vacuum evaporated to a residue. The 3-trimethylsilylethynylnitrobenzene was purified by flash chromatography on silica gel eluted with 2:1 hexanes:methylene chloride.
Fractions containing the pure material were vacuum evaporated to afford pure 3-trimethylsilyl-ethynyl nitrobenzene (4.6 gm). 4.0 gm of this were dissolved in 30 mL of methanol and 1 drop of water containing 1.16 gm of potassium carbonate. After one hour the mixture was vacuum evaporated and diluted with 100 mL of methylene chloride. The organic layer was washed with 100 mL of 1 N hydrochloric acid, dried with magnesium sulfate, filtered and vacuum evaporated to a residue (2.96 gm). 790 mg of this was dissolved in 10 mL of benzene and treated with finely pulverized 87% potassium hydroxide (377 mg, 5.91 mmol), methyl iodide (2 mL) and 10 mg of 18-Crown-6 (Aldrich) at reflux for 16 hours. An additional 0.5 mL of methyl iodide were added and the reflux continued for an additional 2 hours. The cooled reaction mixture was vacuum evaporated to a residue which was diluted with 100 mL of methylene chloride and washed with i 00 mL
of 1 N hydrochloric acid, dried with magnesium sulf te, filtered and vacuum evaporated to an oil. This was purified by flash chromatography on silica gel eluted with 1:1 ' hexanes:methylene chloride. Fractions containing pure 3-(propyn-1-yl)-nitrobenzene v~ere vacuum evaporated to an oil which was used without further purification;
530 mg (61%). 3-(Propyn-1-yl)-nitrobenzene (530 mg, 3.3 mmol), iron powder (400 mg, 7.27 mmol), 3 mL of concentrated hydrochloric acid and 10 mL of methanol were refluxed WO .96/30347 PCT/IB95/00436 for 1 hour. The reaction mixture was filtered and vacuum evaporated to a solid which was partitioned between 100 mL of methylene chloride and 100 mL of 1 N sodium hydroxide. The two phases were filtered and then the organic phase was separated, dried with magnesium sulfate, filtered and vacuum evaporated to an oil which was used 5, directly in the preparation of the title product; 321 mg (78~).
I6.7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yll-(3-ethynyl-4-fluoro phenyl)-amine hydrochloride 4-Chloro-6,7-bis-(2-methoxy-ethoxy)-quinazoline (140 mg, 0.446 mmol) and 3 ethynyt-4-fluoroaniline (66 mg, 0.452 mmol) were reacted in refluxing isopropanol (3 mL) under an atmosphere of NZ for 16 hours. The solvent was removed in vacuo and the residue was partitioned between CHCI3 and saturated aqueous NaHC03. The organic extracts were washed with brine, dried over Na2S04, filtered and concentrated in vacuo.
The crude product was chromatographed on silica using 40% acetone/CHZCIZ to provide 116 mg of the pure title product as its free base. This oil was dissolved in a minimum volume of CHCI3, diluted with several volumes of ether and titrated with 1 M
HCI in ether to precipitate the title product as a white solid (99 mg; 50%;
M.P. 170-190 °C (dec); LC-MS: 412 (MH+); anal. RP18-HPLC RT: 4.33 min.).
I6,7-Bis-(2-methoxy-ethoxyl-quinazolin-4=yll-(5-ethynyl-2-methyl-phenyl-amine hydrochloride 4-Chtoro-6,7-bis-(2-methoxy-ethoxy)-quinazoline (153 mg, 0.49 mmol), pyridine (40 NL) and 3-ethynyl-6-methylaniline (71 mg, 0.54 mmol) were reacted in DMF
(3 mL) at 110 °C under an atmosphere of NZ for 36 hours. The solvent was removed in vacuo and the residue was partitioned between CHCI3 and saturated aqueous NaHC03.
The organic extracts were washed with brine, dried over NazS04, filtered and concentrated in vacuo. The crude product was chromatographed on silica using 40%
acetone/CH2C12 to provide 40 mg (19%) of pure product as its free base. This oil was ' dissolved in a minimum volume of CHCI3, diluted with several volumes of ether, and triturated with 1 M HCI in ether to precipitate the title product as a white solid (M.P. 170 185 °C (dec); LC-MS: 408 (MH+); anal. RP18-HPLC RT: 3.93 min.).
WU 96/30347 PC'T/IB95/00436 (6.7-Bis-(2-chloro-ethoxy)-auinazotin~-y1113-ethvnvf-phenyl)-amine hydrochloride 4-Chloro-6,7-bis-(2-chloro-ethoxy)-quinazoline (600 mg, 1.87 mmol) and 3-ethynyl-aniline (219 mg, 1.87 mmol) were reacted in refluxing isopropanol (15 mL) under an atmosphere of NZ for 2.5 hours. The mixture was cooled to 20 °C and the precipitated product was filtered, washed with isopropanol and ether and dried in vacuo. (707 mg; 86~; M.P. 230-240°C (dec); LC-MS: 402 (MH+); anal. RP18-HPLC RT:
5.35 min.).
j6~2-Chloro-ethoxy)-7-(2-methoxy-ethoxv)-quinazolin-4-vtl-(3-ethvnvl-ahenvll-amine hydrochloride The title product was prepared from 4-chloro-6-(2-chloro-ethoxy)-7-(2-methoxy ethoxy)-quinazoline (399 mg, 1.26 mmol) and 3-ethynyl-aniline (147 mg, 1.26 mmol) as described for Example 29. (515 mg; 94%; M.P. 215-225°C (dec); LC-MS:
398 (MH+);
anal. RP18-HPLC RT: 4.85 min.).
6,7-Bis(2-acetoxV-ethoxyl-4-(3-ethynyl phen lamino)- quinazoline The title product of Example 29 (200 mg, 0.456 mmol) was treated with cesuim acetate (1.75 g, 9.12 mmol) in DMF (3 mL) at 120°C under an atmosphere of NZ for 16 hours. The reaction mixture was partitioned between brine and CHCI3, and the organic extract was washed with brine, dried over NazS04, filtered and concentrated in vacuo to afford an oil (277 mg) which was recrystallized from CH2CI2 J hexane. (184 mg; 90~°;
M.P. 137-138 °C; LC-MS: 450 (MH+); anal. RPiB-HPLC RT: 4.64 min.).
2-j4~3-EthynYl--phenVlamino)-7~2-hydrox -ethoxy)-quinazolin-6-yloxyl-ethanol hydrochloride 6,7-6is-(2-acetoxy-ethoxy)-4-(3-ethynyl-phenyl-amino)-quinazoline (199 mg, 0.443 mmol) in methanol (3 mL) was treated with 7M aqueous KOt-i (0.25 mL). Tt~e mixture was stirred at 20°C for 2 hours, before removing the solvent in vacuo.
The solid ' residue was washed with water to remove salts, and dried azeotropically by dissolution two times in acetonitrile and concentration in vacuo to afford 116 mg of title product as its free base. This material was converted to its HCI salt according to the method used in Example 28 (115 mg; 65~; M.P.215-218°C (dec); LC-MS: 366 (MH+);
anal. RP18-HPLC RT: 3.08 min.).
. ~2-Acetoxy-ethoxy)~-(3-ethynyl-phenylamino)-7-(2-methoxy-ethoxy)-quinazoline 5. The title product of Example 30 (160 mg, 0.368 mmol); was treated with cesium acetate (707 mg, 3.68 mmol) in DMF (3 mL) at 120°C under an atmosphere of NZ for 16 hours. The reaction mixture was partitioned between brine and CHCI3, and the organic extract was washed with brine, dried over Na2S04, filtered and concentrated in vacuo to afford a residue (285 mg) which was recrystallized from ethylacetate / hexane.
(134 mg; M.P.84-87°C; LC-MS: 422 (MH+); anal. RP18-HPLC RT: 4.38 min.).
f7-(2-Chloro-ethoxy)-~2-methoxy-ethoxy~guinazolin-4.-yll-(3-ethynyl_ phenyl-amine hydrochloride This product was prepared from 4-chloro-7-(2-chloro-ethoxy)-6-(2-methoxy ethoxy)-quinazoline (600 mg, 1.89 mmol) and 3-ethynyl-aniline (147 mg, 1.26 mmol) as described for Example 29. (737 mg; 90%; M.P. 225-235°C (dec); LC-MS:
398 (MH*);
anal. RP18-HPLC RT: 4.89 min.).
7-(2-Acetoxv-ethoxy)-4-(3-ethvnyl-phenvlamino)-6-(2-methoxv-ethoxv)-auinazoline The title product of Example 34 (160 mg, 0.368 mmol); was treated with cesium acetate (707 mg, 3.68 mmol) in DMF (3 mL) at 120 °C under an atmosphere of N2 for 16 hours. The reaction mixture was partitioned between brine and CHCI3, and the organic extract was washed with brine, dried over NazS04, filtered and concentrated in vacuo to afford a residue (288 mg) which was recrystallized from ethyl acetate /
hexanes. (134 mg; t~l.P.134-135 °C; LC-MS: 422 (MH+); anal. RP18-HPLC
RT: 4.43 min.).
2- 4- 3-Eth ~_~ nyl-pt~enylamino -6-(2-methox)r-etho~~ uinazolin-7- i-oxyl-c-thanol ' hydrochloride The title product of Example 35 (149 mg, 0.354 mmol) in methanol (3 mL) was treated with 5M aqueous KOH (0.25 mL). The mixture was stirred at 20°C
for 30 minutes before removing the solvent in vacuo. The solid residue was washed with water to remove salts, and dried azeotropically by dissolution two times in acetonitrile and concentration in vacuo to afford 100 mg of title product as its free base.
This material was converted to its HCI salt according to the method used in Example 28 (87 mg; 59 96; M.P.230-235 °C (dec); LC-MS: 380 (MH+); anal. RP18-HPLC RT:
3.42 min.).
j3-Ethynyl-phenyl)-~6-(2-methoxy-ethoxy)-7-f2-(4-methyl-piperazin-1-yl -ethoxyl-quinazolin-4. y~-amine dihydrochloride The title product of Example 34 (110 mg, 0.253 mmol) in DMF (2 mL) was treated with N-methyl-piperazine (281 ~rL, 2.53 mmol) at 110 °C for 16 hours. The reaction mixture was partitioned between CHCI3 and saturated aqueous NaHC03.
The organic extracts were washed with brine, dried over NaZS04, filtered and concentrated in vacuo. The crude product was chromatographed on silica using 15°~
methanol/CHZCIZ to provide 56 mg of pure product as its free base. This white solid was dissolved in a minimum volume of CHCI3, and titrated with 2 equivalents of in ether to precipitate the title product as a white solid (65 mg; 48 %; M.P.
130-142 °C
(dec); LC-MS: 462 (MH+); anal. RP18-HPLC RT: 3.69 min.).
!3-Ethynyl-phenyl-f7-(2-imidazol-1-yl-ethoxy)-~2-methoxy-ethoxy}quinazolin-4-yl]-amine di~drochloride The title product from Example 34 (110 mg, 0.253 mmol) in DMF (2 mL) was treated with imidazole (172 mg, 2.53 mmol) at 110 °C for 48 hours. The reaction mixture was partitioned between CHCI3 and saturated aqueous NaHC03. The organic extracts were washed with brine, dried over NaZS04, filtered and concentrated in vacuo.
The crude product (119 mg) was chromatographed on silica using 10%
methanol/CH2CIz to provide 85 mg of pure title product as its free base. This white solid was dissolved in a minimum volume of CHCl3, and titrated with 2 equivalents of 1 M HCI in ether to precipitate the title product as a white solid (95 mg; 75 %; M.P. 220-227 °C (dec); LC-MS: 430 (MH+); anal. RP18-HPLC RT: 3.75 min.).
(3-Ethynyl-phenyl)-f6-(2-imidazol-1-yl-ethoxy~-7-(2-methox -ethoxrLquinazolin~-yll-amine dihydrochloride The title product of Example 30 (110 mg, 0.253 mmol) in DMF (2 mL) was , treated with imidazole (172 mg, 2.53 mmol) at 110 ° C for 48 hours.
The reaction mixture was partitioned between CHCI3 and saturated aqueous NaHC03. The organic extracts were washed with brine, dried over NazS04, filtered and concentrated in vacuo.
The crude product (125 mg) was chromatographed on silica using 1096 methanol/CHzCl2 to provide 86 mg of pure title product as its free base. This white solid was dissolved in a minimum volume of CHCI3, and titrated with 2 equivalents of 1 M HCI in ether to precipitate the title product as a white solid dihydrochloride salt (95 mg; 78 96; M.P. 85-100 °C (dec); LC-MS: 430 (MH+); anal. RP18-HPLC RT:
4.13 min.).
f 3-Ethynyf-phenyl)-f7-(2-methoxy-ethoxy)-6-(2-morpholin-4-vl-ethoxv)-auinazolin-4-yll-amine dihydrochloride The title product from Example 30 (107 mg, 0.245 mmol) in DMF (2 mL) was treated with morpholine (214 NL, 2.45 mmol) at 80°C for 24 hours. The reaction mixture was partitioned between CHCl3 and saturated aqueous NaHC03. The organic extracts were washed with brine, dried over NaZS04, filtered and concentrated in vacuo.
The crude product (168 mg) was chromatographed on silica using 7.5~
methanol/CHZCIZ to provide 65 mg of pure title product as its free base. This white solid was dissolved in a minimum volume of CHCI3, and titrated with 2 equivalents of 1 M HCI in ether to precipitate the title product as a white solid (88 mg; 59 %; M.P. 115-130 °C (dec); LC-MS: 449 (MH+); anal. RP18-HPLC RT: 4.00 min.).
2-(4-(3-Et~nyl-phen5rlamino~2-methoxy-ethoxy)-- quinazolin-6-yloxyl-ethanol hydrochloride The title product from Example 33 (149 mg, 0.354 mmol) in methanol (3 mL) was ' treated with 5M aqueous KOH (0.25 mL). The mi>aure was stirred at 20°C for 30 minutes before removing the solvent in vacuo. The solid residue was washed with water to remove salts, and dried aze-__otropically by dissolution two times in acetonitrile and concentration in vacuo to afford 95 mg of title product as its free base.
This material was converted to its HCI salt according to the method used in Example 28 (89 mg; 61 96; M.P.190-215 °C (dec); LC-MS: 380 (MH+); anal. RP18-HPLC RT:
3.66 min.).
X6,7-Diethoxy-quinazo(in-4-yl) ~3-ethyny!-ahen~rl)-amine hydrochloride , 5. 6,7-Diethoxyquinazolin-4-one (120 mg, 0.512 mmol), triphenylphosphine (295 mg, 1.126 mmol) and 3 mL of carbon tetrachloride were refluxed for 16 hours.
the reaction mixture was concentrated in vacuo to a residue which was diluted with 3 mL
of isopropyl alcohol and 3-ethynylaniline (66 mg, 0.563 mmol) and refluxed for 3 hours.
The cooled reaction mixture was filtered to afford solid title product which was washed with 10 mL of isopropyl alcohol and dried in vacuo at 70°C, 140 mg (75%); mp 269-270 ° C.
~6,7-Diethoxy-auinazolin-4-y1)-L3-ethynyl-2-methyl-phe~~-amine hydrochloride 4-Chloro-6,7-diethoxyquinazoline (200 mg, 0.792 mmol) and 3-(2'-trimethylsilylethynyl-2-methyl-aniline (168 mg, 0.871 mmol) in 4 mL of tert-butyl alcohol was refluxed for 16 hours. The cooled reaction mixture was diluted with 5 mL
of ethyl ether and filtered to afford solid (6,7-diethoxy-quinazolin-4-yl)-(3-(2'-trimethylsilyl-ethynyl)-2-methyl-phenyl)-amine hydrochloride which was washed with 10 mL of ethyl ether and dried in vacuo at 70°C. This material was desilated directly by treatment with 2 mL of methanol containing 1 drop of water and 100 mg of potassium carbonate for 0.5 hours.
The heterogeneous reaction mixture was filtered through Celite and vacuum evaporated to a residue which was dissolved in excess 1 N HCI in methanol, precipitated with ethyl ether, filtered and dried in vacuo at 70°C to afford the title product;
160 mg (75%); mp 258-259.5 ° C.
(3-Eth~~phenyl)-(6-methyl-auinazolin-4-yl)-zmine hydrochloride 6-Methyl-quina~olir,-4-one (350 mg, 2.18 mmol) was added to a suspension of polymer-supported triphenylphosphine (from Ffuka, 3.63 g of about 3 mmol P/g resin;
10.9 mmol) in a mixture of CCl4 (3.35 g, 21.80 mmol) and 1,2 dichloroethane (10 mL). ' The mixture was heated to 60°C for 2 hours and then the polymer rrdas removed by filtration and washed with dichloroethane. The filtrate was collected in a f ask containing 3-ethynyl-aniline (0.644 g, 2.18 mmol) and concentrated to 5 mL by evaporation. After 4 hours reflux under N2, followed by cooling to 20°C, the title product was collected by filtration (551 mg; 86%; M.P. 256-257°C; LC-MS: 260 (MH+); anal. RP-HPLC RT: 4.41 min).
2-~2-f4-(3-Ethynyl-phenylamino}-6-(2-methoxy-ethoxyl-auinazolin-7-yloxy]!-ethylsulfanyl}-propionic acid ammonium salt The title product of Example 34 (150 mg, 0.34 mmol) was added to a solution of thiolactic acid (100 NL, 1.14 mmol) and KOH (150 mg, 2.7 mmol) in degassed DMF
(5 mL)/ H20 (0.5 mL). The reaction mixture was stirred at 50°C under an atmosphere of NZ for 72 hours and then cooled to room temperature. The pH of the mixture was adjusted to about 4.0 with acetic acid and then partitioned between CHCI3 and brine.
The organic extracts were washed with brine, dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by preparative RP18 HPLC
utilizing a gradient of 15% to 100% CH3CN/pH 4.5, 50 mM ammonium acetate followed by lyophilization of the appropriate pure fractions to afford the title product (28 mg;
18°~; M.P. 95-103°C (dec}; LC-MS: 468 (MH+); anal. RP-HPLC RT:
3.57 min).
~2-(4-(3-Ethyn)rl-phenylamino)-6-(2-methoxy-etho~y-auinazolin-7-yloxyl-ethylsulfan~rl~-acetic acid ammonium salt The title product was prepared from the title product of Example34 and mercaptoacetic acid according to the method of Example45. (3%; LC-MS: 454 (MH+);
anal. RP-HPLC RT: 3.37 min).
4-(3-Ethynyl-phenylaminoZ-6~2-methox~r-ethoxY)-quinazolin-7-of This product was isolated as a more lipophilic product (by preparative RP18 HPLC) from the reaction used to generate the title product of Example46 (5%;
LC-MS:
336 (MH+); anal. RP-HPLC RT: 3.60 min).
~3-eth~n~rlphenyl}-[~2-methoxy-ethoxYL-vinyloxy-guinazolin-4-ylamine and I~2-ethoxy-ethoxy}-7-(2-methoxy-ethoxY~-ctuinazolin-4-yll-(3-eth~nyl-phen~rl -amine hydrochloride The title product of Example 30 (107 mg, 0.245 mmol) was treated with sodium ethoxide (0.582 mmol) in refluxing ethanol (3 mL) for 24 hours. The solvent was removed in vacuo and the product vdas isolated by flash chromatography on silica using 1096 acetone/CHZCI2 to provide 30 mg of the 6-vinyloxy product (33~°; M.P. 113-114°C; LC-MS: 362 (MH+); anal. RP-HPLC RT: 4.84 min). The 6-(2-ethoxy-ethoxy) derivative eluted as a more polar product (45 mg) and was converted to its HCI
salt according to the procedure described for Example28 (4396; M.P. 220-225°C (dec); LC- .
MS: 408 (MH+); anal. RP-HPLC RT: 4.35 min).
4-(3-Ethynyl-phenylamino)-7-(2-methoxy-ethoxy}-guinazofin-6-of hydrochloride (3-Ethynyl-phenyl)-[7-(2-methoxy-ethoxy)-6-vinyloxy-quinazolin-4-yl]-amine (20 mg; from Example 48) was hydrolyzed by treatment with 6M HCI / methanol (30:70; 3 mL) at 50°C for 5 days. The solution was concentrated in vacuo, and the residue was partitioned between CHCI3 and brine at a pH of about 7. The organic extracts were washed with brine, dried over NaZS04, filtered and concentrated in vacuo to afford the title product as its free base (15 mg), which was converted to its HCI salt according to the procedure described for Example 28 (M.P. 135-150°C (dec); LC-MS:
336 (MH+);
anal. RP-HPLC RT: 3.77 min).
1 ~2-f4-!3-Ethynyl-phenyfamino)-6-(2-m ethoxy-ethoxy)-quinazol in-7 yloxyl-ethyl~-1 H-pyridin-4-one hydrochloride NaH (30 mg of 60% in mineral oil, 0.77 mmol) was added to anhydrous DMF
(2.0 mL) followed by pyrid-4-one (79 mg, 0.83 mmol). The mixture was stirred minutes at 22°C until all solids dissolved and the evolution of Hz ceased. The title product of Example 34 (120 mg, 0.28 mmol) and fetrabutylammonium iodide (15 mg) were added and the reaction mixture was stirred at 22°C for 7 days under N2.
Additional pyrid-4-one (79 mg) and NaH (30 mg of 60%) were dissolved in DMF (2 mL) .
and the solution was added to the reaction mixture. After another 4 days stirring the mixture vras partitioned between CHCI3 and brine. The organic extracts were dried over NazS04, filtered and concentrated in vacuo. The crude product was purified by flash chromatography on silica utilizing 10% methanol/ CH2C12 to afford 65 mg of the free base of the title product which was ccnverted to the mono-hydrochloride salt according ' to the procedure described for Example 28 (66 mg; M.P. 240-248°C (dec);
LC-MS: 457 (MH+); anal. RP-HPLC RT: 3.23 min) -4.3-1-d2-f4-3-EthYnyl,~henylamino)-7-(2-methox~-e~ thoxyLquinazolin-6-yloxy]-ethr~l -1 H-pyridin-4-one hydrochloride - ~ The free base of this product was prepared from the title product of Example30 . and the sodium salt of pyrid-4-one as described for Example 50. The free base was isolated by flash chromatography with 15% methanol/CHCI3 and converted to the title product according to the procedure described for Example 28 (32%; M.P. 155-168°C
(dec); LC-MS: 457 (MH+); anal. RP-HPLC RT: 3.45 min).
(3-Ethynyl-phenyls-~6-methoxy-guinazolin-4~r1)-amine hydrochloride A 25 mM solution of 6-methoxy-3H-quinazolin-4-one in 1,2-dichloroethane was added to polymer-supported triphenylphosphine (from Fluka, about 3 mmol P/g polymer; 2.5 mol equiv) and carbon tetrachloride (100 mole equiv). The reaction mixture was heated, with shaking, at 60°C for 21 hours, cooled to 22°C, and a 30 mM solution of the 3-ethynylaniline (1.5 mole equiv) in t-butanoi was added. The resulting mixture was then heated, with shaking, at 60°C for 18 hours followed by cooling to 22°C. The polymer was filtered off and washed twice with methanol. The methanol washes were added to the filtrate and the solution was concentrated in vacuo to afford the title product (73°~; LC-MS: 276 (MH+); anal. RP18-HPLC RT: 5.82 min). For these cases the analytical RP18-HPLC system consisted of a Waters 717 (trademark) autosampler, Waters 996 Photodiode Array Detector (trademark), and Waters 600 quarternary solvent delivery system, and was controlled by Millennium (trademark) software. The aliquots of samples were chromatographed using a linear gradient of 0% to 100°~
acetonitrile/
0.2 M ammonium acetate buffer (pH 4.5) over ten minutes at a flow rate of 3 ml/min.
using a Perkin-Elmer Pecosphere (trademark) (3mm X 3cm) C18 column.
The compounds of Examples 53-94, as their hydrochloride salts, were prepared in an analogous manner to that of Example 52 from the appropriate 3H-quinazolin-4-one derivative and 3-ethynyl-aniline:
LC-MS HPLC RT
Exam;aleProduct % Yield(MH+) (mires}
53 (6-Chloro-quinazolin-4-yl)-(3-ethynyl-60 280, 6.44 phenyl)-amine WO 96130347 PCT/IB95l00436 LC-MS HPLC RT
ExampleProduct 96 Yield(MH+) (mins) 54 [7-Chloro-6-(2,5-dichloro-phenylsulfanyl)-51 456, 8.74 quinazolin-4-ylj-(3-ethynyl-phenyl)-amine 55 7-Chloro-4-(3-ethynyl-phenylamino)-12 305, 6.51 quinazoiine-6-carbonitrile 56 [6-Bromo-7-(4-chloro-phenoxy)-quinazolin-28 450, 8.05 4-ylj-(3-ethynyl-phenyl)-amine 57 [6-(4-Bromo-benzylsulfanyl)-quinazolin-4-50 446, 7.99 ylj-(3-ethynyl-phenyl)-amine 58 (7-Bromo-6-methylsulfanyl-quinazolin-4-yl)-46 370, 6.99 (3-ethynyl-phenyl)-amine 59 {7-Chloro-6-[4-(4-chloro-phenylsulfanyl)-82 514, 9.45 phenoxyj-quinazolin-4-yl }-(3-ethynyl-phenyl)-amine 60 (3-Ethynyl-phenyl)-(7-phenylsulfanyl-88 354 7.40 quinazolin-4-yl)-amine 61 (3-Ethynyl-phenyl)-(6-iodo-quinazolin-4-yl)-64 372 6.81 amine 62 (3-Ethynyl-phenyl)-(6-trifluoromethyl-53 314 6.73 quinazolin-4-yl)-amine 63 [7-Chloro-6-(4-chloro-phenoxy)-quinazolin-78 406, 8.06 4-ylj-(3-ethynyl-phenyl)-amine 64 [7-Chloro-6-(4-chloro-phenylsulfanyl)-68 422, 8.45 quinazolin-4-ylj-(3-ethynyl -phenyl)-amine 65 [7-Chloro-6-(4-methoxy-phenoxy)-88 402, 7.55 quinazolin-4-ylj-(3-ethynyl-phenyl)-amine 66 (7-Chloro-6-(4-ffuoro=phenoxy)-quinazolin-80 390 7.61 4-ylj-(3-ethynyl-phenyl)-amine 67 [6-(4-Ghloro-phenoxy)-quinazolin-4-ylj-(3-79 372, 7.66 ethynyl-phenyl)-amine 68 7-Bromo-4-(3-ethynyl-phenylamino)-61 431, 6.44 quinazoline-6-sulfonic acid 69 ( 6-Bromo-7-chloro-quinazolin-4-~-I)-(3-80 358, 7.17 ethynyl-phenyl)-amine 70 4-(3-Ethynyl-phenylamino)-quinazoline-6-72 271 5.84 carbonitrile LC-MS HPLC RT
Example Product 96 Yield(MH+) (mins) 71 [6-(4-Bromo-phenylsulfany!)-7-chloro-70 466, 8.56 quinazolin-4-yl]-(3-ethynyl-phenyl)-amine 72 {6-[2-(4-Bromo-phenoxy)-ethylsulfanyl]-79 476, 8.11 quinazolin-4-yl}-(3-ethynyl-phenyl)-amine 73 4-[7-Chloro-4-(3-ethynyl-phenylamino)-85 427, 7.56 quinazolin-6-ylsulfanyl-methyl]-benzonitrile 74 [7-Chloro-6-(3-chloro-phenoxy)-quinazolin-80 406, 8.10 4-yl]-(3-ethynyl-phenyl)-amine 75 [6-(3-Bromo-phenoxy)-7-chloro-quinazolin-82 450, 8.22 4-yl]-(3-ethynyl-phenyl)- amine 76 (7-Chloro-6-phenoxy-quinazolin-4-yl)-(3-83 372, 7.59 ethynyl-phenyl)-amine 77 [7-Chloro-6-(4-methylsulfanyl-phenoxy)-86 418, 8.02 quinazoiin-4-yl]-(3-ethynyl-phenyl)-amine 78 [7-Chloro-6-(4-methanesulfonyl-phenoxy)-73 450, 6.73 quinazolin-4-yl]-(3-ethynyl-phenyl)-amine 79 (7-Chloro-6-p-tolyloxy-quinazolin-4-yl)-(3-85 386, 7.95 ethynyl-phenyl)-amine 80 (3-Ethynyl-phenyl)-[6-(4-phenoxy-81 430 8.29 phenoxy)-quinazolin-4-yl]-amine 81 (7-Chloro-6-phenylsulfanyl-quinazolin-4-yl)-80 388, 7.96 (3-ethynyl-phenyl)-amine 82 [6-(3-Chloro-phenoxy)-quinazolin-4-yl]-(3-77 372, 7.71 ethynyl-phenyl)-amine 83 [6-(3,5-Dichloro-phenoxy)-quinazolin-4-yl]-61 406, 8.30 (3-ethynyl-phenyl)-amine 84 [6-(2-Chloro-phenoxy)-quinazolin-4-yl]-(3-70 372, 7.38 ethynyl-phenyl)-amine 85 (7-Chlo~o-6-metharcsulfonyl-quinazolin-4-74 358, 5.74 yl)-(3-efhynyl-phenyl)-amine 86 [6-(3,4-Dichloro-phenoxy)-quinazolin-4-yl]-62 406, 8.14 (3-ethynyl-phenyl)-amine 87 [6-(4-Bromo-phenoxy)-quinazo(in-4-yl]-(3-68 416, 7.81 ethynyl-phenyl)-amine WO 96!30347 PCT/IB95/00436 LC-MS HPLC RT
ExampleProduct 96 Yield(MH+) (mans) 88 [6-(4-Chloro-2-methyl-phenoxy)-quinazolin-73 386, 8.02 4-yl]-(3-ethynyl-phenyl)-amine 89 [7-Chloro-4-(3-ethynyl-phenylamino)-70 351 6.44 ' quinazolin-6-ylsulfanyl]-acetonitrile **
90 (6-Allylsulfanyl-quinazolin-4-yl)-(3-ethynyl-72 318 6.93 phenyl)-amine 91 (7-Chloro-6-propylsulfanyl-quinazolin-4-yl)-69 354, 7.79 (3-ethynyl-phenyl)-amine 92 (7-Chloro-6-methyl-sulfanyl-quinazoiin-4-72 326, 6.94 yl)-(3-ethynyl-phenyl)-amine 93 [7-Chloro-6-(2-methyl-sulfanyl-71 386, 7.56 ethylsulfanyl)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine 94 (6-Chloro-7-methoxy-quinazolin-4.-yl)-(3-87 310, 6.fi5 ethynyl-phenyl)-amine ** [7-Chloro-4-(3-ethynyl-phenylamino)-quinazo(in-6-ylsulfanyl]-acetonitrife was obtained from 2-(7-chloro-4--oxo-3,4-dihydro-quinazolin-6-ylsulfanyl)-acetamide under these conditions.
(6.7-Dibutoxy-quinazolin-4-y~~3-ethynyl-phen r~l -amine hydrochloride 6,7-Dibutoxyquinazolin-4-one (105 mg, 0.362 mmol), triphenylphosphine (208 mg, 0.796 mmol) and 5 mL of carbon tetrachloride were refluxed for 16 hours and the reaction mixture was concentrated in vacuo to a residue which was diluted with 3 mL
of isopropyl alcohol and 3-ethynylaniline (47 mg, 0.398 mmol) and refluxed for 3 hours.
The cooled reaction mixture was filtered to afford solid (6,7-dibutoxy-quinazolin-4-yl)-(3-ethynyl-pha-:~y1)-amine hydrochloride which vYas washed with 10 mL of iscpropyl alcohol and dried in vacuo at 70°C, 92 mg (60%); mp 247-248°C.
~ 6.7-Diisopropox~quinazolin-4-yf)-~3-eth~nyl-phen~rl)-amine hydrochloride 6,7-Diisopropoxyquinazo(in-4-one (55 mg, 0.210 mmo!), triphenyfphosphine (121 mg, 0.462 mma!) and 3 rnL of carbon tetrachloride were refluxed for 16 hours and the reaction mixture was concentrated in vacuo to a residue which was diluted with 3 mL
of isopropyl alcohol and 3-ethynylaniline (30 mg, 0.257 mmol) and refluxed for 3 hours.
The cooled reaction mixture was vacuum evaporated to afford the solid title product which was column chromatographed on silica gel eluted with 5% acetone in methylene chloride containing 0.25% triethylamine. Fractions containing the pure product were concentrated in vacuo to a solid which was dissolved in 2 mL of 1 N HCI in methanol, precipitated with ethyl ether, filtered and dried in vacuo at 70°C to afford the title product; 140 mg (75~); mp 241-242 ° C.
L6-Chloro-7-(2-methoxyethylsulfanyl~guinazolin-4~IL(3-ethynyl-phenyl -amine ~drochloride 6-Chloro-7-(2-methoxyethylsutfanyl)-quinazolin-4-one (200 mg, 0.739 mmol), triphenylphosphine (427 mg, 1.63 mmol) and 0.7 mL of carbon tetrachloride were refluxed in 4 ml of 1,2-dichloroethane for 4 hours, concentrated in vacuo to a residue, diluted with 4 mL of isopropyl alcohol and 3-ethynylaniline (129 mg, 1.104 mmol) and refluxed for 16 hours. The hot reaction mixture was filtered to isolate crude product which was column chromatographed on silica gel eluted with 5°~ methanol in chloroform. Fractions containing the pure product were concentrated in vacuo to afford the title product as a solid; 23 mg (8.4%); mp 230-232°C.
j6.7-Bis-f2-methoxyethoxyl-cLuinazolin-4-yl)-(3-ethynyl-2-methyl-phenyl -amine 6,7-Bis-[2-methoxyethoxy]-4-chloro-quinazoline (90 mg, 0.288 mmol) and 3-(2'-trimethylsilylethynyl-2-methyl-aniline (62 mg, 0.317 mmol) were refluxed in 4 mL of tert-butyl alcohol for 16 hours. The cooled reaction mixture was diluted with 1 mL
of isopropyl alcohol and filtered to afford solid (6,7-bis-(methoxyethoxy)-quinazolin-4-yl)-(3-(2'-trimethylsilyl-ethyn-1yl)-2-methyl-phenyl)-amine hydrochloridewhichwaswashedwith 10 mL of ethyl ether and dried in vacuo at 70°C; 70 mg. Of this material 51 mg was desilated by treatment with in 3 mL of methanol containing 1 drop of water and 50 mg of potassium carbonate for 0.5 hours at room temperature. The heterogeneous ' reaction mixture was filtered through celite and vacuum evaporated to a residue which was dried in vacuo at 70°C to afford the title product as a dry foam;
38 mg (75°i°); mp 232 ° C.
~6,7-Bis-f2-methoxyethoxyl-quinazolin-4-y~-(3-ethyn~il-5'-fluoro-phenyl's-amine hydrochloride 6,7-Bis[2-methoxyethoxyJ-4-chioro-quinazoline (90 mg, 0.288 mmol) and 3-(2'-5, trimethylsilylethynyl-5-fluoro-aniline (69 mg, 0.317 mmol) were refluxed in 3 mL of tert-butyl alcohol for 5 hours. The cooled reaction mixture was diluted with 2 mL
of isopropyl alcohol and filtered to afford solid (6,7-bis-methoxyethoxy-quinazolin-4-yf)-(3-(2'-trimethylsilyl-ethynyl)-5'-fiuoro-phenyl)-amine hydrochloride which was washed with mL of ethyl ether and dried in vacuo at 70°C; 131 mg. All of this material was 10 desilated by dissolution in 3 mL of methanol containing 1 drop of water and 35 mg of potassium carbonate for 0.5 hours at room temperature. The reaction mixture was adjusted to pH 2.5 with aqueous 1 N hydrochloric acid and filtered. The solid was dried in vacuo at 70°C to afford the title product; 92 mg (78%); mp 249-250°C.
~7-Propylsulfanyl-guinazolin-4-yl)-(3-ethyl-phen~rly-amine hydrochloride 7-Propylsulfanyl-quinazolin-4-one (300 mg, 1.36 mmol), triphenylphosphine (785 mg, 2.99 mmol), 1.31 mL of carbon tetrachloride and 5 mL of chloroform were refluxed for 16 hours and the reaction mixture was concentrated in vacuo to a residue which was diluted with 5 mL of isopropyl alcohol and 3-ethynylaniline (175 mg, 1.49 mmol) and refluxed for 3 hours. The cooled reaction mixture was concentrated in vacuo and the residue purified by column chromatography on silica gel eluted with 10%
methanol in chloroform. Fractions containing the pure title product, as the frree amine, were concentrated in vacuo to afford solid which was added to 3 mL of 1 N HCI in methanol.
This solution was evaporated in vacuo to a residue which eras triturated with 4 mL of hot isopropyl alcohol cooled and filtered. The solid thus obtained was dried in vacuo at 70°C to aftord pure title product; 239 mg (55%); mp 2?_9-230°C.
~7-,'2-Methoxyethylsulfan-yl)-c~uirazolin-4=y~(3-eihy~l-phenyl)-amine hydrochloride In the same manner as Example 42 [7-(2-methoxyethylsulfanyl)-quinazolin-4-yl~-(3-ethynyl-phenyl)-amine hydrochloride was prepared from 7-(2-methoxyethylsulfanyl)-quinazolin-4-one (200 mg, 0.847 mmol), triphenylphosphine (533 mg, 2.03 mmol) cnd 3 mL of carbon tetrachloride in 74 % yield; 233 mg; mp 208-?09°C.
j7-Chloro-6-vitro-auinazolin-4 y1-(3-ethynyl-phenyls amine hydrochloride 7-Chloro-6-vitro-quinazolin-4-one(1.002g,4.44mmol),phosphorousoxychloride (11.5 g, 7.51 mmol) and phosphorous pentachloride (1.62 g, 7.74 mmol) were refluxed for 2 hours and the reaction mixture was concentrated in vacuo to a residue which was triturated with toluene and then again with chloroform and dried in vacuo to afford crude 4,7-dichloro-6-vitro-quinazoline. This was dissolved in 35 mL of isopropyl alcohol and 3-ethynylaniline (639 mg, 5.45 mmol) and refluxed for 3 hours. The cooled reaction mixture was filtered to afford the title product as a solid which was washed with 10 mL
of isopropyl alcohol and dried in vacuo at 70°C, 1.055 g (66%); mp 230.8-232.6°C.
~6-Amino-7-chloro-quinazolin-4-yl)-(3-eth~nyl-phenyl-amine hydrochloride (7-Chloro-6-vitro-quinazolin-4-yl)-(3-ethynyl-phenyl)-amine hydrochloride (166 mg, 0.295 mmol} and sodium dithionite (207 mg, 1.19 mmol) were stirred in 1.5 mL
of formic acid for 4 hours at room temperature. 45 mL of methanol were added to the reaction mixture which was set aside for 16 hours at room temperature. The precipitate thus obtained was filtered, triturated with 3% sodium bicarbonate for 0.5 hours and refiltered. The solid was dissolved in 20 mL of 1 N HCI in methanol and precipitated with 200 mL of ethyl ether. This was filtered and dried in vacuo at 70°C to afford the title product, 72 mg (83%); mp 260-265°C.
(3-Ethyl-phenyl~7-methoxy-6-vitro-c~uinazolin-4-~ -amine (7-Chloro-6-vitro-quinazolin-4.-yl)-(3-ethynyl-phenyl)-amine hydrochloride (100 mg, 0.306 mmol and dry sodium methoxide (7 20 mg, 2.22 mmol) ~;~ere stirred in 2 mL of dry 2-methylpyrrolidin-1-one for 8 hours at 30°C. To the cooled reaction mixture 0.93 mL
of 3 N and 1 mL of water were added. Tlje mixture v;~as diluted with 60 mL of water and extracted with two time 60 mL of ethyl acetate. T! ~e pooled crganic layers were vjashed with three times 50 mL of water and 50 mL of brine, dried with magnesium sulfate, filtered and vacuum evaporated to afford the title pr~~duct as a solid; 80 mg (82%); mp 213-218°C dec.
WO 96!30347 PCT/IB95/00436 ~2-f4- 3-Eth~nyl-phenylamino-7-~2-methoxy-ethoxy)-4uinazolin-6-yloxyl-ethylsulfan~i}-acetic acid ammonium salt This product was prepared from the title product of Example 30 and mercaptoacetic acid at 22°C over 10 days according to the method outlined in Example 45. (16%; M.P. 98-113°C (dec); LC-MS 454 (MH+); anal. RP-HPLC
3.24 min.) 6,7-Bis~2-methoxy-ethoxy~-quinazolone To ethyl 3,4-dihydroxybenzoate (36.4 g, 0.200 mol), K~C03 (60.8 g, 0.44 mol) and tetrabutylammonium iodide (750 mg) in degassed acetone (400 mL) was added 2-bromoethyl methyl ether (69.5 g, 47 mL). The mixture was stirred under NZ at reflux for 64 hours. Ether (600 mL) was added to the mixture and after stirring 30 minutes at ° C the precipitated salts were removed by filtration. The filtrate was concentrated in vacuo and the residue was triturated with hexane (500 mL) for 30 minutes and the 15 white solid ethyl 3,4-bis(2-methoxy-ethoxy)benzoate was filtered and dried in vacuo (55.5 g; 93%; M.P. 50-51 °C). A portion of this product (45.7 g, 0.158 mol) in acetic acid (150 mL) was treated dropwise with cone. HN03 (40 mL) at 5°C and the solution stirred 24 hours before pouring into cold H20 (1.6 L). The mixture was extracted with ethyl acetate (1.1 L), and the organic phase was washed three times with 200 mL HzO, 20 and brine, dried over Na2S04, filtered and concentrated in vacuo to afford ethyl 4,5-bis-(2-methoxy-ethoxy)-2-vitro-benzoate (54.3 g) as a brown oil. This vitro product (52.0 g, 0.15 mol) was dissolved in ethanol (1000 mL) containing 1 equivalent of HCI
(generated in the ethanol by prior addition of 11 mL acetyl chloride), PtO2sH20 (1.0 g) was added, and the mixture was hydrogenated under 45 psi HZ for 6 hours. The catalyst was removed by filtration through Celite, and the filtrate was concentrated in vacuo to a thick slurry which was diluted with ether (400 mL). The solid white hydrochloride salt of ethyl 2-amir:o-4,5-Lis-(2-methoxy-ethoxy)benzoate vdas filtered and dried in vscuo (4~.7 g; 88%). A portion of this rnaterial (42 g, 0.12 mcl) and ammonium for~r~ate (7.6 g, O.i2 mol) were disssolved in formamide (63 mL) and the stirred mixture was heated to 160-165 °C under an atmosphere of NZ for 3 hours. H20 (200 mL) vras added and after cooli~-~c the precipitated crude title product was recovered by filtration, washed with cold HzO, and dried in vacuo. The filtrate was extracted five times with CHCI3, and the pooled organic extracts were washed with brine, dried over Na2S04, and concentrated in vacuo . The residue and crude quinazolone precipitate were combined, triturated in hot acetonitrile (250 mL) for 30 minutes, cooled to 20 °C and treated with ether (250 mL). After cooling to 4 °C the white solid was filtered and dried in vacuo (30.4 g, 86~; GC-MS m/z 294 (M+)).
4-Chloro-6.7-bis-(2-methoxy-ethoxy)-quinazoline To 6,7-bis(2-methoxy-ethoxy)-quinazolone (500 mg, 1.7 mmol), from Preparation 1, in CHCI3 (10 mL) containing one drop of DMF was added oxalylchloride (490VL, 5.6 mmol) in several portions over 5 minutes. Once foaming ceased the solution was refluxed 1.5 hours. The solvent was removed in vacuo and the residue was dissolved in 1,2-dichloroethane (20 mL) and washed two times with 80 mL saturated aqueous NaZC03. The organic phase was dried over NaZS04, and concentrated in vacuo to afford solid title product (520 mg, 92%; M.P. 108-109 °C).
4-Chloro-6.7-bis-(2-chloro-ethoxyl-cluinazoline.4-chloro-6-(2-chloro-ethoxy)-7-(2-methoxy-ethoxy,L uinazoline and 4-chloro-6,7-bis-(2-methoxy-ethoxy)-quinazoline and 4-chloro-7-(2-chloro-ethoxy)-6-f2-methoxy-ethoxyZ quinazoline 6,7-Bis(2-methoxy-ethoxy}-quinazolone (5.4 g, 18.3 mmol), from Preparation 1, and pyridine (3.0 mL, 37 mmol) were heated in refluxing POCI3 (22 mL) under an atmosphere of dry nitrogen for 2.5 hours. Following concentration of the mixture in vacuo at 60°C the residue was dissolved in CHCI3 (150 mL) and carefully added in portions with stirring to cold saturated aqueous NaHC03 (100 mL}. The mixture was stirred 10 min. after the addition was complete and the organic phase was separated, washed with brine, dried over Na2S04, and concentrated in vacuo. The residue was filash chromatographed on silica using a gradient of 20% to 60% ethyl acetate/hexanes to afford 3.41 g of 4-chloro-6,7-bis-(2-methoxy-ethoxy)-quinazoline, 234 mg of ~-chloro 6-(2-chloro-ethaxy)-7-(2-meitaoxy-ethoxy)-quinazoline, 532 mg of 4-chloro-7-(2-chloro ethoxy}-6-(2-methoxy-ethoxy}-quinazoline, and 330 mg of 4-chloro-6,7-bis-(2-chloro ' ethoxy}-quinazoline.
Claims (26)
1. The compound (6,7-dimethoxyquinazolin-4-yl)-(3-ethynylphenyl)amine or a pharmaceutically acceptable salt thereof.
2. A compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein:
m is 1, 2, or 3;
each R1 is independently selected from hydrogen, halo, hydroxyl, amino, hydroxyamino, carboxyl, (C1-C4)alkoxycarbonyl, nitro, guanidino, ureido, carbamoyl, cyano, trifluoromethyl, (R6)2N-carbonyl, and phenyl-W-alkyl wherein W is selected from a single bond, O, S and NH;
or each R1 is independently selected from aminocarbonylmethyl, aminocarbonylethyl, cyano-(C1-C4)-alkyl and R9 wherein R9 is selected from the group consisting of R5, R5O, (R6)2N, R7C(=O), R5ONH, A and R5Y; wherein R5 is (C1-C4)alkyl; R6 is hydrogen or R5 wherein R5s are the same or different; R7 is R5, R5O or (R6)2N; A is selected from piperidino, morpholino, pyrrolindo, 4-R6-piperazin-1-yl, imidazol-1-yl, 4-pyridon-1-yl, carboxy-(C1-C4)-alkyl, phenoxy, phenyl, phenylsulfanyl, (C2-C4) -alkenyl and (R6)2N-carbonyl-(C1-C4)-alkyl; and Y is selected from S, SO and SO2; the alkyl moieties in (R6)2N are optionally substituted with halo or R9 wherein R9 is defined as above, and the alkyl moieties in R5 and R5O are optionally substituted with halo, (C2-C4)alkanoyloxy, HOC(=O), phenyl, R6O, C6H5Y, CN, or R9 wherein R9 and R6 are defined as above, and wherein the resulting groups are optionally substituted with halo or R9 with the proviso that a nitrogen, oxygen or sulfur atom can not be attached to the same carbon atom, and with the further proviso that no more than three "R9" units may comprise R1;
or each R1 is independently selected from R5-sulfonylamino, phthalimido-(C1-C4)-alkylsulfonylamino, benzamido, benzenesulfonylamino, 3-phenylureido, 2-oxopyrrolodin-1-yl, 2,5-dioxopyrrolodin-1-yl, and R10-(C2-C4)-alkanoylamino wherein R10 is selected from halo, R6O, (C2-C4)-alkanoyloxy, R7C(=O), (R6)2N and carboxyl; and wherein the benzamido or benzenesulfonylamino or phenyl or phenoxy or anilino or phenylsulfanyl substituent in R1 may optionally bear one or two halogens, (C1-C4)alkyl, cyano, methansulfonyl or (C1-C4)-alkoxy substituents; or any two R1s taken together with the carbons to which they are attached form a 5-8 membered ring comprising one or two heteroatoms selected from oxygen, sulfur or nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic;
R2 is selected from hydrogen and (C1-C6)-alkyl;
n is 1 or 2;
each R3 is independently selected from hydrogen, (C1-C6)-alkyl, amino, halo and hydroxyl; and R4 is azido or R11-ethynyl wherein R11 is hydrogen or (C1-C6)alkyl which may be substituted by a substituent selected from amino, hydroxyl, R5O, R5NH and (R5)2N, in which R5 is as defined above.
or a pharmaceutically acceptable salt thereof, wherein:
m is 1, 2, or 3;
each R1 is independently selected from hydrogen, halo, hydroxyl, amino, hydroxyamino, carboxyl, (C1-C4)alkoxycarbonyl, nitro, guanidino, ureido, carbamoyl, cyano, trifluoromethyl, (R6)2N-carbonyl, and phenyl-W-alkyl wherein W is selected from a single bond, O, S and NH;
or each R1 is independently selected from aminocarbonylmethyl, aminocarbonylethyl, cyano-(C1-C4)-alkyl and R9 wherein R9 is selected from the group consisting of R5, R5O, (R6)2N, R7C(=O), R5ONH, A and R5Y; wherein R5 is (C1-C4)alkyl; R6 is hydrogen or R5 wherein R5s are the same or different; R7 is R5, R5O or (R6)2N; A is selected from piperidino, morpholino, pyrrolindo, 4-R6-piperazin-1-yl, imidazol-1-yl, 4-pyridon-1-yl, carboxy-(C1-C4)-alkyl, phenoxy, phenyl, phenylsulfanyl, (C2-C4) -alkenyl and (R6)2N-carbonyl-(C1-C4)-alkyl; and Y is selected from S, SO and SO2; the alkyl moieties in (R6)2N are optionally substituted with halo or R9 wherein R9 is defined as above, and the alkyl moieties in R5 and R5O are optionally substituted with halo, (C2-C4)alkanoyloxy, HOC(=O), phenyl, R6O, C6H5Y, CN, or R9 wherein R9 and R6 are defined as above, and wherein the resulting groups are optionally substituted with halo or R9 with the proviso that a nitrogen, oxygen or sulfur atom can not be attached to the same carbon atom, and with the further proviso that no more than three "R9" units may comprise R1;
or each R1 is independently selected from R5-sulfonylamino, phthalimido-(C1-C4)-alkylsulfonylamino, benzamido, benzenesulfonylamino, 3-phenylureido, 2-oxopyrrolodin-1-yl, 2,5-dioxopyrrolodin-1-yl, and R10-(C2-C4)-alkanoylamino wherein R10 is selected from halo, R6O, (C2-C4)-alkanoyloxy, R7C(=O), (R6)2N and carboxyl; and wherein the benzamido or benzenesulfonylamino or phenyl or phenoxy or anilino or phenylsulfanyl substituent in R1 may optionally bear one or two halogens, (C1-C4)alkyl, cyano, methansulfonyl or (C1-C4)-alkoxy substituents; or any two R1s taken together with the carbons to which they are attached form a 5-8 membered ring comprising one or two heteroatoms selected from oxygen, sulfur or nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic;
R2 is selected from hydrogen and (C1-C6)-alkyl;
n is 1 or 2;
each R3 is independently selected from hydrogen, (C1-C6)-alkyl, amino, halo and hydroxyl; and R4 is azido or R11-ethynyl wherein R11 is hydrogen or (C1-C6)alkyl which may be substituted by a substituent selected from amino, hydroxyl, R5O, R5NH and (R5)2N, in which R5 is as defined above.
3. The compound or salt according to claim 2, wherein:
R2 is hydrogen, and R4 is R11-ethynyl wherein R11 is hydrogen or (C1-C6)-alkyl which may be substituted by a substituent selected from amino, hydroxyl, R5O, R5NH and (R5)2N, in which R5 is (C1-C4)alkyl.
R2 is hydrogen, and R4 is R11-ethynyl wherein R11 is hydrogen or (C1-C6)-alkyl which may be substituted by a substituent selected from amino, hydroxyl, R5O, R5NH and (R5)2N, in which R5 is (C1-C4)alkyl.
4. The compound or salt according to claim 3, wherein:
m is 1 or 2;
R1 is independently selected from hydrogen; hydroxyl;
amino; hydroxyamino; carboxyl; nitro; carbamoyl; ureido;
(C1-C4)alkyl optionally substituted with halo, R6O, HOC(=O), (R6)2NC(=O), A or (R6)2N;
(C1-C4)alkoxy optionally substituted with halo, R6O, (C2-C4)-alkanoyloxy, HOC(=O), (R6)2N, A or phenyl;
(R5)2N;
R5NH optionally substituted halo, (C2-C4)alkanoyloxy, R6O, R7C(=O), (R6)2N, A, C6H5Y or CN;
(R6)2N(C=O); R5ONH; R5S; (C1-C4)-alkylsulfonylamino;
phthalimido-(C1-C4)-alkylsulfonylamino; 3-phenylureido;
2-oxopyrrolidin-1-yl; 2,5-dioxopyrrolidin-1-yl; halo(C2-C4)-alkanoylamino; hydroxy- (C2-C4)-alkanoylamino; (C2-C4)-alkanaoyloxy-(C2-C4)-alkanoylamino; (C1-C4)-alkoxy-(C2-C4)-alkanoylamino; carboxy-(C2-C4)-alkanoylamino; (C1-C4)-alkoxycarbonyl-(C2-C4)-alkanoylamino; carbamoyl-(C2-C4)-alkanoylamino; N-(C1-C4)-alkylcarbamoyl-(C2-C4)-alkanoylamino;
N,N-di-[(C1-C4)-alkyl]carbamoyl-(C2-C4)-alkanoylamino; amino-(C2-C4)-alkanoylamino; (C1-C4)-alkyl-amino-(C2-C4)-alkanoylamino;
di-(C1-C4)-alkyl-amino-(C2-C4)-alkanoylamino; and wherein the phenyl or phenoxy or anilino substituent in R1 may optionally bear one or two halo, (C1-C4)-alkyl or (C1-C4)-alkoxy substituents; or any two R1s taken together with the carbons to which they are attached form a 5-8 membered ring comprising one or two heteroatoms selected from oxygen, sulfur and nitrogen; and wherein the alkyl groups or alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic;
each R3 is independently selected from hydrogen, methyl, ethyl, amino, halo and hydroxyl; and R4 is R11-ethynyl wherein R11 is hydrogen.
m is 1 or 2;
R1 is independently selected from hydrogen; hydroxyl;
amino; hydroxyamino; carboxyl; nitro; carbamoyl; ureido;
(C1-C4)alkyl optionally substituted with halo, R6O, HOC(=O), (R6)2NC(=O), A or (R6)2N;
(C1-C4)alkoxy optionally substituted with halo, R6O, (C2-C4)-alkanoyloxy, HOC(=O), (R6)2N, A or phenyl;
(R5)2N;
R5NH optionally substituted halo, (C2-C4)alkanoyloxy, R6O, R7C(=O), (R6)2N, A, C6H5Y or CN;
(R6)2N(C=O); R5ONH; R5S; (C1-C4)-alkylsulfonylamino;
phthalimido-(C1-C4)-alkylsulfonylamino; 3-phenylureido;
2-oxopyrrolidin-1-yl; 2,5-dioxopyrrolidin-1-yl; halo(C2-C4)-alkanoylamino; hydroxy- (C2-C4)-alkanoylamino; (C2-C4)-alkanaoyloxy-(C2-C4)-alkanoylamino; (C1-C4)-alkoxy-(C2-C4)-alkanoylamino; carboxy-(C2-C4)-alkanoylamino; (C1-C4)-alkoxycarbonyl-(C2-C4)-alkanoylamino; carbamoyl-(C2-C4)-alkanoylamino; N-(C1-C4)-alkylcarbamoyl-(C2-C4)-alkanoylamino;
N,N-di-[(C1-C4)-alkyl]carbamoyl-(C2-C4)-alkanoylamino; amino-(C2-C4)-alkanoylamino; (C1-C4)-alkyl-amino-(C2-C4)-alkanoylamino;
di-(C1-C4)-alkyl-amino-(C2-C4)-alkanoylamino; and wherein the phenyl or phenoxy or anilino substituent in R1 may optionally bear one or two halo, (C1-C4)-alkyl or (C1-C4)-alkoxy substituents; or any two R1s taken together with the carbons to which they are attached form a 5-8 membered ring comprising one or two heteroatoms selected from oxygen, sulfur and nitrogen; and wherein the alkyl groups or alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic;
each R3 is independently selected from hydrogen, methyl, ethyl, amino, halo and hydroxyl; and R4 is R11-ethynyl wherein R11 is hydrogen.
5. The compound or salt according to claim 3, wherein:
each R1 is independently selected from hydrogen, hydroxyl, amino, hydroxyamino, nitro, carbamoyl, ureido, R5 optionally substituted with halo, R6O, HOC(=O) or H2NC(=O);
R5O optionally substituted with halo, R6O, (C2-C4)-alkanoyloxy, HOC(=O), (R6)2N, A or phenyl;
R5NH, (R5)2N, R5NHC(=O), (R5)2NC(=O), R5S, phenyl-(C2-C4)-alkoxy and wherein the phenyl substituent in R1 may optionally bear one or two halo, R5 or R5O substituents; or any two R1s taken together with the carbons to which they are attached form a 5-8 membered ring comprising one or two heteroatoms selected from oxygen, sulfur and nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic.
each R1 is independently selected from hydrogen, hydroxyl, amino, hydroxyamino, nitro, carbamoyl, ureido, R5 optionally substituted with halo, R6O, HOC(=O) or H2NC(=O);
R5O optionally substituted with halo, R6O, (C2-C4)-alkanoyloxy, HOC(=O), (R6)2N, A or phenyl;
R5NH, (R5)2N, R5NHC(=O), (R5)2NC(=O), R5S, phenyl-(C2-C4)-alkoxy and wherein the phenyl substituent in R1 may optionally bear one or two halo, R5 or R5O substituents; or any two R1s taken together with the carbons to which they are attached form a 5-8 membered ring comprising one or two heteroatoms selected from oxygen, sulfur and nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic.
6. The compound or salt according to claim 2 wherein:
R2 is hydrogen, and R4 is azido.
R2 is hydrogen, and R4 is azido.
7. The compound or salt according to claim 6, wherein:
m is 1 or 2, each R1 is independently selected from hydrogen;
hydroxyl; amino; hydroxyamino; carboxyl; nitro; carbamoyl;
ureido; (C1-C4)alkyl optionally substituted with halo, R6O, HOC(=O), (R6)2NC(=O), A or (R6)2N;
R4NH optionally substituted halo, (C2-C4)-alkanoyloxy, R6O, R7C(=O), (R6)2N, A, C6H5Y or CN;
(R6)2N(C=O); R5ONH; R5S; (C1-C4)-alkylsulfonylamino;
phthalimido-(C1-C4)-alkylsulfonylamino; 3-phenylureido;
2-oxopyrrolidin-1-yl; 2, 5-dioxopyrrolidin-1-yl; halo-(C2-C4)-alkanoylamino; hydroxy-(C2-C4)-alkanoylamino; (C2-C4)-alkanoyloxy-(C2-C4)-alkanoylamino; (C1-C4)-alkoxy-(C2-C4)-alkanoylamino; carboxy-(C2-C4)-alkanoylamino; (C1-C4)-alkoxycarbonyl-(C2-C4)-alkanoylamino; carbamoyl-(C2-C4)-alkanoylamino; N-(C1-C4)-alkylcarbamoyl-(C2-C4)-alkanoylamino;
N,N-di-[(C1-C4)-alkyl]carbomoyl-(C2-C4)-alkanoylamino; amino-(C2-C4)-alkanoylamino; (C1-C4)-alkyl-amino-(C2-C4)-alkanoylamino;
di-(C1-C4)-alkyl-amino-(C2-C4)-alkanoylamino; and wherein the phenyl or phenoxy or anilino substituent in R1 may optionally bear one or two halo, (C1-C4)-alkyl or (C1-C4)-alkoxy substituents; or any two R1s taken together with the carbons to which they are attached form a 5-8 membered ring comprising one or two heteroatoms selected from oxygen, sulfur and nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic;
and each R3 is independently selected from hydrogen, methyl, ethyl, amino, halo and hydroxyl
m is 1 or 2, each R1 is independently selected from hydrogen;
hydroxyl; amino; hydroxyamino; carboxyl; nitro; carbamoyl;
ureido; (C1-C4)alkyl optionally substituted with halo, R6O, HOC(=O), (R6)2NC(=O), A or (R6)2N;
R4NH optionally substituted halo, (C2-C4)-alkanoyloxy, R6O, R7C(=O), (R6)2N, A, C6H5Y or CN;
(R6)2N(C=O); R5ONH; R5S; (C1-C4)-alkylsulfonylamino;
phthalimido-(C1-C4)-alkylsulfonylamino; 3-phenylureido;
2-oxopyrrolidin-1-yl; 2, 5-dioxopyrrolidin-1-yl; halo-(C2-C4)-alkanoylamino; hydroxy-(C2-C4)-alkanoylamino; (C2-C4)-alkanoyloxy-(C2-C4)-alkanoylamino; (C1-C4)-alkoxy-(C2-C4)-alkanoylamino; carboxy-(C2-C4)-alkanoylamino; (C1-C4)-alkoxycarbonyl-(C2-C4)-alkanoylamino; carbamoyl-(C2-C4)-alkanoylamino; N-(C1-C4)-alkylcarbamoyl-(C2-C4)-alkanoylamino;
N,N-di-[(C1-C4)-alkyl]carbomoyl-(C2-C4)-alkanoylamino; amino-(C2-C4)-alkanoylamino; (C1-C4)-alkyl-amino-(C2-C4)-alkanoylamino;
di-(C1-C4)-alkyl-amino-(C2-C4)-alkanoylamino; and wherein the phenyl or phenoxy or anilino substituent in R1 may optionally bear one or two halo, (C1-C4)-alkyl or (C1-C4)-alkoxy substituents; or any two R1s taken together with the carbons to which they are attached form a 5-8 membered ring comprising one or two heteroatoms selected from oxygen, sulfur and nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic;
and each R3 is independently selected from hydrogen, methyl, ethyl, amino, halo and hydroxyl
8. The compound or salt according to claim 6 wherein each R1 is independently selected from hydrogen; hydroxyl;
amino; hydroxyamino; nitro; carbomoyl; ureido; (C1-C4)alkyl optionally substituted with halo, R6O, HOC(=O) or H2NC(=O);
(C1-C4)alkoxy optionally substituted with halo, R6O, (C2-C4)-alkanoyloxy, HOC(=O), (R6)2N, A or phenyl;
R5NH; (R5)2N; R5NHC(=O); (R5)2NC(=O); R5S; or phenyl-(C2-C4)-alkoxy and wherein the phenyl substituent in R1 may optionally bear one or two halo, R5 or R5O substituents; or any two R1s taken together with the carbons to which they are attached form a 5-8 membered ring comprising one or two heteroatoms selected from oxygen, sulfur and nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic.
amino; hydroxyamino; nitro; carbomoyl; ureido; (C1-C4)alkyl optionally substituted with halo, R6O, HOC(=O) or H2NC(=O);
(C1-C4)alkoxy optionally substituted with halo, R6O, (C2-C4)-alkanoyloxy, HOC(=O), (R6)2N, A or phenyl;
R5NH; (R5)2N; R5NHC(=O); (R5)2NC(=O); R5S; or phenyl-(C2-C4)-alkoxy and wherein the phenyl substituent in R1 may optionally bear one or two halo, R5 or R5O substituents; or any two R1s taken together with the carbons to which they are attached form a 5-8 membered ring comprising one or two heteroatoms selected from oxygen, sulfur and nitrogen; and wherein the alkyl groups and alkyl portions of the alkoxy or alkylamino groups may be straight chained or if comprised of at least three carbons may be branched or cyclic.
9. The compound or salt of claim 8, wherein R3 is halo and R1 is hydrogen or R5O.
10. The compound or salt of claim 9, wherein R5 is methyl.
11. The compound or salt of claim 2, 3 or 6, wherein:
R1 is each independently selected from halo, hydroxyl, amino, hydroxyamino, carboxyl, (C1-C4) alkoxycarbonyl, nitro, guanidino, ureido, carbamoyl, cyano, trifluoromethyl, (R6)2N-carbonyl (in which R6 is hydrogen or (C1-C4) alkyl) , cyano- (C1-C4) alkyl, (C1-C4) alkyl, (C1-C4) alkoxy, (R6)2N (in which R6 is as defined above), (C1-C4) alkyl-CO-, (R6) 2N-CO- (in which R6 is as defined above), piperindino, morpholino, pyrrolidino, 4-R6-piperazin-1-yl (in which R6 is as defined above), imidazol-1-yl, 4-pyridon-1-yl, carboxy-(C1-C4)alkyl, phenoxy, phenyl, phenylsulfanyl, (C2-C4) alkenyl, (R6)2N-carbonyl- (C1-C4) alkyl (in which R6 is as defined above) , (C1-C4) alkyl-Y- (in which Y is S, SO or SO2) , (C1-C4) alkylsulfanylamino, phthalimido- (C1-C4)alkylsulfonylamino, benzamido, benzensulfonylamino, 4-toluenesulfonylamino, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, (C1-C4)alkyl which is substituted by halo, R6O or (R6)2N (in which R6 is as defined above), or (C1-C4) alkoxy which is substituted by halo, R6O or (R6)2N (in which R6 is defined as above); or two R1s together form methylenedioxy.
R1 is each independently selected from halo, hydroxyl, amino, hydroxyamino, carboxyl, (C1-C4) alkoxycarbonyl, nitro, guanidino, ureido, carbamoyl, cyano, trifluoromethyl, (R6)2N-carbonyl (in which R6 is hydrogen or (C1-C4) alkyl) , cyano- (C1-C4) alkyl, (C1-C4) alkyl, (C1-C4) alkoxy, (R6)2N (in which R6 is as defined above), (C1-C4) alkyl-CO-, (R6) 2N-CO- (in which R6 is as defined above), piperindino, morpholino, pyrrolidino, 4-R6-piperazin-1-yl (in which R6 is as defined above), imidazol-1-yl, 4-pyridon-1-yl, carboxy-(C1-C4)alkyl, phenoxy, phenyl, phenylsulfanyl, (C2-C4) alkenyl, (R6)2N-carbonyl- (C1-C4) alkyl (in which R6 is as defined above) , (C1-C4) alkyl-Y- (in which Y is S, SO or SO2) , (C1-C4) alkylsulfanylamino, phthalimido- (C1-C4)alkylsulfonylamino, benzamido, benzensulfonylamino, 4-toluenesulfonylamino, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, (C1-C4)alkyl which is substituted by halo, R6O or (R6)2N (in which R6 is as defined above), or (C1-C4) alkoxy which is substituted by halo, R6O or (R6)2N (in which R6 is defined as above); or two R1s together form methylenedioxy.
12. The compound or salt of claim 2 or 6, wherein:
R1 is each independently selected from the group consisting of methoxy, ethoxy, propoxy, isopropoxy, butoxy, nitro, amino, methanesulfonylamino, 4-toluenesulfonylamino, 2-phthalimidoeth-1-yl sulfonylamino, guanidino, carbomethoxy, 2-methoxyethoxy, methanesulfonyl, ethanesulfonyl, 2-chloroethoxy, 2-acetoxyethoxy, 2-hydroxyethoxy, 2-(4-methyl-piperazin-1-yl)ethoxy, 2-(morpholin-4-yl)ethoxy, aminomethyl, aminocarbonylmethyl, and aminocarbonylethyl; or two R1s together form methylenedioxy.
R1 is each independently selected from the group consisting of methoxy, ethoxy, propoxy, isopropoxy, butoxy, nitro, amino, methanesulfonylamino, 4-toluenesulfonylamino, 2-phthalimidoeth-1-yl sulfonylamino, guanidino, carbomethoxy, 2-methoxyethoxy, methanesulfonyl, ethanesulfonyl, 2-chloroethoxy, 2-acetoxyethoxy, 2-hydroxyethoxy, 2-(4-methyl-piperazin-1-yl)ethoxy, 2-(morpholin-4-yl)ethoxy, aminomethyl, aminocarbonylmethyl, and aminocarbonylethyl; or two R1s together form methylenedioxy.
13. The compound or salt of claim 2, wherein the compound is selected from the group consisting of:
(6,7-dimethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6,7-dimethoxyquinazolin-4-yl)-[3-(3'-hydroxypropyn-1-yl-phenyl]-amine;
[3-(2'-(aminomethyl)-ethynyl)phenyl] - (6,7-dimethoxyquinazolin-4-yl)-amine;
[(3-ethynylphenyl)-(6-nitroquinazolin-4-yl)-amine;
(6,7-dimethoxyquinazolin-4-yl)-(4-ethynylphenyl)-amine;
(6,7-dimethoxyquinazolin-4-yl)-(3-ethynyl-2-methylphenyl)-amine;
(6-aminoquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(3-ethynylphenyl)-(6-methanesulfonylaminoquinazolin-4-yl)-amine;
(3-ethynylphenyl)-(6,7-methylenedioxyquinazolin-4-yl) -amine ;
(6,7-dimethoxyquinazolin-4-yl)-(3-ethynyl-6-methylphenyl)-amine;
(3-ethynylphenyl)-(7-nitroquinazolin-4-yl)-amine;
(3-ethynylphenyl)-[6-(4'-toluenesulfonylamino) quinazolin-4-yl]-amine;
(3-ethynylphenyl)-(6-[2'-phthalimido-eth-1'-yl-sulfonylamino]quinazolin-4-yl}-amine;
(3-ethynylphenyl)-(6-guanidinoquinazolin-4-yl)-amine;
(7-aminoquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(3-ethynylphenyl)-(7-methoxyquinazolin-4-yl)-amine;
(6-carbomethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(7-carbomethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine;
[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynyl-phenyl)amine;
(3-azidophenyl)-(6,7-dimethoxyquinazolin-4-yl)amine;
(3-azido-5-chlorophenyl)-(6,7-dimethoxyquinazolin -4-yl)amine;
(4-azidophenyl)-(6,7-dimethoxyquinazolin-4-yl)amine;
(3-ethynylphenyl)-(6-methansulfonyl-quinazolin-4-yl)-amine;
(6-ethansulfanyl-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6,7-dimethoxy-quinazolin-4-yl)-(3-ethynyl-4-fluoro-phenyl)-amine;
(6,7-dimethoxy-quinazolin-4-yl)-[3-(propyn-1'-yl-phenyl)]-amine;
[6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(5-ethynyl-2-methyl-phenyl)-amine;
[6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-4-fluoro-phenyl)-amine;
[6,7-bis-(2-chloro-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
[6-(2-chloro-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
[6,7-bis-(2-acetoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
2-[4-(3-ethynyl-phenylamino)-7-(2-hydroxy-ethoxy)-quinazolin-6-yloxy]-ethanol;
[6-(2-acetoxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
[7-(2-chloro-ethoxy)-6-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
[7-(2-acetoxy-ethoxy)-6-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
2-[4-(3-ethynyl-phenylamino)-6-(2-hydroxy-ethoxy)-quinazolin-7-yloxy]-ethanol;
2-[4-(3-ethynyl-phenylamino)-7-(2-methoxy-ethoxy)-quinazolin-6-yloxy]-ethanol;
2-[4-(3-ethynyl-phenylamino)-6-(2-methoxy-ethoxy)-quinazolin-7-yloxy]-ethanol;
[6-(2-acetoxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
(3-ethynyl-phenyl)-{6-(2-methoxy-ethoxy)-7-[2-(4-methyl-piperazin-1-yl)-ethoxy]-quinazolin-4-yl)-amine;
(3-ethynyl-phenyl)-[7-(2-methoxy-ethoxy)6-(2-morpholin-4-yl ethoxy)-quinazolin-4-yl]-amine;
(6,7-diethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(6,7-dibutoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(6,7-diiospropoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(6,7-diethoxyquinazolin-1-yl)-(3-ethynyl-2-methyl-phenyl)-amine;
[6,7-bis-(2-methoxy-ethoxy)-quinazolin-1-yl]-(3-ethynyl-2-methyl-phenyl)-amine;
(3-ethynylphenyl)-[6-(2-hydroxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-1-yl]-amine;
[6,7-bis-(2-hydroxy-ethoxy)-quinazolin-1-yl]-(3-ethynylphenyl)-amine; and 2-[4-(3-ethynyl-phenylamino)-6-(2-methoxy-ethoxy)-quinazolin-7-yloxy]-ethanol.
(6,7-dimethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6,7-dimethoxyquinazolin-4-yl)-[3-(3'-hydroxypropyn-1-yl-phenyl]-amine;
[3-(2'-(aminomethyl)-ethynyl)phenyl] - (6,7-dimethoxyquinazolin-4-yl)-amine;
[(3-ethynylphenyl)-(6-nitroquinazolin-4-yl)-amine;
(6,7-dimethoxyquinazolin-4-yl)-(4-ethynylphenyl)-amine;
(6,7-dimethoxyquinazolin-4-yl)-(3-ethynyl-2-methylphenyl)-amine;
(6-aminoquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(3-ethynylphenyl)-(6-methanesulfonylaminoquinazolin-4-yl)-amine;
(3-ethynylphenyl)-(6,7-methylenedioxyquinazolin-4-yl) -amine ;
(6,7-dimethoxyquinazolin-4-yl)-(3-ethynyl-6-methylphenyl)-amine;
(3-ethynylphenyl)-(7-nitroquinazolin-4-yl)-amine;
(3-ethynylphenyl)-[6-(4'-toluenesulfonylamino) quinazolin-4-yl]-amine;
(3-ethynylphenyl)-(6-[2'-phthalimido-eth-1'-yl-sulfonylamino]quinazolin-4-yl}-amine;
(3-ethynylphenyl)-(6-guanidinoquinazolin-4-yl)-amine;
(7-aminoquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(3-ethynylphenyl)-(7-methoxyquinazolin-4-yl)-amine;
(6-carbomethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine;
(7-carbomethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine;
[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynyl-phenyl)amine;
(3-azidophenyl)-(6,7-dimethoxyquinazolin-4-yl)amine;
(3-azido-5-chlorophenyl)-(6,7-dimethoxyquinazolin -4-yl)amine;
(4-azidophenyl)-(6,7-dimethoxyquinazolin-4-yl)amine;
(3-ethynylphenyl)-(6-methansulfonyl-quinazolin-4-yl)-amine;
(6-ethansulfanyl-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6,7-dimethoxy-quinazolin-4-yl)-(3-ethynyl-4-fluoro-phenyl)-amine;
(6,7-dimethoxy-quinazolin-4-yl)-[3-(propyn-1'-yl-phenyl)]-amine;
[6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(5-ethynyl-2-methyl-phenyl)-amine;
[6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-4-fluoro-phenyl)-amine;
[6,7-bis-(2-chloro-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
[6-(2-chloro-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
[6,7-bis-(2-acetoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
2-[4-(3-ethynyl-phenylamino)-7-(2-hydroxy-ethoxy)-quinazolin-6-yloxy]-ethanol;
[6-(2-acetoxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
[7-(2-chloro-ethoxy)-6-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
[7-(2-acetoxy-ethoxy)-6-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
2-[4-(3-ethynyl-phenylamino)-6-(2-hydroxy-ethoxy)-quinazolin-7-yloxy]-ethanol;
2-[4-(3-ethynyl-phenylamino)-7-(2-methoxy-ethoxy)-quinazolin-6-yloxy]-ethanol;
2-[4-(3-ethynyl-phenylamino)-6-(2-methoxy-ethoxy)-quinazolin-7-yloxy]-ethanol;
[6-(2-acetoxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;
(3-ethynyl-phenyl)-{6-(2-methoxy-ethoxy)-7-[2-(4-methyl-piperazin-1-yl)-ethoxy]-quinazolin-4-yl)-amine;
(3-ethynyl-phenyl)-[7-(2-methoxy-ethoxy)6-(2-morpholin-4-yl ethoxy)-quinazolin-4-yl]-amine;
(6,7-diethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(6,7-dibutoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(6,7-diiospropoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(6,7-diethoxyquinazolin-1-yl)-(3-ethynyl-2-methyl-phenyl)-amine;
[6,7-bis-(2-methoxy-ethoxy)-quinazolin-1-yl]-(3-ethynyl-2-methyl-phenyl)-amine;
(3-ethynylphenyl)-[6-(2-hydroxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-1-yl]-amine;
[6,7-bis-(2-hydroxy-ethoxy)-quinazolin-1-yl]-(3-ethynylphenyl)-amine; and 2-[4-(3-ethynyl-phenylamino)-6-(2-methoxy-ethoxy)-quinazolin-7-yloxy]-ethanol.
14. The compound or salt of claim 2, wherein the compound is selected from the group consisting of:
(6,7-dipropoxyquinazolin-4-yl)-(3-ethynyl-phenyl)-amine;
(6,7-diethoxyquinazolin-4-yl)-(3-ethynyl-5-fluoro-phenyl)-amine;
(6,7-diethoxyquinazolin-4-yl)-(3-ethynyl-4-fluoro-phenyl)-amine;
(6,7-diethoxyquinazolin-4-yl)-(5-ethynyl-2-methyl-phenyl)-amine;
(6,7-diethoxyquinazolin-4-yl)-(3-ethynyl-4-methyl-phenyl)-amine;
(6-aminomethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminomethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-ethoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylethyl-7-ethoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-isopropoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-propoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylethyl-7-isopropoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; and (6-aminocarbonylethyl-7-propoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine.
(6,7-dipropoxyquinazolin-4-yl)-(3-ethynyl-phenyl)-amine;
(6,7-diethoxyquinazolin-4-yl)-(3-ethynyl-5-fluoro-phenyl)-amine;
(6,7-diethoxyquinazolin-4-yl)-(3-ethynyl-4-fluoro-phenyl)-amine;
(6,7-diethoxyquinazolin-4-yl)-(5-ethynyl-2-methyl-phenyl)-amine;
(6,7-diethoxyquinazolin-4-yl)-(3-ethynyl-4-methyl-phenyl)-amine;
(6-aminomethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminomethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-ethoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylethyl-7-ethoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-isopropoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-propoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylmethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine;
(6-aminocarbonylethyl-7-isopropoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; and (6-aminocarbonylethyl-7-propoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine.
15. The compound or salt of claim 2, wherein the compound is selected from the group consisting of:
(6,7-diethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(3-ethynylphenyl) - [6- (2-hydroxy-ethoxy) -7- (2-methoxy-ethoxy)-quinazolin-1-yl]-amine;
[6,7-bis- (2-hydroxy-ethoxy) -quinazolin-1-yl] - (3-ethynylphenyl)-amine;
[6,7-bis- (2-methoxy-ethoxy) -quinazolin-1-yl] - (3-ethynylphenyl)-amine;
(6,7-dimethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(3-ethynylphenyl)-(6-methanesulfonylamino-quinazolin-1-yl)-amine; and (6-amino-quinazolin-1-yl)-(3-ethynylphenyl)-amine.
(6,7-diethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(3-ethynylphenyl) - [6- (2-hydroxy-ethoxy) -7- (2-methoxy-ethoxy)-quinazolin-1-yl]-amine;
[6,7-bis- (2-hydroxy-ethoxy) -quinazolin-1-yl] - (3-ethynylphenyl)-amine;
[6,7-bis- (2-methoxy-ethoxy) -quinazolin-1-yl] - (3-ethynylphenyl)-amine;
(6,7-dimethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine;
(3-ethynylphenyl)-(6-methanesulfonylamino-quinazolin-1-yl)-amine; and (6-amino-quinazolin-1-yl)-(3-ethynylphenyl)-amine.
16. A process for preparing a compound of the formula:
(wherein R1, R2, R3, R4, m and n are as defined in claim 2) , which comprises:
a) treating a compound of the formula:
(wherein R1 and m have the meanings given in claim 2), with CCl4 and an optionally substituted triarylphosphine, optionally supported on an inert polymer, of the formula Ar3P
(wherein each Ar is an optionally substituted (C6-C10)aryl group and each of the substituents is independently selected from (C1-C6) alkyl) ; and b) treating the product of step a) with a compound of the formula:
(wherein R2, R3 and n have the meanings given above and J is Y
or R4, wherein Y is bromo, iodo or trifluoromethanesulfonyloxy and R4 has the meaning given above), with the proviso that when J is Y then the product of step b) must further be treated with an alkyne.
(wherein R1, R2, R3, R4, m and n are as defined in claim 2) , which comprises:
a) treating a compound of the formula:
(wherein R1 and m have the meanings given in claim 2), with CCl4 and an optionally substituted triarylphosphine, optionally supported on an inert polymer, of the formula Ar3P
(wherein each Ar is an optionally substituted (C6-C10)aryl group and each of the substituents is independently selected from (C1-C6) alkyl) ; and b) treating the product of step a) with a compound of the formula:
(wherein R2, R3 and n have the meanings given above and J is Y
or R4, wherein Y is bromo, iodo or trifluoromethanesulfonyloxy and R4 has the meaning given above), with the proviso that when J is Y then the product of step b) must further be treated with an alkyne.
17. The process of claim 16 wherein each aryl group is selected from phenyl, naphth-1-yl and naphth-2-yl.
18. The process of claim 17 wherein each aryl group is independently substituted with from zero to the maximum number of (C1-C6) alkyl groups.
19. The process of claim 17 wherein each Ar is phenyl.
20. The process of claim 16 wherein the triarylphosphine is supported on an inert polymer.
21. The process of claim 20 wherein the polymer is a divinylbenzene-cross-linked polymer of styrene.
22. A pharmaceutical composition for the treatment of hyperproliferative diseases in a mammal which comprises (a) a therapeutically effective amount of a compound of any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof and (b) a pharmaceutically acceptable carrier.
23. A composition as recited in claim 22 wherein the hyperproliferative disease is cancer.
24. A composition as recited in claim 23 wherein the disease is brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, oesophageal, gynecological or thyroid cancer.
25. A composition as recited in claim 22 wherein the hyperproliferative disease is noncancerous.
26. The composition of claim 25 wherein the noncancerous disease is a benign hyperplasia of skin or prostate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41330095A | 1995-03-30 | 1995-03-30 | |
| US08/413,300 | 1995-03-30 | ||
| PCT/IB1995/000436 WO1996030347A1 (en) | 1995-03-30 | 1995-06-06 | Quinazoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2216796A1 CA2216796A1 (en) | 1996-10-03 |
| CA2216796C true CA2216796C (en) | 2003-09-02 |
Family
ID=23636708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002216796A Expired - Lifetime CA2216796C (en) | 1995-03-30 | 1995-06-06 | Quinazoline derivatives |
Country Status (43)
Families Citing this family (564)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| TW321649B (en) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| JPH11507329A (en) * | 1995-04-27 | 1999-06-29 | ゼネカ リミテッド | Quinazoline derivatives |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (en) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | CHINAZOLE DERIVATIVES AND THEIR USE AS VEGF INHIBITORS |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| EA001595B1 (en) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Irreversible inhibitors of tyrosine kinases. |
| GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| CA2258548C (en) * | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6090096A (en) | 1997-04-23 | 2000-07-18 | Heartport, Inc. | Antegrade cardioplegia catheter and method |
| DE19743435A1 (en) | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidine derivatives |
| US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| JP4652569B2 (en) * | 1998-04-29 | 2011-03-16 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | N- (3-ethynylphenylamino) -6,7-bis (2-methoxyethoxy) -4-quinazolineamine mesylate anhydride and monohydrate |
| US6384223B1 (en) | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
| US6270747B1 (en) | 1998-08-18 | 2001-08-07 | The University Of California | In vitro and in vivo assay for agents which treat mucus hypersecretion |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (en) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | Heteroaromatic bicyclic derivatives useful as anticancer agents |
| YU13200A (en) * | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Process and intermediates for preparing anti-cancer compounds |
| HK1044769B (en) | 1999-06-21 | 2005-02-25 | 贝林格尔英格海姆法玛两合公司 | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof |
| US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
| JP2003504363A (en) * | 1999-07-09 | 2003-02-04 | グラクソ グループ リミテッド | Anilinoquinazolines as protein tyrosine kinase inhibitors |
| CA2384282A1 (en) * | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
| GB9922173D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| GB9925958D0 (en) | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
| KR100881105B1 (en) | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Quinazolin Derivatives as VEGF Inhibitors |
| UA74803C2 (en) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use |
| US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| ES2267748T3 (en) | 2000-04-07 | 2007-03-16 | Astrazeneca Ab | QUINAZOLINE COMPOUNDS. |
| UA73993C2 (en) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition |
| EP1170011A1 (en) * | 2000-07-06 | 2002-01-09 | Boehringer Ingelheim International GmbH | Novel use of inhibitors of the epidermal growth factor receptor |
| WO2002016352A1 (en) | 2000-08-21 | 2002-02-28 | Astrazeneca Ab | Quinazoline derivatives |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| JP4564713B2 (en) | 2000-11-01 | 2010-10-20 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Nitrogen heterocyclic compounds, and methods for making nitrogen heterocyclic compounds and intermediates thereof |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| MX368013B (en) | 2001-02-19 | 2019-09-13 | Novartis Ag | Cancer treatment. |
| JP2002293773A (en) * | 2001-03-30 | 2002-10-09 | Sumika Fine Chemicals Co Ltd | Method for producing quinazoline derivative |
| RU2332415C2 (en) * | 2001-04-27 | 2008-08-27 | Вертекс Фармасьютикалз Инкорпорейтед | Pyrazole derivatives, useful as inhibitors of protein kinase |
| WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
| US7132427B2 (en) | 2001-06-21 | 2006-11-07 | Ariad Pharmaceuticals, Inc. | Quinazolines and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| AU2003206068A1 (en) | 2002-03-01 | 2003-09-16 | Pfizer Inc. | Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents |
| US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| DE10221018A1 (en) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy |
| PT1505959E (en) | 2002-05-16 | 2009-02-05 | Novartis Ag | Use of edg receptor binding agents in cancer |
| UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
| WO2004008099A2 (en) | 2002-07-15 | 2004-01-22 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| WO2004046101A2 (en) | 2002-11-20 | 2004-06-03 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors |
| US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| US20060167026A1 (en) * | 2003-01-06 | 2006-07-27 | Hiroyuki Nawa | Antipsychotic molecular-targeting epithelial growth factor receptor |
| GB0302882D0 (en) * | 2003-02-07 | 2003-03-12 | Univ Cardiff | Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss |
| US7148231B2 (en) | 2003-02-17 | 2006-12-12 | Hoffmann-La Roche Inc. | [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph |
| US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| PA8595001A1 (en) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | NEW CONDENSED HETEROAROMATIC COMPOUNDS THAT ARE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF) |
| ATE508747T1 (en) | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-KIT KINASE INHIBITORS |
| JP2006523638A (en) * | 2003-04-16 | 2006-10-19 | エフ．ホフマン−ラ ロシュ アーゲー | Quinazoline compounds |
| GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| CL2004001120A1 (en) | 2003-05-19 | 2005-04-15 | Irm Llc | COMPOUNDS DERIVED FROM AMINA REPLACED WITH HETEROCICLES, IMMUNOSUPPRESSORS; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT DISEASES MEDIATED BY LYMPHOCYTE INTERACTIONS, SUCH AS AUTOIMMUNE, INFLAMMATORY, INFECTIOUS, CANCER DISEASES. |
| CA2527680A1 (en) | 2003-05-30 | 2005-06-02 | Astrazeneca Uk Limited | Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor |
| WO2005001053A2 (en) | 2003-06-09 | 2005-01-06 | Samuel Waksal | Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist |
| JP2006527235A (en) | 2003-06-10 | 2006-11-30 | エフ．ホフマン−ラ ロシュ アーゲー | 1,3,4-Triazaphenalene and 1,3,4,6-tetraazaphenalene derivatives |
| AU2004253967B2 (en) | 2003-07-03 | 2010-02-18 | Cytovia, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| DK1660090T3 (en) * | 2003-08-14 | 2012-12-17 | Array Biopharma Inc | QUINAZOLINE ANALOGS AS RECEPTOR-TYROSINKINASE INHIBITORS |
| CA2536140A1 (en) * | 2003-08-18 | 2005-02-24 | Pfizer Products Inc. | Dosing schedule for erbb2 anticancer agents |
| ES2314444T3 (en) | 2003-08-29 | 2009-03-16 | Pfizer Inc. | TIENOPIRIDINE-PHENYLACETAMIN AND ITS USEFUL DERIVATIVES AS NEW ANTIANGIOGEN AGENTS. |
| ATE395346T1 (en) | 2003-09-16 | 2008-05-15 | Astrazeneca Ab | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| DE10349113A1 (en) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Process for the preparation of aminocrotonyl compounds |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| AU2004309166B2 (en) | 2003-12-23 | 2008-02-21 | Pfizer Inc. | Novel quinoline derivatives |
| DE602005010824D1 (en) | 2004-02-03 | 2008-12-18 | Astrazeneca Ab | quinazoline derivatives |
| EP2650286A1 (en) * | 2004-02-19 | 2013-10-16 | Rexahn Pharmaceuticals, Inc. | Quinazoline derivatives and therapeutic use thereof |
| CA2560305C (en) | 2004-03-19 | 2016-07-05 | Imclone Systems Incorporated | Human anti-epidermal growth factor receptor antibody |
| ES2425749T3 (en) | 2004-03-31 | 2013-10-17 | The General Hospital Corporation | Method for determining the response of cancer to treatments directed at the epidermal growth factor receptor |
| DK2253614T3 (en) | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP inhibitors |
| BRPI0510717B8 (en) | 2004-05-06 | 2021-05-25 | Bioresponse Llc | use of 3,3'-diindolylmethane (dim) or 2-(indol-3-ylmethyl)-3,3'-diindolylmethane (ltr) |
| NZ579482A (en) | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
| WO2006002422A2 (en) | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| ATE428421T1 (en) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | MEDICAL COMPOSITION WITH IMPROVED STABILITY AND REDUCED GELING PROPERTIES |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| ATE501148T1 (en) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTI-TUMOR AGENTS |
| PE20060777A1 (en) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
| ATE497762T1 (en) | 2004-12-30 | 2011-02-15 | Bioresponse Llc | USE OF DIINDOLYLMETHANE-RELATED INDOLES FOR THE TREATMENT AND PREVENTION OF DISEASES RELATED TO THE RESPIRATORY SYNCYTIAL VIRUS |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| US7625911B2 (en) | 2005-01-12 | 2009-12-01 | Mai De Ltd. | Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion |
| CN102580084B (en) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | The fixed dosage of HER antibody is administered |
| CN101146532B (en) | 2005-01-21 | 2012-05-09 | 阿斯泰克斯治疗有限公司 | Pharmaceutical compounds |
| GB0501999D0 (en) * | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| DK1854789T3 (en) * | 2005-02-23 | 2013-10-21 | Shionogi & Co | QUINAZOLINE DERIVATIVES WITH TYROSIN-KINASE INHIBITORIC ACTIVITY |
| KR20070107151A (en) | 2005-02-26 | 2007-11-06 | 아스트라제네카 아베 | Quinazolin Derivatives as Tyrosine Kinase Inhibitors |
| SI1859793T1 (en) | 2005-02-28 | 2011-08-31 | Eisai R&D Man Co Ltd | Novel combinational use of a sulfonamide compound in the treatment of cancer |
| AU2006235487B2 (en) * | 2005-04-12 | 2011-12-22 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
| CN1854130B (en) * | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | Chinazoline derivative, its production, medicinal composition and use |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CA2612449A1 (en) | 2005-06-17 | 2006-12-28 | Imclone Systems Incorporated | Receptor antagonists for treatment of metastatic bone cancer |
| WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
| JP4989476B2 (en) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Methods for assaying the effects of angiogenesis inhibitors |
| JP2009505658A (en) | 2005-08-24 | 2009-02-12 | ブリストル−マイヤーズ スクイブ カンパニー | Biomarkers and methods for determining susceptibility to epidermal growth factor receptor modulators |
| ATE488513T1 (en) | 2005-09-20 | 2010-12-15 | Astrazeneca Ab | 4-(1H-INDAZOLE-5-YLAMINO)QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| AU2006309551B2 (en) | 2005-11-07 | 2012-04-19 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| JP5688877B2 (en) | 2005-11-11 | 2015-03-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Quinazoline derivatives for the treatment of cancer diseases |
| NO20220050A1 (en) | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendocrine tumor treatment |
| WO2007060691A2 (en) * | 2005-11-23 | 2007-05-31 | Natco Pharma Limited | A novel process for the preparation of erlotinib |
| PL1959955T3 (en) * | 2005-12-05 | 2011-04-29 | Pfizer Prod Inc | Method of treating abnormal cell growth |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
| CN101003514A (en) * | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | Derivative of quinazoline, preparation method and usage |
| AP2008004569A0 (en) | 2006-02-03 | 2008-08-31 | Imclone Systems Inc | IGR-IR antagonists as adjuvants for treatment of prostrate cancer |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| US20090098137A1 (en) | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| CA2644143C (en) | 2006-04-05 | 2013-10-01 | Novartis Ag | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| AR060358A1 (en) | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | QUINAZOLINS FOR THE INHIBITION OF PDK 1 |
| AU2007240496A1 (en) | 2006-04-19 | 2007-11-01 | Novartis Ag | Indazole compounds and methods for inhibition of CDC7 |
| NZ572299A (en) | 2006-05-09 | 2010-07-30 | Novartis Ag | Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof |
| CN104706637A (en) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | Antitumor agent for thyroid cancer |
| WO2007138612A2 (en) * | 2006-05-25 | 2007-12-06 | Vittal Mallya Scientific Research Foundation | A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4- yl]-(3-ethynylphenyl)amine hydrochloride |
| WO2007138613A2 (en) * | 2006-05-25 | 2007-12-06 | Vittal Mallya Scientific Research Foundation | A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride |
| CA2659307A1 (en) | 2006-07-28 | 2008-01-31 | Synthon B.V. | Crystalline erlotinib |
| PL2383297T3 (en) | 2006-08-14 | 2013-06-28 | Xencor Inc | Optimized antibodies that target CD19 |
| WO2008026748A1 (en) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| ES2372217T3 (en) | 2006-09-12 | 2012-01-17 | Genentech, Inc. | PROCEDURES AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF LUNG CANCER USING THE GENE OF PDGFRA, KIT OR KDR AS A GENETIC MARKER. |
| AU2007299080B2 (en) | 2006-09-18 | 2013-04-18 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
| WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
| EP2079739A2 (en) | 2006-10-04 | 2009-07-22 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8586621B2 (en) | 2006-10-27 | 2013-11-19 | Michael A. Zeligs | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles |
| US8372856B2 (en) * | 2006-10-27 | 2013-02-12 | Synthon Bv | Hydrates of erlotinib hydrochloride |
| EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
| US8343950B2 (en) * | 2006-12-15 | 2013-01-01 | Concert Pharmaceuticals, Inc. | Quinazoline derivatives and methods of treatment |
| JPWO2008088088A1 (en) | 2007-01-19 | 2010-05-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pancreatic cancer treatment composition |
| CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| AU2008212999A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
| CN101245050A (en) | 2007-02-14 | 2008-08-20 | 上海艾力斯医药科技有限公司 | 4-aniline quinazoline derivative salt |
| US20100069458A1 (en) | 2007-02-15 | 2010-03-18 | Peter Wisdom Atadja | Combination of lbh589 with other therapeutic agents for treating cancer |
| ES2573931T3 (en) | 2007-02-21 | 2016-06-13 | Natco Pharma Limited | New erlotinib hydrochloride polymorphisms and preparation method |
| SI2132573T1 (en) | 2007-03-02 | 2014-07-31 | Genentech, Inc. | Predicting response to a her dimerisation inhbitor based on low her3 expression |
| CA2682013C (en) * | 2007-04-04 | 2015-06-30 | Cipla Limited | Process for preparation of erlotinib and its pharmaceutically acceptable salts |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| PL2171090T3 (en) | 2007-06-08 | 2013-09-30 | Genentech Inc | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2009030224A2 (en) * | 2007-09-07 | 2009-03-12 | Schebo Biotech Ag | Novel quinazoline compounds and the use thereof for treating cancerous diseases |
| US8080558B2 (en) | 2007-10-29 | 2011-12-20 | Natco Pharma Limited | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| CL2008003449A1 (en) | 2007-11-21 | 2010-02-19 | Imclone Llc | Antibody or fragments thereof against the macrophage / rum stimulating protein receptor; pharmaceutical composition comprising it; use to inhibit angiogenesis, tumor growth, proliferation, migration and invasion of tumor cells, activation of rum or phosphorylation of mapk and / or akt; and use to treat cancer. |
| EP2240475B1 (en) | 2007-12-20 | 2013-09-25 | Novartis AG | Thiazole derivatives used as pi 3 kinase inhibitors |
| HRP20150279T1 (en) | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| CN101918374A (en) | 2008-01-18 | 2010-12-15 | 纳特科制药有限公司 | 6.7-dialkoxyquinazoline derivatives for use in the treatment of cancer-related disorders |
| TWI472339B (en) | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
| US8497369B2 (en) | 2008-02-07 | 2013-07-30 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| AU2009228765B2 (en) | 2008-03-24 | 2012-05-31 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| CN101544609A (en) | 2008-03-25 | 2009-09-30 | 上海艾力斯医药科技有限公司 | Crystallization form of 4-anilinoquinazoline derivatives |
| GEP20125708B (en) | 2008-03-26 | 2012-12-10 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases b |
| CN102083801A (en) * | 2008-03-28 | 2011-06-01 | 康瑟特制药公司 | Quinazoline derivatives and methods of treatment |
| JP5739802B2 (en) | 2008-05-13 | 2015-06-24 | アストラゼネカ アクチボラグ | 4- (3-Chloro-2-fluoroanilino) -7-methoxy-6-{[1- (N-methylcarbamoylmethyl) piperidin-4-yl] oxy} quinazoline fumarate |
| NZ589143A (en) | 2008-05-14 | 2012-02-24 | Genomic Health Inc | Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels |
| CN101584696A (en) | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | Composition containing quinazoline derivatives, preparation method and use |
| DE102008031039A1 (en) | 2008-06-30 | 2009-12-31 | Dömling, Alexander, Priv.-Doz. Dr. | Use of N-phenylquinazolin-4-amine derivatives as receptor tyrosine kinase inhibitor for accompanying treatment of organ transplantations |
| EP2313397B1 (en) | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method |
| ES2704986T3 (en) | 2008-10-16 | 2019-03-21 | Celator Pharmaceuticals Inc | Combinations of a water-soluble liposomal camptothecin with cetuximab or bevacizumab |
| EP2349235A1 (en) | 2008-11-07 | 2011-08-03 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
| EP2355821A1 (en) | 2008-11-11 | 2011-08-17 | Eli Lilly and Company | P70 s6 kinase inhibitor and egfr inhibitor combination therapy |
| JP2012512884A (en) | 2008-12-18 | 2012-06-07 | ノバルティス アーゲー | Novel polymorphic form of 1- (4- {1-[(E) -4-cyclohexyl-3-trifluoromethyl-benzyloxyimino] -ethyl} -2-ethyl-benzyl) -azetidine-3-carboxylic acid |
| KR20110101159A (en) | 2008-12-18 | 2011-09-15 | 노파르티스 아게 | New salt |
| US20120115840A1 (en) | 2008-12-18 | 2012-05-10 | Lech Ciszewski | Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid |
| WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
| PL2391366T3 (en) | 2009-01-29 | 2013-04-30 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
| EP2213281A1 (en) | 2009-02-02 | 2010-08-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| JP2012519170A (en) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | INSITU method for monitoring EMT status of tumor cells in vivo |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2408479A1 (en) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
| CN102438995B (en) | 2009-03-26 | 2014-12-17 | 兰贝克赛实验室有限公司 | Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof |
| WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| PT2451445T (en) | 2009-07-06 | 2019-07-10 | Boehringer Ingelheim Int | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
| US9050341B2 (en) * | 2009-07-14 | 2015-06-09 | Natco Pharma Limited | Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (en) | 2009-08-12 | 2012-09-28 | Новартис Аг | HETEROCYCLIC HYDRAZONES AND THEIR APPLICATION FOR THE TREATMENT OF CANCER AND INFLAMMATION |
| NZ598220A (en) | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| CA2771432A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
| IN2012DN01693A (en) | 2009-08-26 | 2015-06-05 | Novartis Ag | |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| EP2494070A2 (en) | 2009-10-30 | 2012-09-05 | Bristol-Myers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
| AU2010317167B2 (en) | 2009-11-04 | 2012-11-29 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as MEK inhibitors |
| CA2780875A1 (en) | 2009-11-13 | 2011-05-19 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| CN102770456B (en) | 2009-12-04 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | Multispecific antibodies, antibody analogs, compositions and methods |
| EA201200823A1 (en) | 2009-12-08 | 2013-02-28 | Новартис Аг | HETEROCYCLIC DERIVATIVES OF SULPHONAMIDES |
| CU24130B1 (en) | 2009-12-22 | 2015-09-29 | Novartis Ag | ISOQUINOLINONES AND REPLACED QUINAZOLINONES |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| EP2348020A1 (en) | 2009-12-23 | 2011-07-27 | Esteve Química, S.A. | Preparation process of erlotinib |
| RU2012132278A (en) | 2010-01-12 | 2014-02-20 | Ф. Хоффманн-Ля Рош Аг | TRICYCLIC HETEROCYCLIC COMPOUNDS CONTAINING THEIR COMPOSITIONS AND WAYS OF THEIR APPLICATION |
| AU2011222867B2 (en) | 2010-03-04 | 2014-03-06 | Annika Algars | Method for selecting patients for treatment with an EGFR inhibitor |
| US20130096104A1 (en) | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| JP2013528357A (en) | 2010-03-29 | 2013-07-11 | ザイムワークス，インコーポレイテッド | Antibody with enhanced or suppressed effector function |
| WO2011130654A1 (en) | 2010-04-16 | 2011-10-20 | Genentech, Inc. | Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy |
| DE202010006543U1 (en) | 2010-05-07 | 2010-09-09 | Ratiopharm Gmbh | Erlotinibresinat |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| US20110288086A1 (en) | 2010-05-21 | 2011-11-24 | Jianqi Li | Polycyclic quinazolines, preparation thereof, and use thereof |
| WO2011147102A1 (en) * | 2010-05-28 | 2011-12-01 | 翔真生物科技股份有限公司 | Synthetic method for 6,7-substituents-4-aniline quinazoline |
| CN102958523B (en) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | Use of combined antineoplastic agents with kinase inhibitory effects |
| UA112517C2 (en) | 2010-07-06 | 2016-09-26 | Новартіс Аг | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES |
| EP2595629A1 (en) * | 2010-07-23 | 2013-05-29 | Generics [UK] Limited | Pure erlotinib |
| AR082418A1 (en) | 2010-08-02 | 2012-12-05 | Novartis Ag | CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO |
| TW201217387A (en) | 2010-09-15 | 2012-05-01 | Hoffmann La Roche | Azabenzothiazole compounds, compositions and methods of use |
| JP2013537210A (en) | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | 17α-hydroxylase / C17,20-lyase inhibitor |
| IT1402029B1 (en) | 2010-10-14 | 2013-08-28 | Italiana Sint Spa | PROCEDURE FOR THE PREPARATION OF ERLOTINIB |
| EP2637692A4 (en) | 2010-11-12 | 2014-09-10 | Scott & White Healthcare | ANTIBODIES AGAINST THE MARKER 8 TUMOR ENDOTHELIAL |
| BR112013011520A2 (en) | 2010-11-19 | 2019-09-24 | Hoffmann La Roche | pyrazolo pyridines and pyrazolo pyridines and their use as tyk2 inhibitors |
| US9012464B2 (en) | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| DE102010053124A1 (en) | 2010-12-01 | 2012-06-06 | Volkswagen Ag | Clutch, particularly for transmission of motor vehicle, particularly dual clutch for automatic or automated dual clutch transmission, has friction clutch, which is connected with motor shaft on one side |
| WO2012085815A1 (en) | 2010-12-21 | 2012-06-28 | Novartis Ag | Bi-heteroaryl compounds as vps34 inhibitors |
| EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
| US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| MX343706B (en) | 2011-01-31 | 2016-11-18 | Novartis Ag | Novel heterocyclic derivatives. |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| WO2012122058A2 (en) | 2011-03-04 | 2012-09-13 | Newgen Therapeutics, Inc. | Alkyne substituted quinazoline compound and methods of use |
| AU2012225246B2 (en) | 2011-03-10 | 2016-01-21 | Omeros Corporation | Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| CN103402519B (en) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | Therapeutic agent for tumor |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| GB201106870D0 (en) | 2011-04-26 | 2011-06-01 | Univ Belfast | Marker |
| US9029399B2 (en) | 2011-04-28 | 2015-05-12 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
| WO2012155339A1 (en) * | 2011-05-17 | 2012-11-22 | 江苏康缘药业股份有限公司 | 4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof |
| JP6038128B2 (en) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | A biomarker for predicting and evaluating the reactivity of thyroid and renal cancer subjects to lenvatinib compounds |
| EA201391820A1 (en) | 2011-06-09 | 2014-12-30 | Новартис Аг | HETEROCYCLIC SULPHONAMIDE DERIVATIVES |
| US8859586B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
| WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| CN102267952B (en) * | 2011-06-21 | 2013-12-11 | 天津市汉康医药生物技术有限公司 | Quinazoline compound and preparation method and application thereof |
| KR20140025530A (en) | 2011-06-27 | 2014-03-04 | 노파르티스 아게 | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
| US8575339B2 (en) * | 2011-07-05 | 2013-11-05 | Xueheng Cheng | Derivatives of erlotinib |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| KR20140047160A (en) | 2011-08-12 | 2014-04-21 | 에프. 호프만-라 로슈 아게 | Indazole compounds, compositions and methods of use |
| WO2013025446A2 (en) | 2011-08-12 | 2013-02-21 | Omeros Corporation | Anti-fzd10 monoclonal antibodies and methods for their use |
| EP3795145A3 (en) | 2011-08-17 | 2021-06-09 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
| EP2751285B2 (en) | 2011-08-31 | 2020-04-01 | Genentech, Inc. | Method for sensitivity testing of a tumour for a egfr kinase inhibitor |
| CA2848809A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase |
| CN103827115A (en) | 2011-09-20 | 2014-05-28 | 弗·哈夫曼-拉罗切有限公司 | Imidazopyridine compounds, compositions and methods of use |
| EP2761025A1 (en) | 2011-09-30 | 2014-08-06 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
| HU230483B1 (en) | 2011-10-10 | 2016-07-28 | Egis Gyógyszergyár Nyrt. | Erlotinib salts |
| EP2766497A1 (en) | 2011-10-13 | 2014-08-20 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
| PT2771342T (en) | 2011-10-28 | 2016-08-17 | Novartis Ag | Purine derivatives and their use in the treatment of disease |
| WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| EP2794594A1 (en) | 2011-12-22 | 2014-10-29 | Novartis AG | Quinoline derivatives |
| JO3398B1 (en) | 2011-12-22 | 2019-10-20 | Novartis Ag | 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis |
| US9126980B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| EP2794591A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| WO2013096051A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| BR112014015308A8 (en) | 2011-12-23 | 2017-06-13 | Novartis Ag | compounds for inhibiting bcl2 interaction with binding counterparts |
| EP2794592A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| UY34591A (en) | 2012-01-26 | 2013-09-02 | Novartis Ag | IMIDAZOPIRROLIDINONA COMPOUNDS |
| AU2013229786B2 (en) | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| US20130259867A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| AU2013243097A1 (en) | 2012-04-03 | 2014-10-09 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2013173283A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| EP2855483B1 (en) | 2012-05-24 | 2017-10-25 | Novartis AG | Pyrrolopyrrolidinone compounds |
| EP2861256B1 (en) | 2012-06-15 | 2019-10-23 | The Brigham and Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
| WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
| WO2014037961A1 (en) | 2012-09-04 | 2014-03-13 | Shilpa Medicare Limited | Crystalline erlotinib hydrochloride process |
| TW201422625A (en) | 2012-11-26 | 2014-06-16 | Novartis Ag | Solid form of dihydro-pyrido-oxazine derivative |
| KR20150098605A (en) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Amorphous form of quinoline derivative, and method for producing same |
| WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
| US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
| WO2014118112A1 (en) | 2013-01-29 | 2014-08-07 | Synthon B.V. | Pharmaceutical composition comprising erlotinib hydrochloride |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| US9834575B2 (en) | 2013-02-26 | 2017-12-05 | Triact Therapeutics, Inc. | Cancer therapy |
| KR20150130491A (en) | 2013-03-13 | 2015-11-23 | 제넨테크, 인크. | Pyrazolo compounds and uses thereof |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | Combination of kinase inhibitors and uses thereof |
| EP2976085A1 (en) | 2013-03-21 | 2016-01-27 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
| WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
| UY35675A (en) | 2013-07-24 | 2015-02-27 | Novartis Ag | SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA |
| WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| EP3041474B1 (en) | 2013-09-05 | 2020-03-18 | Genentech, Inc. | Antiproliferative compounds |
| WO2015035410A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutic, Inc. | Cancer therapy |
| JP6282745B2 (en) | 2013-09-12 | 2018-02-21 | ハロザイム インコーポレイテッド | Modified anti-epidermal growth factor receptor antibody and method of use thereof |
| BR112015032713B1 (en) | 2013-09-17 | 2023-03-21 | Obi Pharma, Inc | COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A THERAPEUTICLY EFFECTIVE AMOUNT OF THE PHARMACEUTICAL COMPOSITION, AND USE OF THE COMPOUND |
| KR20160060100A (en) | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | Substituted aminopyrimidine compounds and methods of use |
| TW201605857A (en) | 2013-10-03 | 2016-02-16 | 赫孚孟拉羅股份公司 | Therapeutic inhibitors of CDK8 and uses thereof |
| TW201605450A (en) | 2013-12-03 | 2016-02-16 | 諾華公司 | Combination of Mdm2 inhibitor and BRAF inhibitor and their use |
| CN105979947A (en) | 2013-12-06 | 2016-09-28 | 诺华股份有限公司 | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| JP2017507900A (en) | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Method for treating HER2-positive cancer using PD-1 axis binding antagonist and anti-HER2 antibody |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| WO2015145388A2 (en) | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| WO2015148867A1 (en) | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| KR20160146747A (en) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
| SG11201607969XA (en) | 2014-03-31 | 2016-10-28 | Genentech Inc | Anti-ox40 antibodies and methods of use |
| BR112016022499A2 (en) | 2014-04-03 | 2017-08-15 | Invictus Oncology Pvt Ltd | SUPRAMOLECULAR COMBINATORY THERAPEUTIC PRODUCTS |
| WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| CA2954862A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
| PT3524595T (en) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | HIGHLY PURE QUINOLINE DERIVATIVE AND METHOD FOR PRODUCTION THEREOF |
| CN107074823B (en) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | Therapeutic compounds and their uses |
| EP3193866A1 (en) | 2014-09-19 | 2017-07-26 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
| CN107912040B (en) | 2014-10-10 | 2021-04-06 | 基因泰克公司 | Pyrrolidinamide compounds as histone demethylase inhibitors |
| US20170252335A1 (en) | 2014-10-17 | 2017-09-07 | Novartis Ag | Combination of Ceritinib with an EGFR Inhibitor |
| CA2908441A1 (en) | 2014-10-28 | 2016-04-28 | Cerbios-Pharma Sa | Process for the preparation of erlotinib |
| CA2966523A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
| WO2016073380A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment |
| US20160152720A1 (en) | 2014-11-06 | 2016-06-02 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
| MA40943A (en) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS |
| MA40940A (en) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS |
| CN107108613B (en) | 2014-11-10 | 2020-02-25 | 基因泰克公司 | Bromo domain inhibitors and their uses |
| SG10201807625PA (en) | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| EP3632915A1 (en) | 2014-11-27 | 2020-04-08 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| WO2016082879A1 (en) * | 2014-11-27 | 2016-06-02 | Synthon B.V. | Pharmaceutical composition comprising erlotinib hydrochloride |
| KR20170094165A (en) | 2014-12-23 | 2017-08-17 | 제넨테크, 인크. | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
| WO2016105503A1 (en) | 2014-12-24 | 2016-06-30 | Genentech, Inc. | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
| JP2018503373A (en) | 2014-12-30 | 2018-02-08 | ジェネンテック， インコーポレイテッド | Methods and compositions for cancer prognosis and treatment |
| EP3242872B1 (en) | 2015-01-09 | 2019-07-03 | Genentech, Inc. | (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer |
| EP3242874B1 (en) | 2015-01-09 | 2018-10-31 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
| WO2016112251A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
| EP3250571B1 (en) | 2015-01-29 | 2022-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| WO2016123387A1 (en) | 2015-01-30 | 2016-08-04 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| MA41598A (en) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES |
| LT3263106T (en) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | METHOD OF REDUCING BITTERNESS OF QUINOLINE DERIVATIVES |
| CN104725327B (en) * | 2015-03-03 | 2017-08-25 | 山东大学 | A kind of environment-friendly preparation method of erlotinib Hydrochloride |
| KR102662228B1 (en) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | Combination of PD-1 antagonists and VEGFR/FGFR/RET tyrosine kinase inhibitors to treat cancer |
| KR20180002653A (en) | 2015-04-07 | 2018-01-08 | 제넨테크, 인크. | Antigen binding complexes having an agonistic activity activity and methods of use |
| ES2835866T5 (en) | 2015-05-12 | 2024-12-02 | Hoffmann La Roche | Therapeutic and diagnostic procedures for cancer |
| ES2789500T5 (en) | 2015-05-29 | 2023-09-20 | Hoffmann La Roche | Therapeutic and diagnostic procedures for cancer |
| MX2017015937A (en) | 2015-06-08 | 2018-12-11 | Genentech Inc | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists. |
| JP2018521019A (en) | 2015-06-08 | 2018-08-02 | ジェネンテック， インコーポレイテッド | Method of treating cancer using anti-OX40 antibody |
| MX373231B (en) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | ANTICANCER AGENT. |
| KR102689256B1 (en) | 2015-06-17 | 2024-07-30 | 제넨테크, 인크. | Methods for treating locally advanced or metastatic breast cancer using PD-1 axis binding antagonists and taxanes |
| CN105017162B (en) * | 2015-06-26 | 2017-10-27 | 陕西师范大学 | 4 pairs of propenylbenzene amido quinazoline derivatives and its application in antineoplastic is prepared |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| ES2862727T3 (en) | 2015-08-26 | 2021-10-07 | Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio | Fused tricyclic compounds as protein kinase inhibitors |
| EP3340990B1 (en) | 2015-08-28 | 2019-09-25 | Novartis AG | Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer |
| US10935544B2 (en) | 2015-09-04 | 2021-03-02 | Obi Pharma, Inc. | Glycan arrays and method of use |
| JP2018527362A (en) | 2015-09-11 | 2018-09-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | Substituted heteroaryl compounds and methods of use |
| PE20181046A1 (en) | 2015-09-25 | 2018-07-03 | Genentech Inc | ANTI-TIGIT ANTIBODIES AND METHODS OF USE |
| RU2018119085A (en) | 2015-11-02 | 2019-12-04 | Новартис Аг | SCHEME OF INTRODUCTION OF THE PHOSPHATIDYLINOSITOL-3-KINASE INHIBITOR |
| MY196817A (en) | 2015-12-16 | 2023-05-03 | Genentech Inc | Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer |
| KR20180097615A (en) | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Methods for the treatment of CEA-positive cancers using PD-1 axis-binding antagonists and anti-CEA / anti-CD3 bispecific antibodies |
| JP6821693B2 (en) | 2016-02-29 | 2021-01-27 | ジェネンテック， インコーポレイテッド | Treatment and diagnosis for cancer |
| BR112018070097A2 (en) | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | antibody, hybridoma, pharmaceutical composition, method for treating cancer in an individual, method for inhibiting cancer cell proliferation, method for diagnosing cancer in an individual, method for treating a human patient, method for imaging an individual, conjugate of antibody-antibody (adc) method for treating cancer, bispecific antibody and method for preparing a homogeneous antibody population |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| KR20180134347A (en) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | Diagnosis and Treatment of Cancer |
| MX2018012493A (en) | 2016-04-15 | 2019-06-06 | Genentech Inc | METHODS TO CONTROL AND TREAT CANCER. |
| KR20190003958A (en) | 2016-04-15 | 2019-01-10 | 제넨테크, 인크. | Treatment and monitoring of cancer |
| KR20230110820A (en) | 2016-04-22 | 2023-07-25 | 오비아이 파머 인코퍼레이티드 | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| EP3464270B1 (en) | 2016-05-24 | 2022-02-23 | Genentech, Inc. | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer |
| JP7014736B2 (en) | 2016-05-24 | 2022-02-01 | ジェネンテック， インコーポレイテッド | Pyrazolopyridine derivatives for the treatment of cancer |
| WO2017214452A1 (en) | 2016-06-08 | 2017-12-14 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| US20200129519A1 (en) | 2016-06-08 | 2020-04-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| CN110072545A (en) | 2016-07-27 | 2019-07-30 | 台湾浩鼎生技股份有限公司 | Immunogenicity/therapeutic glycan pool object and application thereof |
| US11643456B2 (en) | 2016-07-29 | 2023-05-09 | Obi Pharma, Inc. | Human antibodies, pharmaceutical compositions and methods |
| WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| CA3038712A1 (en) | 2016-10-06 | 2018-04-12 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| WO2018078143A1 (en) | 2016-10-28 | 2018-05-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy |
| WO2018081648A2 (en) | 2016-10-29 | 2018-05-03 | Genentech, Inc. | Anti-mic antibidies and methods of use |
| TWI822055B (en) | 2016-11-21 | 2023-11-11 | 台灣浩鼎生技股份有限公司 | Conjugated biological molecules, pharmaceutical compositions and methods |
| CN110366550A (en) | 2016-12-22 | 2019-10-22 | 美国安进公司 | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d as KRAS G12C inhibitors for the treatment of lung, pancreatic or colorectal cancer ]pyridazine and pyrido[2,3-d]pyrimidine derivatives |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| TW201837467A (en) | 2017-03-01 | 2018-10-16 | 美商建南德克公司 | For the diagnosis and treatment of cancer |
| CN106928069B (en) * | 2017-03-21 | 2019-03-19 | 上海玉函化工有限公司 | A kind of preparation method of 4,5- bis- (2- methoxy ethoxy) -2- ethyl nitrobenzoate |
| CN110505883A (en) | 2017-04-13 | 2019-11-26 | 豪夫迈·罗氏有限公司 | Interleukin-2 immunoconjugates, CD40 agonists, and optionally PD-1 axis binding antagonists for use in methods of treating cancer |
| RU2019134940A (en) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | TREATMENT OF HEPATOCELLULAR CARCINOMA |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| CN107200715B (en) * | 2017-06-22 | 2020-05-29 | 陕西师范大学 | Quinazoline derivatives and their application in the preparation of antitumor drugs |
| JP7760242B2 (en) | 2017-07-21 | 2025-10-27 | ジェネンテック， インコーポレイテッド | Cancer treatment and diagnosis methods |
| MX2020000903A (en) | 2017-08-11 | 2020-07-22 | Genentech Inc | ANTI-CD8 ANTIBODIES AND USES THEREOF. |
| KR102811888B1 (en) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | Diagnosis and treatment of cancer |
| AU2018329920B2 (en) | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| CN111868039A (en) * | 2017-09-26 | 2020-10-30 | 加利福尼亚大学董事会 | Compositions and methods for treating cancer |
| US11369608B2 (en) | 2017-10-27 | 2022-06-28 | University Of Virginia Patent Foundation | Compounds and methods for regulating, limiting, or inhibiting AVIL expression |
| TW201923089A (en) | 2017-11-06 | 2019-06-16 | 美商建南德克公司 | Diagnostic and therapeutic methods for cancer |
| WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| AU2019207535B2 (en) | 2018-01-15 | 2021-12-23 | Epiaxis Therapeutics Pty Ltd | Agents and methods for predicting response to therapy |
| KR102737185B1 (en) | 2018-01-20 | 2024-12-05 | 선샤인 레이크 파르마 컴퍼니 리미티드 | Substituted aminopyrimidine compounds and methods of use thereof |
| CN117402114A (en) | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | Compounds for the treatment of kinase dependent disorders |
| CR20250117A (en) | 2018-01-26 | 2025-05-09 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| CA3088198A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| TWI660728B (en) * | 2018-02-09 | 2019-06-01 | National Chiao Tung University | Quinazolinamine derivatives and pharmaceutical compositions and uses thereof |
| CN111836831A (en) | 2018-02-26 | 2020-10-27 | 豪夫迈·罗氏有限公司 | Administration for Anti-TIGIT Antagonist Antibody and Anti-PD-L1 Antagonist Antibody Therapy |
| EP3788053B1 (en) | 2018-05-04 | 2024-07-10 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| MA52564A (en) | 2018-05-10 | 2021-03-17 | Amgen Inc | KRAS G12C INHIBITORS FOR CANCER TREATMENT |
| JP2021524744A (en) | 2018-05-21 | 2021-09-16 | ナノストリング テクノロジーズ，インコーポレイティド | Molecular gene signature and how to use it |
| US11096939B2 (en) | 2018-06-01 | 2021-08-24 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2020012204A (en) | 2018-06-11 | 2021-03-31 | Amgen Inc | KRAS G12C INHIBITORS TO TREAT CANCER. |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| MY205645A (en) | 2018-06-23 | 2024-11-02 | Genentech Inc | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
| TW202504930A (en) | 2018-06-27 | 2025-02-01 | 台灣浩鼎生技股份有限公司 | Glycosynthase variants for glycoprotein engineering and methods of use |
| CN110642796B (en) * | 2018-06-27 | 2023-03-17 | 烟台药物研究所 | Quinazoline derivative and application thereof |
| WO2020018789A1 (en) | 2018-07-18 | 2020-01-23 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
| EP3847154A1 (en) | 2018-09-03 | 2021-07-14 | F. Hoffmann-La Roche AG | Carboxamide and sulfonamide derivatives useful as tead modulators |
| AU2019342099A1 (en) | 2018-09-19 | 2021-04-08 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
| KR102739487B1 (en) | 2018-09-21 | 2024-12-10 | 제넨테크, 인크. | Diagnostic methods for triple-negative breast cancer |
| JP2022502495A (en) | 2018-09-25 | 2022-01-11 | ブラック ダイアモンド セラピューティクス，インコーポレイティド | Quinazoline derivatives as tyrosine kinase inhibitors, compositions, methods of their preparation, and their use |
| CN113194954A (en) | 2018-10-04 | 2021-07-30 | 国家医疗保健研究所 | EGFR inhibitors for the treatment of keratoderma |
| US12404540B2 (en) | 2018-10-17 | 2025-09-02 | The University Of Queensland | Epigenetic biomarker and uses therefor |
| EP3867646A1 (en) | 2018-10-18 | 2021-08-25 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
| JP7516029B2 (en) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds |
| AU2019384118B2 (en) | 2018-11-19 | 2025-06-12 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
| JP2022513967A (en) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Heteroarylamide useful as a KIF18A inhibitor |
| MA54543A (en) | 2018-12-20 | 2022-03-30 | Amgen Inc | KIF18A INHIBITORS |
| AU2019401495B2 (en) | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| JP7686559B2 (en) | 2018-12-20 | 2025-06-02 | アムジエン・インコーポレーテツド | KIF18A inhibitor |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| CN113396230A (en) | 2019-02-08 | 2021-09-14 | 豪夫迈·罗氏有限公司 | Methods of diagnosis and treatment of cancer |
| CN113677994B (en) | 2019-02-27 | 2025-09-09 | 外延轴治疗股份有限公司 | Methods and agents for assessing T cell function and predicting response to therapy |
| WO2020176748A1 (en) | 2019-02-27 | 2020-09-03 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies |
| MX2021010323A (en) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Bicyclic heterocyclyl compounds and uses thereof. |
| MX2021010319A (en) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof. |
| WO2020223233A1 (en) | 2019-04-30 | 2020-11-05 | Genentech, Inc. | Prognostic and therapeutic methods for colorectal cancer |
| CN114269376A (en) | 2019-05-03 | 2022-04-01 | 豪夫迈·罗氏有限公司 | Methods of treating cancer with anti-PD-L1 antibodies |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| WO2020236947A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
| CN112300279A (en) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | Methods and compositions directed to anti-CD 73 antibodies and variants |
| EP4007752B1 (en) | 2019-08-02 | 2025-09-24 | Amgen Inc. | Kif18a inhibitors |
| EP4007753B1 (en) | 2019-08-02 | 2025-09-24 | Amgen Inc. | Kif18a inhibitors |
| EP4007756B1 (en) | 2019-08-02 | 2025-12-24 | Amgen Inc. | Kif18a inhibitors |
| EP4007638A1 (en) | 2019-08-02 | 2022-06-08 | Amgen Inc. | Pyridine derivatives as kif18a inhibitors |
| AU2020328598A1 (en) | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| TWI873176B (en) | 2019-09-04 | 2025-02-21 | 美商建南德克公司 | Cd8 binding agents and uses thereof |
| JP2022551422A (en) | 2019-09-26 | 2022-12-09 | エグゼリクシス， インコーポレイテッド | Pyridone compounds and methods of use in modulating protein kinases |
| JP2022548978A (en) | 2019-09-27 | 2022-11-22 | ジェネンテック， インコーポレイテッド | Dosing for Treatment with Drugs Anti-TIGIT and Anti-PD-L1 Antagonist Antibodies |
| EP4048671B1 (en) | 2019-10-24 | 2026-03-18 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| JP2023511472A (en) | 2019-10-29 | 2023-03-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Bifunctional compounds for the treatment of cancer |
| TW202132316A (en) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras inhibitors |
| AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| IL322454A (en) | 2019-11-04 | 2025-09-01 | Revolution Medicines Inc | Ras inhibitors |
| KR20220092580A (en) | 2019-11-06 | 2022-07-01 | 제넨테크, 인크. | Diagnosis and treatment methods for the treatment of blood cancer |
| CA3156359A1 (en) | 2019-11-08 | 2021-05-14 | Adrian Liam Gill | Bicyclic heteroaryl compounds and uses thereof |
| WO2021094379A1 (en) | 2019-11-12 | 2021-05-20 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| TW202130618A (en) | 2019-11-13 | 2021-08-16 | 美商建南德克公司 | Therapeutic compounds and methods of use |
| JP2023501528A (en) | 2019-11-14 | 2023-01-18 | アムジエン・インコーポレーテツド | Improved Synthesis of KRAS G12C Inhibitor Compounds |
| JP7837865B2 (en) | 2019-11-14 | 2026-03-31 | アムジエン・インコーポレーテツド | Improved synthesis method for KRAS G12C inhibitor compounds |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| CA3164995A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2021142026A1 (en) | 2020-01-07 | 2021-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
| WO2021148396A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| TW202142230A (en) | 2020-01-27 | 2021-11-16 | 美商建南德克公司 | Methods for treatment of cancer with an anti-tigit antagonist antibody |
| WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
| WO2021202959A1 (en) | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| EP4143345A1 (en) | 2020-04-28 | 2023-03-08 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
| AU2021293038A1 (en) | 2020-06-16 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating triple-negative breast cancer |
| KR20230024368A (en) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| EP4172628A1 (en) | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery |
| US20230235408A1 (en) | 2020-06-30 | 2023-07-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| JP2023536602A (en) | 2020-08-03 | 2023-08-28 | ジェネンテック， インコーポレイテッド | Diagnostic and therapeutic methods for lymphoma |
| WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| CA3193273A1 (en) | 2020-08-27 | 2022-03-03 | Enosi Therapeutics Corporation | Methods and compositions to treat autoimmune diseases and cancer |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2023544450A (en) | 2020-09-23 | 2023-10-23 | エラスカ・インコーポレイテッド | Tricyclic pyridones and pyrimidone |
| CN116406291A (en) | 2020-10-05 | 2023-07-07 | 基因泰克公司 | Administration of Therapy with Anti-FCRH5/Anti-CD3 Bispecific Antibody |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| JP7849366B2 (en) | 2020-12-22 | 2026-04-21 | キル・レガー・セラピューティクス・インコーポレーテッド | SOS1 inhibitors and their use |
| AU2022221124A1 (en) | 2021-02-12 | 2023-08-03 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
| CA3211063A1 (en) | 2021-02-19 | 2022-08-25 | Exelixis, Inc. | Pyridone compounds and methods of use |
| KR20240017811A (en) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | RAS inhibitors for the treatment of cancer |
| TW202309052A (en) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ras inhibitors |
| JP2024516450A (en) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | Covalent RAS inhibitors and uses thereof |
| KR20240026948A (en) | 2021-05-25 | 2024-02-29 | 에라스카, 아이엔씨. | Sulfur-containing heteroaromatic tricyclic KRAS inhibitor |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| AU2022315530A1 (en) | 2021-07-20 | 2024-01-18 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
| TW202321261A (en) | 2021-08-10 | 2023-06-01 | 美商伊瑞斯卡公司 | Selective kras inhibitors |
| EP4405360A4 (en) | 2021-09-23 | 2025-08-20 | Erasca Inc | POLYMORPHOUS FORMS OF AN EGFR INHIBITOR |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| US12275745B2 (en) | 2021-11-24 | 2025-04-15 | Genentech, Inc. | Therapeutic compounds and methods of use |
| US12110276B2 (en) | 2021-11-24 | 2024-10-08 | Genentech, Inc. | Pyrazolo compounds and methods of use thereof |
| CN119212994A (en) | 2021-12-17 | 2024-12-27 | 建新公司 | Pyrazolopyrazine compounds as SHP2 inhibitors |
| WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| KR20240156373A (en) | 2022-03-07 | 2024-10-29 | 암젠 인크 | Method for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile |
| JP2025510572A (en) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | Methods for treating immunorefractory lung cancer |
| JP2025510910A (en) | 2022-03-31 | 2025-04-15 | アストラゼネカ・アクチエボラーグ | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AKT INHIBITORS FOR THE TREATMENT OF CANCER - Patent application |
| IL315770A (en) | 2022-04-01 | 2024-11-01 | Genentech Inc | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| JP2025517650A (en) | 2022-05-11 | 2025-06-10 | ジェネンテック， インコーポレイテッド | Administration for Treatment with Anti-FcRH5/Anti-CD3 Bispecific Antibody |
| KR20250022049A (en) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | Method for determining the efficacy of a treatment for lung cancer comprising an anti-PD-L1 antagonist and an anti-TIGIT antagonist antibody |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CA3259492A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| AU2023305619A1 (en) | 2022-07-13 | 2025-01-23 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| KR20250040020A (en) | 2022-07-19 | 2025-03-21 | 제넨테크, 인크. | Dosage regimen for treatment with anti-FCRH5/anti-CD3 bispecific antibodies |
| WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
| AU2023322637A1 (en) | 2022-08-11 | 2024-11-14 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
| AU2023322638A1 (en) | 2022-08-11 | 2024-11-28 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
| JP2025526726A (en) | 2022-08-11 | 2025-08-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Bicyclic Tetrahydroazepine Derivatives |
| AU2023358792A1 (en) | 2022-10-14 | 2025-04-17 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
| JP2025538859A (en) | 2022-10-21 | 2025-12-02 | 公益財団法人川崎市産業振興財団 | Non-adsorbing or super stealth vesicles |
| WO2024088808A1 (en) | 2022-10-24 | 2024-05-02 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
| KR20250093336A (en) | 2022-10-25 | 2025-06-24 | 제넨테크, 인크. | Treatment and Diagnosis Methods for Multiple Myeloma |
| EP4665735A1 (en) | 2023-02-17 | 2025-12-24 | Erasca, Inc. | Kras inhibitors |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (en) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | MACROCYCLIC RAS INHIBITORS |
| AR132338A1 (en) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | RAS INHIBITORS |
| CN121100123A (en) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Crystalline forms of Ras inhibitors |
| CN121464140A (en) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Crystalline forms of RAS inhibitors, compositions containing the same, and methods of use thereof |
| TW202508595A (en) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | Combination therapy for a ras related disease or disorder |
| AU2024270495A1 (en) | 2023-05-05 | 2025-10-09 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| KR20260021689A (en) | 2023-06-08 | 2026-02-13 | 제넨테크, 인크. | Macrophage Signatures for Lymphoma Diagnosis and Treatment |
| WO2025024257A1 (en) | 2023-07-21 | 2025-01-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202515614A (en) | 2023-08-25 | 2025-04-16 | 美商建南德克公司 | Methods and compositions for treating non-small cell lung cancer |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202542151A (en) | 2023-12-22 | 2025-11-01 | 美商銳格醫藥有限公司 | Sos1 inhibitors and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025176843A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof |
| TW202547461A (en) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026030476A1 (en) | 2024-07-30 | 2026-02-05 | Genentech, Inc. | Precision medicine for optimal dosage of combined therapies systems and methods of use thereof |
| WO2026030464A1 (en) | 2024-07-30 | 2026-02-05 | Genentech, Inc. | Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU400048A1 (en) * | 1970-12-14 | 1973-10-03 | ||
| SU466233A1 (en) * | 1973-06-08 | 1975-04-05 | Всесоюзный научно-исследовательский химико-фармацевтический институт им. С.Орджоникидзе | Method for producing 2-methyl-4-dialkylaminoalkylaminoquinazoline derivatives |
| SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| US5258518A (en) * | 1992-04-01 | 1993-11-02 | G. D. Searle & Co. | 2-substituted tertiary carbinol derivatives of deoxynojirimycin |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
-
1995
- 1995-06-06 DE DE69536015T patent/DE69536015D1/en not_active Expired - Lifetime
- 1995-06-06 AT AT01104696T patent/ATE446955T1/en not_active IP Right Cessation
- 1995-06-06 MX MX9707453A patent/MX9707453A/en active IP Right Grant
- 1995-06-06 EP EP10186213A patent/EP2295415A1/en not_active Ceased
- 1995-06-06 ES ES95918713T patent/ES2161290T3/en not_active Expired - Lifetime
- 1995-06-06 EP EP09174228.8A patent/EP2163546B1/en not_active Expired - Lifetime
- 1995-06-06 CA CA002216796A patent/CA2216796C/en not_active Expired - Lifetime
- 1995-06-06 EP EP16171536.2A patent/EP3103799B1/en not_active Expired - Lifetime
- 1995-06-06 DE DE69522717T patent/DE69522717T2/en not_active Expired - Lifetime
- 1995-06-06 JP JP08529113A patent/JP3088018B2/en not_active Expired - Lifetime
- 1995-06-06 EP EP95918713A patent/EP0817775B1/en not_active Expired - Lifetime
- 1995-06-06 AT AT95918713T patent/ATE205483T1/en active
- 1995-06-06 ES ES01104696T patent/ES2332984T3/en not_active Expired - Lifetime
- 1995-06-06 PT PT95918713T patent/PT817775E/en unknown
- 1995-06-06 WO PCT/IB1995/000436 patent/WO1996030347A1/en not_active Ceased
- 1995-06-06 DK DK95918713T patent/DK0817775T3/en active
- 1995-06-06 EP EP01104696A patent/EP1110953B1/en not_active Expired - Lifetime
- 1995-06-06 DE DE200512000053 patent/DE122005000053I2/en active Active
-
1996
- 1996-03-05 TW TW085102699A patent/TW454000B/en not_active IP Right Cessation
- 1996-03-07 AP APAP/P/1996/000788A patent/AP735A/en active
- 1996-03-21 IL IL12999596A patent/IL129995A/en not_active IP Right Cessation
- 1996-03-21 IL IL189037A patent/IL189037A/en not_active IP Right Cessation
- 1996-03-21 IL IL11759896A patent/IL117598A/en active Protection Beyond IP Right Term
- 1996-03-21 IL IL129994A patent/IL129994A/en not_active IP Right Cessation
- 1996-03-25 SK SK387-96A patent/SK283762B6/en not_active IP Right Cessation
- 1996-03-25 MA MA24190A patent/MA23831A1/en unknown
- 1996-03-25 SK SK56-2003A patent/SK283763B6/en not_active IP Right Cessation
- 1996-03-25 AR ARP960101903A patent/AR002723A1/en active IP Right Grant
- 1996-03-25 PE PE1996000207A patent/PE43897A1/en not_active IP Right Cessation
- 1996-03-27 NZ NZ286263A patent/NZ286263A/en not_active IP Right Cessation
- 1996-03-28 EG EG26996A patent/EG24229A/xx active
- 1996-03-28 CN CN96102992A patent/CN1066142C/en not_active Expired - Lifetime
- 1996-03-28 UA UA96031214A patent/UA44254C2/en unknown
- 1996-03-29 HU HU9600834A patent/HU229120B1/en active Protection Beyond IP Right Term
- 1996-03-29 CZ CZ1996931A patent/CZ294967B6/en not_active IP Right Cessation
- 1996-03-29 MY MYPI96001194A patent/MY117896A/en unknown
- 1996-03-29 TR TR96/00265A patent/TR199600265A1/en unknown
- 1996-03-29 AU AU50406/96A patent/AU703638B2/en not_active Expired
- 1996-03-29 OA OA60807A patent/OA10277A/en unknown
- 1996-03-29 BR BRPI9601200-5A patent/BR9601200B1/en not_active IP Right Cessation
- 1996-03-29 HR HR960147A patent/HRP960147B1/en not_active IP Right Cessation
- 1996-03-29 ZA ZA9602522A patent/ZA962522B/en unknown
- 1996-03-29 SI SI9600102A patent/SI9600102A/en active Search and Examination
- 1996-03-29 RU RU0096106055K patent/RU2694252C2/en active Protection Beyond IP Right Term
- 1996-03-29 NO NO961299A patent/NO308740B1/en not_active IP Right Cessation
- 1996-03-29 SG SG1996006639A patent/SG43262A1/en unknown
- 1996-03-29 RU RU0096106055A patent/RU2694252C3/en active IP Right Grant
- 1996-03-29 CO CO96015833A patent/CO4410333A1/en unknown
- 1996-03-29 CZ CZ19972067A patent/CZ295145B6/en not_active IP Right Cessation
- 1996-03-30 SA SA96160707A patent/SA96160707B1/en unknown
- 1996-03-30 KR KR1019960009659A patent/KR100232335B1/en not_active Expired - Lifetime
-
1997
- 1997-09-29 FI FI973832A patent/FI120646B/en not_active IP Right Cessation
- 1997-09-29 PL PL96313541A patent/PL186843B1/en unknown
-
1999
- 1999-05-17 IL IL12999599A patent/IL129995A0/en unknown
- 1999-05-17 IL IL12999499A patent/IL129994A0/en active IP Right Grant
- 1999-05-17 IL IL12999699A patent/IL129996A0/en unknown
- 1999-06-23 AU AU35854/99A patent/AU3585499A/en not_active Abandoned
-
2001
- 2001-10-30 GR GR20010401942T patent/GR3037070T3/en unknown
-
2005
- 2005-12-14 LU LU91209C patent/LU91209I2/en unknown
-
2006
- 2006-01-02 NL NL300214C patent/NL300214I2/en unknown
- 2006-03-06 NO NO2006004C patent/NO2006004I2/en unknown
- 2006-03-15 FR FR06C0010C patent/FR06C0010I2/fr active Active
-
2014
- 2014-01-21 HU HUS1400001C patent/HUS1400001I1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2216796C (en) | Quinazoline derivatives | |
| US5747498A (en) | Alkynyl and azido-substituted 4-anilinoquinazolines | |
| EP0831829B1 (en) | Heterocyclic ring-fused pyrimidine derivatives | |
| US5475001A (en) | Quinazoline derivatives | |
| US5955464A (en) | 4-anilinoquinazoline derivatives bearing a heteroaryl substituted at the 6-position and possessing anti-cell-proliferation properties | |
| US6395733B1 (en) | Heterocyclic ring-fused pyrimidine derivatives | |
| WO2009057139A2 (en) | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents | |
| AU778961B2 (en) | Intermediates for the preparation of 4-(substituted phenylamino)quinazoline derivatives | |
| HK1231045A1 (en) | Quinazoline derivatives | |
| HK1231045A (en) | Quinazoline derivatives | |
| HK1141804A (en) | Quinazoline derivatives | |
| HK1042083A (en) | Quinazoline derivatives | |
| HK1038740B (en) | Quinazoline derivatives | |
| HK1231045B (en) | Quinazoline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20150608 |